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Abstract
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with
diagnostics and treatments that are ineffective at stopping the progression. This thesis
examines new ways of both diagnosing and treating ALS, including 1) a gadolinium
tetanus toxin C fragment (Gd-TTC) biomarker for axonal retrograde transport, 2) TTC-
conjugated biodegradable nanoparticles, and 3) poly(glycerol-co-sebacate) acrylate
(PGSA) and 3D scaffolds for human embryonic stem cell (hESC) and neuronal
encapsulation.
A Gd-TTC conjugate was developed and characterized that was shown to be
highly visible under MRI and preserved the functionality of the native TTC protein in
vitro. Live animal MRI imaging and immunofluorescent staining of the spinal cord
showed that the conjugate was transported to the central nervous system (CNS) and
localized in motor neurons. H&E staining and biodistribution studies showed that Gd-
TTC was well tolerated and bioavailable. Quantification of MRI and staining images
showed that Gd-TTC was retrograde transported and that that this rate decreased during
the disease progression of ALS in a transgenic mouse model, suggesting that Gd-TTC
could be used as a biomarker for neurodegenerative diseases.
TTC-conjugated nanoparticles were developed by synthesizing PLGA-PEG-biotin
and using biotin binding proteins (avidin, streptavidin, and neutravidin) to specifically
conjugate TTC to the nanoparticle surface. TTC nanoparticles were shown to selectively
target neurons and not other cell types in vitro. Subsequent in vivo experiments showed
that nanoparticles were well tolerated and that TTC was co-localized with neurons
unilaterally, suggesting that TTC-conjugated nanoparticles may be a useful drug delivery
system.
Porous PGSA scaffolds were prepared and characterized by porosity, swelling,
mass loss, toxicity and mechanical properties, and subsequently used to encapsulated
hESC and neuroblastoma cells in vitro. Neuroblastoma cells proliferated and formed
matrix fibrils, and fluorescent staining of undifferentiated hESCs showed the presence of
all three germ layers. In vivo experiments showed that porous PGSA scaffolds were well-
tolerated and promoted vascular ingrowths.
Thesis Supervisors: Robert Langer, ScD (Institute Professor, MIT) and Robert H. Brown,
MD-DPhil (Director Day Neuromuscular Laboratory, MGH, and Professor, Harvard
Medical School)
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Chapter 1: Introduction
1.1.0 Amyotrophic Lateral Sclerosis
1.1.1 Background
Amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease) is a
neurodegenerative disease affecting both upper and lower motor neurons in the central
nervous system. There is currently no cure for ALS, and most people who are diagnosed
with ALS usually will die within 3-5 years after loss of motor function and muscle
atrophy. Approximately 5000 new cases of ALS are made each year in the US, primarily
in patients who are older than age 50. Despite the low incidence rate of the disease, ALS
has gained much public attention and is more well known by most people than other
neurodegenerative diseases, largely because several famous people have been diagnosed
with ALS (Lou Gehrig and Stephen Hawking, among others). Because of this, funding
for basic science and clinical trials research is available with the goal of someday finding
a cure to ALS.
1.1.2 Causes
The causes of ALS are not well understood. However, it is known that in a small
fraction of patients (approximately 10%), ALS is caused by a genetic mutation. Of these
cases that are caused genetically, most are recessively inherited, and approximately 20%
of these cases are caused by mutations in the superoxide dismutatase I (SOD 1) gene.
SOD1 is responsible for maintaining free radical and oxidation states, and for this reason,
some of the current clinical trials that are being conducted have targeted these pathways.
C 2008 Massachusetts Institute of Technology. All rights reserved.
This knowledge of SOD 1 mutations has led to the generation of a number of transgenic
animal models for ALS, including the G93A mouse model, a rat model, and an
earthworm model. However, in the vast majority of cases of ALS, the cause of the
disease is not known. Researchers suggest that environmental factors and apoptosis
could play a role as possible risk factors for the disease, but more research is needed to
understand relative and absolute contributions.
1.1.3 Symptoms
The early symptoms of ALS often go unnoticed or are misdiagnosed as common
signs of aging. These symptoms include the loss in strength and balance most often in
the arms and legs, reduced balance and coordination, and difficulty walking. Less
common early symptoms include a difficulty in speech and swallowing.
Late stage symptoms of ALS include total loss of motor function in the limbs,
inability to walk, and reduced activity in other motor neuron function. This leads to
difficulty swallowing, eating, talking, and breathing in patients with late stage ALS.
Visible symptoms of the disease are associated with secondary symptoms such as muscle
atrophy. However, ALS is not thought to affect other critical systems, and patients
maintain their cognitive ability throughout the disease. For this reason, treatments that
improve motor neuron function could have significant impacts on patient quality of life.
C 2008 Massachusetts Institute of Technology. All rights reserved.
1.1.4 Diagnostics
A diagnosis of ALS is usually made after early symptoms have been present for
extended periods. This is partially because ALS is rare, and many doctors misdiagnose
the symptoms as signs of aging. An accurate and reliable diagnosis is further
complicated because there is no single test for ALS. Instead, it is usually made by ruling
out other conditions by conducting a series of tests. These tests include evaluating nerve
conduction velocity, using an MRI to eliminate cancer as a possibility, and muscle or
nerve biopsy. Even with these tests, the results and a series of physical examinations is
used to make a final diagnosis, and often a patient has been seen by multiple neurologists
before a diagnosis is made. It is clear that more effective and earlier diagnostics would
help
1.1.5 Treatments
There is currently only one FDA-approved therapeutic for ALS, Riluzole, that
prolongs survival by approximately six months in most patients. Riluzole is only
successful in delaying the progression of ALS, but it is not a cure. It is largely believed
that the mechanism of riluzole includes a decrease in the amount of glutamate released by
neurons. Many researchers suggest that an earlier diagnostic test would enable more
successful treatments. Additionally, if we better understand the cause of ALS and the
mechanisms for progression, therapeutics could be developed to target certain pathways.
Unfortunately, despite the large number of completed and ongoing trials, most of the
completed clinical trials have been largely unsuccessful.
© 2008 Massachusetts Institute of Technology. All rights reserved.
In additional to pharmaceutical therapeutics, ALS therapies rely largely on
supportive care including breathing assistance and physical therapy. This treatment
includes the use of mechanical assistance such as walkers and braces, as well as
prescription therapeutics including drugs to reduce muscle fatigue. During late stage
ALS, devices that assist with voice communication can be used as patients often lose
their ability to talk coherently, as well as devices that assist with breathing such as
respiratory ventilators. It is widely viewed that this care does not prevent disease
progression but instead improves patient quality of life.
1.1.6 Experimental approaches
There are a number of experimental approaches that are being studied as possible
treatments for ALS. At this time, they are not FDA approved, and are at various stages of
development. Studies are aimed at treating all symptoms of ALS including reducing
apoptosis, decreasing local free radical formation, and administering various neurotrophic
factors. Additionally, FDA-approved drugs for other indications and diseases are being
studied for possible benefit in ALS. Outside of the clinic, there is a wide range of
research that is being conducted including next generation RNAi therapeutics, stem cell
therapeutics, and gene therapy. Most of these therapeutics are predicted to be years or
even decades away from clinical use.
In additional to a number of clinical trials 1-4 that test new therapeutics,
researchers are evaluating the role of supportive treatments 5, 6. Researchers have also
made contributions in understanding the mechanisms of ALS with clinical samples and in
transgenic animal models 7, 8. The SOD1 protein continues to be the topic of much
research and progress is being made in understanding its contribution 9-14, as well as other
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genes that may contribute to ALS progression 5-"7. Next generation therapeutics
including gene therapy 18-23 and RNAi/siRNA 24-26 are also being developed that treat a
number of symptoms of ALS including apoptosis 27, reduced levels of neurotrophic
factors 28, DNA repair mechanisms 29, and exploring the role of hypoxia in ALS 30-33
Additionally, VEGF 34, 35 and IGF-1 36-39 are among the many molecules that are
currently being tested as a possible ALS therapeutic. It is not yet clear which
experimental approaches will be most successful, and more research is needed to
understand the relative and absolute role of stopping ALS progression for each
therapeutic.
1.2.0 Magnetic resonance imaging
1.2.1 Overall background
Magnetic resonance imaging (MRI) is a method that is commonly used clinically
to visualized tissue. MRI utilized a magnetic field to generate an image of local tissue
including: brain and spinal cord imaging, tumors, cardiac tissue and vasculature, and
joints and cartilage. MRI differs from other imaging methods including positron
emission tomography (PET), which detects radioisotopes and generates an image,
because it has much higher resolution than PET. Additionally, a foreign radiolabeled
product is not required to generate images; however, often an MRI contrast agent is
administered for certain applications. Generally, MRI is considered very safe, but it
cannot be performed with patients who have any metals that are sensitive to a magnetic
field such as certain implants because the strong magnetic field would cause internal
motion. One of the most common side effects in patients is a feeling of claustrophobia
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because the imaging scan can take several hours to complete. Usually, the magnetic
fields that are used in clinical MRIs have field strengths between 0.5-3 Tesla. However,
experimental MRIs for non-human use have 14T magnetic strengths, or even higher.
Despite the high resolution images given by MRI, machines are very expensive to
purchase and operate, and often doctors make decisions about whether to give an MRI
imaging session based on cost considerations.
1.2.2 Methods of Imaging
The images from an MRI are obtained by generating a strong magnetic field and
by measuring the rate at which protons align with the magnetic field. The relaxivity, or
rate at which the protons return to their native state, is different for each type of tissue,
and can be affected by fluid levels or the presence of a contrast agent. There are several
types of scans on an MRI, and all have the goal of maximizing the signal contrast and
generating maximum signal to noise in the tissue of interest. Generally, there are two
types of relaxivity: longitudinal relaxivity which is associated with TI contrast, and
transverse relaxivity, which is associated with T2 contrast. Usually, the rate that protons
return to their native longitudinal state is faster for T2 contrast by approximately an order
of magnitude, but this rate is affected by the overall strength of the magnetic field. A
modified type of T2 sequence is often used for functional MRI brain imaging to account
for local differences in field strength.
Various contrast agents can be administered that can enhance the signal of either
T1 or T2 contrast. Gadolinium is often used clinically to enhance Tl and makes tissue
appear whiter in the presence of this agent 40, 41. Gadolinium is toxic in its native form,
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but is usually administered with a chelate which allows interaction with protons on water
molecules but reduces tissue toxicity. Additionally, recent studies have suggested that
there may be additional safety issues with the use of gadolinium for patients at high risk
of kidney failure, and the FDA has approved additional warning labels for gadolinium
based products to account for this. There are also T2 contrast agents, such as iron core
nanoparticles that can lead to an enhanced T2 signal that is darker compared to local
tissue 42-44. Often nanoparticles are functionalized to allow interaction with antibody
molecules for targeting applications in tumors45' 46. These studies could be expanded to
other research areas including targeting the central nervous system.
1.2.3 Research involving ALS
MRI is commonly used as one of the primary methods to diagnose ALS,
specifically by ruling out cancer of the brain and spinal cord as a primary diagnosis.
Additionally, researchers have used experimental MRI sequences to study the
progression of ALS 47-60. These studies have ranged from quantifying the size of the
spinal cord using MRI to assess the disease progression to using more sophisticated
diffusion tensor sequences. These methods are currently experimental, are not FDA-
approved as an ALS diagnostic, and are not used by clinicians outside of a research
environment. The use of MRI in monitoring the progression of ALS could see increasing
use with the development of specific biomarker contrast agents.
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1.3.0 Drug Delivery
1.3.1 Background
Many therapeutics are delivered via oral or injectable administration routes.
However, it is often difficult to maintain drug concentrations within the therapeutic
window. If drug concentrations are too high, side effects can occur (including death), but
if drug concentrations are too low, the therapeutic is often not effective. Additionally,
drug clearance rates including the first pass metabolism (clearance in the hepatic system)
eliminate the drug from the system over time. This is complicated by the fact that
different drugs have various therapeutic windows and clearance rates. The liver is
responsible for breaking drugs down into metabolites that can be cleared from the kidney,
but metabolites can be toxic. Models to predict drug toxicity are often inadequate
because initial in vitro screens are conducted with cells in a 2D culture system that do not
represent the liver microenvironment 61. These issues and considerations affect the
overall bioavailability and biodistribution over time, and are the cause of the failure for
many candidate drugs failing prior to and during clinical trials. Controlled and more
effective drug delivery can alleviate many of these problems.
1.3.2 Biodegradable Polymers
The field of drug delivery has seen advancement by the development of
biodegradable and biocompatible synthetic polymers. These polymers include
poly(lactic-co-glycolic acid) (PLGA), poly(lactic acid) (PLA), and poly(glycolic acid)
(PGA). These polymers vary by their core composition, degradation rates, and drug
release profiles, but are all generally considered well tolerated and are utilized in FDA-
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approved products. They degrade into either lactic acid or glycolic acid and water, and as
they degrade, an encapsulated therapeutic is released. Initial polymer studies were used
to treat brain tumors and improve survival 62-68, and since that point, significant
advancements have been made in polymer design and in understanding release 69-73. The
next generation polymers that are being developed include polymers with positive
charges that may enhance gene delivery, and those that have different degradation
profiles and release characteristics. Therefore, the drug release can be controlled for
many compounds for each application.
1.3.3 Blood Brain Barrier (BBB)
Delivering therapeutic agents to the CNS is of great importance but has remained
challenging in part because of difficulties in penetrating the blood brain barrier (BBB), a
layer of endothelial cells bound by tight junctions. Most drugs that are larger than -400
daltons do not pass through the BBB with high efficiency 74. Various approaches have
been used to administer agents to the CNS including concentrated mannitol, vascular
endothelial growth factor (VEGF), ultrasound, encapsulation within nanoparticles, and
retrograde transport. Of these, mannitol remains the most widely used clinically,
primarily for applications in cancer treatment. Ultrasound and VEGF administration
remain an active field of ongoing research. In addition, nanoparticle (both non-targeted
and targeted) and retrograde transport approaches have been used successfully to
penetrate the BBB.
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1.3.4 Microparticles and nanoparticles
Microparticles (1-1000um) and nanoparticles (1-1000nm) are often defined by
their size and are can be synthesized from commonly used polymers, including PLA,
PLGA, and PLG. These nanoparticles and microparticles are usually used to encapsulate
and release a therapeutic agent usually over a period of days to months, with minimal
toxicity 69. Nanoparticles can be administered either through non-targeted or targeted
delivery. During the latter, a protein, aptamer, peptide sequence, or other targeting
molecule specific for a receptor is attached to the outside of the polymer nanoparticle.
Targeted nanoparticles offer the potential for local delivery, reducing any systemic side
effects of the encapsulated therapeutic, and may reduce systemic clearance rates (i.e.
from the kidney, liver, or macrophages) 75. This is important as common routes of
nanoparticle administration include intravenous and intramuscular delivery, both of
which may lead to rapid clearance and reduced efficacy with certain applications. Many
studies have found that the incorporation of polyethylene glycol (PEG) to the polymer
chain reduces clearance rates and may improve overall efficacy 76
Most nanoparticles are not efficient at penetrating the CNS because of a
combination of their size, surface charge, and hydrophobic properties 74. However, their
smaller size (in comparison with larger microparticles) may allow for greater BBB
penetration. Recently, non-targeted polymer nanoparticles prepared from
polybutylcyanoacrylate (PCBA) polymer encapsulating a variety of drugs and coated
with a polysorbate 80 surfactant have been shown to penetrate the BBB 77-81. The
mechanism for uptake is not fully understood, but is proposed to take place via receptor
mediated endocytosis in brain endothelial cells (ref) 82. However, in contrast to PLA,
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PLG, and PLGA polymers that are currently used in FDA-approved applications, PCBA
polymers would need to be studied more extensively before they are widely used
clinically 83. Targeted nanoparticles may allow for boundaries such as the BBB to be
penetrated by facilitating endocytosis or transcytosis across brain endothelial cells, or by
utilizing retrograde transport to bypass the BBB.
1.4.0 Retrograde transport
1.4.1 Background
Axonal retrograde transport is an important cellular process used by neurons to
transport proteins, small molecules, and even cell organelles from the terminal end of a
neuron towards the cell body. Different molecules are transported via different
mechanisms of axonal transport. Specifically, axonal retrograde transport is usually
subdivided into molecules that are transported via fast transport (50-400mm/day) and
slow transport (less than 10mm/day). The mechanisms of both fast and slow transport
are still being investigated, but fast transport is largely thought to be mediated by dyenin
and slow transport is mediated by kinesins.
1.4.2 Molecules that use retrograde transport
Retrograde transport is utilized by viruses (i.e. herpes) and bacterial toxins (i.e.
tetanus toxoid) to bypass the BBB and efficiently penetrate the CNS. This process has
evolved over millions of years, and is highly efficient, often leading to the toxicity of
many of these molecules. In addition, molecules such as manganese are transported via
this mechanism, and have been used as MRI contrast agents. Other molecules that are
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transported retrogradely include: poliovirus, wheat germ agglutinin (WGA), and rabies.
Many of these molecules are being studied both to understand the mechanism of transport
and to utilize natural mechanisms of transport for drug delivery.
1.4.3 Use as a delivery vehicle
Researchers have used retrograde transport to deliver genes and protein
conjugates to the CNS with therapeutic efficacy 36, 84. This approach offers the possibility
of selectively targeting a specific region of the CNS that is a function of the injection site.
This is in contrast to non-targeted intravenous administration that would likely penetrate
the entire CNS equally. However, one concern with using this approach is a possible
immune response, which may be particularly important in patients diagnosed with cancer
or those taking immunosupressive medications. The immune response will likely be a
function of the retrograde transport molecule used and previous immunizations to that
molecule. Recently, the tetanus toxin C fragment (the non-toxic binding portion of the
tetanus toxoid that is efficiently retrograde transported in neurons) was conjugated to
nanoparticles and shown to target neuroblastoma cells in vitro 8. It is not clear yet
whether this approach will lead to nanoparticles penetrating the CNS with high efficiency
in vivo.
1.4.4 Retrograde transport and ALS
In addition to using retrograde transport as a delivery system, this important
cellular process is well studied as it relates to the progression of neurodegenerative
disease such as ALS. It has been shown that ALS is impaired preceding the visible
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symptoms of ALS 86-9 1. Additionally, there has been some progress made in using
biomarkers to monitor this transport such as manganese 92. However, it is expected that
by utilizing bacterial or viral toxin fragments, we may gather additional insight into the
disease progression and generate biomarkers with more clinical utility.
1.5.0 Stem cells
1.5.1 Background and derivation
One therapeutic area of interest for ALS is tissue engineering from stem cells.
This offers a mechanism to treat advanced cases of ALS, where motoneurons have
significantly degenerated, and may help to restore lost limb function. This approach
could be used in parallel with pharmaceutical agents to treat ALS both on a molecular
and cellular level.
Stem cells are undifferentiated (unspecialized) cells that reside among
differentiated (specialized) cells in a tissue or organ and have the capability for self-
renewal (producing identical copies of themselves) throughout their lifetime. A stem cell
is also capable of producing more mature (specialized) cell types of the specific tissue or
organ in which it resides through differentiation93 . This allows the existence of a constant
pool of specialized cells needed for homeostasis. To some extent, this pool also allows
the replacement of dead, injured, or diseased cells (regeneration of injured tissue in an
organ).
There are two primary classifications of stem cells: adult stem cells and
embryonic stem cells. Adult stem cells are partially differentiated stem cells that
maintain some pluripotency, but cannot become any cell type. In contrast, embryonic
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stem cells can differentiate into any cell type. This makes embryonic stem cells
particularly useful for studies aimed at better understanding developmental biology and
those or for studies in which multiple cell types interact together in a cell
microenvironment. Mouse embryonic stem cells have been studied for several decades,
but human embryonic stem cells (hESC) were recently derived approximately ten years
ago.
1.5.2 Ethical considerations
There has recently been controversy and ethical debate regarding the use of hESC
for research purposes. The primary arguments center around whether it is acceptable to
use cells that have been derived from a fertilized embryo. Specifically, hESC were
developed from early embryos in a laboratory that were to be discarded from in vitro
fertilization clinics. At present, the National Institutes of Health have provided
guidelines which limit government funding to only cell lines that have already been
derived. The research in this study used only NIH-approved hESC lines. It is clear that
more research will be needed before we understand any ethical considerations and the
role of stem cells in any clinical treatments or tissue engineering applications.
1.5.3 Differentiation (including neuronal)
One active focus of current research involves guiding the differentiation of
undifferentiated stem cells into certain cell types and tissues. hESC are exposed to a
variety of microenviroment conditions, nanotopography, and growth factors to induce
differentiation. However, most cell populations remain mixed and this process is not
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well understood. It is clear that a variety of factors contribute to cell differentiation and
more research is needed.
Researchers are investigating new ways to promote neuronal differentiation with
some applications for ALS 94-96. There are a variety of markers for neuronal
differentiation that are used including: nestin, Soxl, beta-3 tubulin, TuJ, and MAP2.
These markers may have basal expression levels in undifferentiated stem cells, so it is
important to compare these levels to appropriate controls. It is clear that having a high
population of neural cells could advance tissue engineering research.
Research has been successful at generating high relative fractions of stem cells
that express neuronal markers and exhibit neuronal characteristics. Usually, a variety of
growth factors are used for differentiation studies, but it is also possible to use
microfluidic technology as well 97-104. However, this research must be expanded to
include a 3D environment to move closer to a therapeutically relevant tissue engineering
approach.
1.5.4 Undifferentiation
One field of active research is maintaining cells in an undifferentiated
environment. Various markers are used show that cells are undifferentiated including
nanog, Oct4, and SSEA4, which are transcription factors. However, these markers are
not always equally expressed even in undifferentiated and pluripotent cells. Therefore,
more accurate and specific markers would help researchers to better quantify each cell
population. Certain scaffolds have been produced including those prepared from
hyaluronic acid (HA) that can maintain cells in an undifferentiated environment 105
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Often, synthetic scaffolds are preferred because any many applications have a long term
clinical goal which would be complicated with animal derived products.
1.5.5 Applications ofstem cells for ALS
Stem cells have recently been used as an experimental approach to treat ALS.
Most of this research is still being conducted in an animal model, and there is no FDA-
approved treatment for ALS that utilizes stem cells at the present time. However,
research in animal models is advancing rapidly, and progress is being made. Stem cells
are currently being tested as both supportive and replacement therapies for ALS, meaning
they could either reduce the rate at which motor neurons lose motor function and support
recovery, or serve as a template for new neural connections 106. For example, recently
researchers have shown that stem cell grafts that were transplanted into rats grew axons
and synapsed with neighboring cells 107-112. However, this research does not demonstrate
that there will be an improvement in recovery in movement and motor neuron function.
It is also becoming more clear that stem cells function together with their
microenvironment and other cells in a highly dynamic process over the ALS disease
progression, and that understanding this microenvironment will be critical in developing
therapeutically relevant treatments 106, 13, 114. Therefore, researchers are utilizing growth
factors and cytokines to control stem cell fate and improve motor neuron function in
ALS, or genetically engineering stem cells to upregulate expression of these growth
factors 115s. It is most likely that a combination approach will be required for successful
therapy "5
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1.5.6 Hydrogels and scaffolds
It is well-established that differences exist between cells grown in
two dimensional (2D) culture and cells found in their native 3D environment,
where they are surrounded by other cells and held in a complex network of
extracellular matrix (ECM). In developing tissue, a unique 3D microenvironment
with specific mechanical properties is formed by the ECM and various regulators.
Cellular microenvironments in vivo are immobilized within tissue and are bound
to ECM proteins that control mechanical stiffness by both chemical and
biophysical cues. This matrix elasticity has been shown to direct stem cell lineage
differentiation. However, it is still not clear how hESC sense 3D matrix elasticity
and translate that into self renewal and tumor formation signals. It is therefore
desirable to study cell differentiation in conditions that closely resemble the
natural 3D microenvironment because these cell matrix interactions may more
accurately represent in vivo conditions.
Three-dimensional scaffolds can be used to provide for a template for cell
proliferation and differentiation. Certain scaffolds may more accurately mimic the native
chemical and mechanical microenvironment of stem cells 116-120. A number of natural
and synthetic biomaterials have been used as cell scaffolds or for cell encapsulation (i.e.
Matrigel, hyaluronic acid, collagen, dextran etc.). However, most scaffolds do not have
the range of mechanical properties observed in vivo, and they lose strength and integrity
as cells proliferate.
Bioelastomer materials may provide a flexible scaffold for the 3D culture of cells.
Poly(glycerol sebacate) (PGS) was developed and shown to be biocompatibile both in
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vitro and in vivo 121, 122. A recent modification to PGS incorporated acrylate groups into
the polymer backbone that allowed for photo-polymerization with well-defined and
tunable mechanical properties resembling those of native soft tissue. Additionally, PGSA
was shown to support the culture of neuroblastomas and human embryonic stem cells in
vitro, and to be highly biocompatible in vivo. These studies could lead to new therapeutic
options for neurodegenerative diseases including ALS.
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1.6.0 Overall goals
The overall goal of this thesis is to make a contribution to scientific research by
developing next generation methods to diagnose and treat ALS. To this end, we have
conducted a three prong approach: 1) using a gadolinium tetanus toxin C fragment (Gd-
TTC) conjugate as a biomarker and early diagnostic, 2) using a nanoparticle-based drug
delivery system to bypass the blood brain barrier, penetrate the central nervous system,
and selectively target neurons, and 3) using a combination of natural and synthetic
polymers and growth factors in a 3D scaffold to enable human embryonic stem cell
differentiation into neurons for tissue engineering applications. We feel that given our
multidisciplinary expertise, this approach was the most efficient way to lead to high
impact solutions in an established field of research. It is our expectation that our
contribution will give ideas to others in the fields of drug delivery and neurodegenerative
research.
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1.7.0 Format of this document
This thesis document begins with an introduction of topics that are pertinent to
our overall goals, and then is organized into chapters the follow the specific aims of this
thesis. Following research chapters is a section focusing on future work for the logical
next steps following this thesis, and then a list of appendices. The appendices are
organized in a way such that they follow the format of the thesis chapters. They contain
an appendix summary, supplemental data, results from early experiments, and alternative
analysis of data that was previously presented. It is our goal that these data will further
guide researchers in what experiments are successful, and what experiments will be high
risk.
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Chapter 2: Development of a gadolinium tetanus toxin C
fragment conjugate biomarker for in vivo MRI visualization of
axonal retrograde transport in an amyotrophic lateral sclerosis
mouse model
2.1.0 Abstract
Amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease) is a neurodegenerative
disease with ineffective treatments at stopping the disease progression. We have
developed a gadolinium tetanus toxin C fragment conjugate (Gd-TTC) that was shown to
be highly visible under MRI, as determined by relaxivity experiments, and preserved the
neuroblastoma cell binding properties of the native protein in vitro. Live animal and ex
vivo MRI imaging showed that Gd-TTC transport could be visualized in the lumbar
spinal cord following a hindlimb intramuscular injection in mice. Histological analysis
confirmed these observations and confirmed that Gd-TTC was localized in the ventral
horn of motor neurons in the lumbar spinal cord. H&E staining showed that Gd-TTC was
well tolerated and biodistribution studies showed that it remained in high concentrations
near the site of injection after 48 hours. The Gd-TTC was used to quantify reductions in
axonal retrograde transport efficiency in a transgenic mouse model for ALS over the
disease progression. We therefore conclude that the Gd-TTC conjugate may have
applications as a minimally-invasive biomarker for neurodegenerative disease including
ALS.
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2.2.0 Introduction
Amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease) is a degenerative
disease that affects motor neurons, causing progressive paralysis and death, typically
within 5 years. An estimated 30,000 patients in the US are diagnosed with ALS; about
5,000 new cases arise every year. Although progress is being made in understanding the
causes of the disease and in developing new treatments for ALS, there is still much work
to be done 25, 36, 123, 124. Only a single compound is FDA-approved for ALS, and its benefit
is marginal 125-127. A major challenge in treating ALS and other neurodegenerative
diseases is directly targeting the central nervous system (CNS), a compartment that is
difficult to penetrate because it is protected by the blood-brain barrier (BBB). Several
methods have been used to penetrate the BBB including physical disruption by osmotic
pressure, nanoparticles, and retrograde transport, but progress is still needed in this field
36, 81, 84
Retrograde transport from distal axon terminals to the neuronal cell body is an
essential process in neurons; it is used to transport enzymes, vesicles, and mitochondria,
and is exploited by viruses and bacterial pathogens as a route to intoxicate motor neurons
128-131. The mechanism of retrograde transport is not well understood but is known to
involve microtubules, dynactin and dynein. Additionally, retrograde transport can be
divided into fast and slow components. Fast retrograde transport (speed -400mm/day) is
specific to membrane bound organelles, whereas slow retrograde transport (-5mm/day) is
used to transport soluble proteins that are not membrane-bound. It is becoming well
established that retrograde axonal transport of substances from the periphery to motor
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neuron cell bodies can be used as an effective route to penetrate the CNS and bypass the
BBB.
One problem in ALS therapy trials is that the disorder is usually not diagnosed
until symptoms are advanced, precluding possible benefit from early intervention. A
major limitation in devising therapies for ALS and other disorders affecting motor
neurons is the absence of biomarkers that permit relatively rapid testing of drug efficacy.
In the absence of such biomarkers, the gold standard in ALS therapeutics is analysis of
survival; unfortunately, survival analyses are lengthy and expensive. Our knowledge of
ALS disease progression has formed the basis for several transgenic animal models that
are widely used in research laboratories in these studies. However, it is likely that
physiological parameters that reflect the disease process could also serve as surrogate
markers for the disease. This concept is exemplified in the muscle disorder polymyositis,
for which heightened blood levels of the skeletal muscle enzyme creatine kinase
accurately reflect the activity of the underlying muscle inflammation. To date, the only
physiological indicators of motor nerve function are electromyographic assessments of
the integrity of the motor unit. Regrettably, these measurements do not closely correlate
with the stage and activity of the disease. Confounding the situation in ALS, these
parameters, like the clinical presentation, do not become diagnostically useful until the
disease is well advanced. For these reasons, it is striking that in experimental models of
motor neuron disease, such as transgenic ALS mice, the process of axonal transport
appears to be significantly deranged early in the course of motor neuron disease. This
raises the possibility that techniques that allow one to non-invasively and accurately to
define rates of axonal transport in humans would greatly enhance the diagnosis of motor
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neuron diseases. Such methods would potentially serve as the desired biomarkers for
motor neuron dysfunction that would facilitate and accelerate drug testing.
One important element in our early studies has been the use of a non-toxic
fragment of tetanus toxin, known as tetanus toxin C fragment or TTC. TTC is the
neuronal binding portion of the native tetanus toxin. It demonstrates extremely high
affinity binding to the neuronal ganglioside GTlb that is the tetanus receptor. Because
GT1b is located selectively the surfaces of neurons, TTC shows highly selective neuronal
binding. Moreover, once it binds to neurons, TTC, like tetanus itself, is readily taken up
in endosomes and efficiently transported via retrograde transport from the distal axonal
terminus to the neuronal cell body. We and others have found that TTC binding and
transport in neurons is quantitative both in vitro and in vivo; TTC is routinely used in
experimental systems to provide quantitative assessment of retrograde axonal transport in
motor neurons. The overall goal of this study is to develop a minimally invasive
biomarker by conjugating gadolinium, a clinically used and highly MRI visible molecule,
to TTC and to evaluate this as a biomarker for ALS and other neurodegenerative
diseases.
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2.3.0 Methods
2.3.1 Synthesis of Gd-TTC and Gd-BSA: A gadolinium protein labeling kit (BioPAL;
Worcester, MA) was used to chemically conjugate gadolinium to TTC (Roche Applied
Science; Indianapolis, IN) and BSA (Sigma; St. Louis, MO), according to the
manufacturer's directions. Briefly, 4 mg protein was dissolved in 1.4mL 0.2M carbonate
buffer (pH 8.9, final protein concentration 2.86mg/mL). 393uL of IM sodium acetate
containing IM sodium hydroxide and 6.66uL IM GdCI3 were added in sequence to
7.3umol of an amine-reactive gadolinium chelate. The chelate was vortexed for
approximately 2 minutes and allowed to incubate for 5 minutes at RT. 100uL of the
subsequent chelate was incubated with 4mg of the protein under gentle stirring for 2
hours. Subsequent product was dialyzed with PBS for 2 hours (RT), 2 hours (RT), and
overnight (4'C) against a 10 kDa dialysis cassette (Pierce Biotechnology). Dialysis
medium was exchanged between each dialysis period. Protein was lyophilized and stored
at -20 0 C until use.
2.3.2 Protein characterization: Gadolinium conjugates were prepared as described above.
Protein samples (BSA, Gd-BSA, TTC, or Gd-TTC) were mixed 1:1 with a dilutent (95%
blue, 5% beta-mercaptanol) and heated for 5 minutes at 95C to denature the protein. 20uL
of protein samples and 10uL of the ladder standard were loaded into a 15% SDS gel
(COMPANY) in lx tris-glycine buffer. BSA and Gd-BSA protein concentrations were
20ug/mL, and TTC and Gd-TTC protein concentrations were 50ug/mL. The gel was run
for 55 minutes at 200V, stained in Coomassie blue solution for -3h, and then destained in
acetic acid solution overnight. Gels were photographed using a digital camera.
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2.3.3 Culture of N18-RE-105 neuroblastoma cells: N18-RE-105 neuroblastoma cells
were grown with previous methods as those previously described 85. Briefly,
neuroblastoma cells were cultured in DMEM and supplemented with HAT supplement
(100uM sodium hypoxanthine, 400nM aminopterin, 16uM thymidine), 10% FBS, and 1%
penicillin/streptomycin. All cells were grown in filtered flasks in an incubator at 95% air
and 5% carbon dioxide. Media was changed every 48 hours, and cells were passaged with
EDTA-trypsin when confluent. All media reagents were purchased from Invitrogen. N18-
RE-105 cells were a generous gift of Dr. Jonathan Francis at the Massachusetts General
Hospital.
2.3.4 Cell binding assay andflow cytometry: N18-RE-105 cells (106 cells/mL) were
removed from culture and incubated with Gd-BSA, TTC, or Gd-TTC (final protein
concentration 10ug/mL) in 500uL of media containing 10% FBS for 60 minutes on ice.
Cells were then incubated with a mouse monoclonal antibody against TTC (Roche
Applied Science, Indianapolis, IN) at 10ug/mL for 60 minutes on ice. Cells were then
incubated with a FITC-conjugated fluorescent anti-mouse secondary antibody with a 1:50
final dilution for 45 minutes on ice. Cells were washed with PBS containing 1% BSA 3x
by centrifugation (3 minutes, 4C, 1500rpm) in between each incubation and after the final
antibody incubation. Negative controls lacking protein, primary antibody, or secondary
antibody were conducted analogously to verify antibody specificity. Cells were analyzed
using a FACScan flow cytometer (Becton Dickinson) to measure fluorescence (488nm
excitation, 530nm and 650nm emission) as previously described. Briefly, cells were
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incubated with propidium iodide (5ug/mL), and cell populations were gated based on
forward/side scatter and propidium iodide fluorescence to remove debris and dead cells
from analysis. A total of at least 10,000 gated events were obtained for each sample. Data
was analyzed using FlowJo software (Tree Star) to generate histograms of each sample.
2.3.5 MRI relaxivity measurements: Gd-TTC and Gd-BSA dissolved in PBS with final
protein concentrations between 5mg/mL to 40ug/mL in 1:2 dilutions and placed in a 96
well plate. The signal intensity was determined at seven different inversion times for each
protein concentration that were determined to give linear range fits with signal intensity
(inversion times between 10 milliseconds and 10 seconds) using a Bruker NMR Minispec
(Billerica, MA) as previously described 45. Relaxivity values were determined using the
following equation: M, (TI) = M (1- e"" ; T = 1 / R,, where M(TI) represents the signal
intensity at each inversion time, Moo represents the signal intensity at high inversion
times, TI represents each inversion time, and R1 represents the signal relaxivity.
Relaxivity values were determined for each protein concentration using best-fit functions
in OriginLab software and plotted as a function of protein concentration (OriginLab,
Northhamption, MA). Each reported value represents the cumulative average of over
5,000 independent measurements.
2.3.6 MRI imaging qf Protein Contrast (1.5T): Gd-TTC and Gd-BSA were dissolved in
PBS at concentrations between 3mg/mL and 190uL/mL in 1:2 dilutions and placed in a
96-well plate. PBS was placed in all wells and in the space between wells to provide a
direct comparison in magnetic contrast and to minimize artifacts induced by the plate.
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Samples were pulsed with a 90-180-90 inversion recovery MRI protocol using a 1.5T
magnet with inversion times varied between 20-4000ms. Images were captured and
processed using ImageJ software (National Institutes of Health, Bethesda, MD) for
analysis.
2.3.7 Animal study approval and injections: All animal protocols were approved by the
SRAC committee on animal care at the Massachusetts General Hospital. Mice (8-16
weeks) were anesthetized with 130mg/kg ketamine and 10mg/kg xylazine via an
intraperitoneal injection. Mice were shaved and an incision was made exposing the right
quadriceps under aseptic conditions. Three 25uL injections containing Gd-TTC, Gd-
BSA, Eu-TTC, or Eu-BSA (20mg/mL) or a PBS negative control were made into the
muscle using a 26G Hamilton syringe (1.5mg protein injected). The wound was sutured
and the animal was allowed to recover.
2.3.8 9.4T MRI live animal imaging (in vivo): Animals were anesthetized under
isoflurane/N 20/0 2 (1.5-2% isoflurane) and restrained in a headholder at 38C using a
water blanket. A custom-made MRI surface coil was secured on the animal's back and
centered around the lumbar spinal cord region. Animals were placed in a 9.4T magnetic
field for imaging. Axial cross sections were taken of the animals at various echo times
(20-4000ms) and recovery times (5-50ms) using a standard 90-180-90 inversion recovery
MRI sequence, similar to those previously described . Section thickness ranged between
0.5-1.5mm, with a 2.5x2.5cm FOV, and resolution up to 256x256. Images were
processed using ImageJ software (National Institutes of Health, Bethesda, MD).
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2.3.9 Transcardial perfusion and spinal cord isolation: Animals were sacrificed using
CO 2 asphyxia. An incision was made opening the animal's sternum, and a 30G needle
was inserted into the left ventricle. The right atrium was cut, and the animal was perfused
with PBS until blood cleared. Perfusion medium was switched to 4% paraformaldehyde
solution and perfused for 15 minutes. The spinal cord was gently removed from the
vertebrate using forceps and blunt dissection, and cut into cervical, thoracic, and lumbar
sections. Tissue was fixated in 4% paraformaldehyde overnight. For
immunohistochemistry experiments, tissue was incubated in 10% sucrose for 12 hours,
and then in 30% sucrose solution for 12 hours, each overnight at 4C until sectioning.
Tissue for MRI ex vivo imaging and hematoxylin/eosion staining was stored in PBS until
imaging or mounting.
2.3.10 14T MRI spinal cord imaging (ex vivo): The spinal cord from Gd-TTC injected
mice was fixed as described above and placed in an NMR tube in non-magnetic Fluoro
solution. Axial cross sections were taken of the spinal cord at various echo times (20-
1000ms) and recovery times (5-50ms) using a standard 90-180-90 inversion recovery
MRI sequence, similar to those previously described . Section thickness ranged between
0.5-1.5mm, with a 2.5x2.5cm FOV, and resolution up to 256x256. Images were
processed using ImageJ software (National Institutes of Health, Bethesda, MD).
2.3.11 Hematoxylin and Eosion staining: Spinal cords of PBS, TTC, or Gd-TTC injected
mice were prepared as described above. Tissue was dehydrated in graded ethanol (70 -
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100%), embedded in paraffin, sectioned axially using a microtome (4um), and stained
with H&E.
2.3.12 Immunohistochemistry staining for TTC and NeuN: Mice injected with either TTC
or Gd-TTC were sacrificed 24-48 hours post injection. Samples were placed in Tissue-
Tek OCT gel (Sakura Finetechnical Co, Tokyo, Japan), frozen on dry ice, and stored at -
80'C till cryostat sectioning. Tissue was blocked and permeabilized in using PBS
containing 0.3% Triton-100 and 10% FBS for lh at RT. Tissue was incubated with rabbit
anti-TTC (1:1000, Rockland Immunochemicals; Gilbertsville, PA) and mouse anti-NeuN
(1:500, Chemicon; Billerica, MA) containing 0.1% Triton-100 and 10% FBS overnight at
4C. Tissue was washed in PBS 3x to remove unbound primary antibodies. Tissue was
incubated with Cy3 conjugated goat anti-rabbit (1:1000, Jackson Immunoresearch; West
Grove, PA) and FITC conjugated goat anti-mouse (1:100, Sigma; St. Louis, MO)
containing 0.1% Triton-100 and 10% FBS for 1.5 hours at RT. Tissue was washed 3x in
PBS to remove unbound secondary antibody. Tissue was mounted using Vectashield
fluorescent mounting medium containing DAPI (Vector Laboratories; Burlingame, CA)
and imaged using a Nikon E800 microscope.
2.3.13 Biodistribution (in vivo) and neutron irratiation analysis: Europium-conjugated
TTC and BSA were prepared analogously to preparation of gadolinium conjugated
described above, but using EuCl3 instead of GdC13 and a europium protein conjugation
kit from BioPAL (Worcester, MA). Mice were injected with Eu-TTC, Eu-BSA, or PBS.
Mice were sacrificed 48 hours post injection, and the following organs were harvested
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and weighed: spinal cord, blood, spleen, heart, lungs, liver, kidney, brain, injected
quadriceps, and uninjected quadriceps. Tissue was oven dried at 70C overnight and sent
to BioPAL (Worcester, MA) for neutron irradiation analysis and quantification of
europium content in each tissue using a short activation protocol. Briefly, tissue was
exposed to a field of thermal neutrons for one minute. Tissue was stored for 24 hours to
allow short-lived activation products to decay. Spectroscopic analysis was performed on
each sample and reported as disintegrations per minute (dpm) measured for europium.
Measurement normalization and corrections were made at BioPAL to account for inter-
radionuclide crossover and tracer decay during the counting period. Instruments were
calibrated to account for differences in sample volume and geometry. All sample analysis
was conducted within one week of the removal of tissue.
2.3.14 Image analysis and quantification: ImageJ (NIH, Bethesda, MD) and Matlab
(Mathworks; Natick, MA) were used for all image processing. A region of interest
corresponding to the ventral horn in the lumbar spinal cord was determined, and ImageJ
was used to determine pixel intensity over the entire region and automatically grouped
into 256 bins. Data was then inputted into Matlab and fit to a normal distribution using
built-in functions. Average distribution values for each corresponding side were analyzed
and, sorted into positive and negative sides, and expressed as a normalized ratio for each
set of wildtype or ALS animals.
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2.4.0 Results and Discussion
2.4.1 Conjugation ofgadolinium to TTC
We hypothesized that gadolinium could be conjugated to TTC to produce an MRI
contrast agent biomarker for axonal retrograde transport. We reasoned that gadolinium 1)
has high TI magnetic contrast properties, 2) is widely used clinically as an imaging agent,
and 3) is small in molecular weight relative to the size of TTC and is therefore expected
to minimally affect transport. Gadolinium was incubated with a functionalized chelate
and subsequently conjugated to primary amine groups on TTC and purified by dialysis
(see Figure la). Gadolinium was also conjugated to BSA and the resulting conjugate was
used as a control protein for all experiments, having both molecular weight and amino
acid composition similar to that of TTC.
To verify successful conjugation and to determine whether unconjugated protein
remained in each sample, we ran Gd-TTC and Gd-BSA against unconjugated controls on
an SDS page gel and processed samples with a Coomassie blue stain (see Figure ib).
Both Gd-TTC and Gd-BSA showed higher molecular weights and wider distributions
than the respective unconjugated TTC or BSA protein, suggesting successful chelate
conjugation. Based on molecular weight standards and neglecting any effect of the
chelate on protein mobility, the ratio of conjugated chelate to protein was estimated to be
7.1 for Gd-TTC and 5.6 for Gd-BSA. Additionally, bands corresponding to unconjugated
protein were absent in Gd-TTC and Gd-BSA samples, suggesting that gadolinium
conjugation was successful and products contained only trace unconjugated protein.
2.4.2 Characterization of Magnetic Relaxivity
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We characterized the MRI relaxivity properties of Gd-TTC and Gd-BSA, 1) to
determine the approximate number of gadolinium molecules that were conjugated to each
molecule of protein, and 2) to obtain relaxivity values that could be used in subsequent
studies to quantify rates and efficiency of retrograde transport in vivo. The magnetic
contrast of conjugates was verified by visual inspection using a Ti-weighted 1.5T MRI
sequence in a phantom 96-well plate containing 1:2 serial dilutions of Gd-TTC and Gd-
BSA (Figure Ic). In a separate experiment, preparations containing Gd-TTC and Gd-
BSA in various concentrations (39ug/mL - 5mg/mL in 2:1 serial dilutions) were analyzed
by a modified Bruker mini-spec auto NMR to determine conjugate relaxivity. For each
conjugate at each concentration, an inversion recovery sequence was run and signal
intensity was quantified to determine R1 (Figure Id-e). The R1 value was plotted as a
function of inversion time for each concentration and fit to a linear function to determine
the relaxivity of each contrast agent (Figure If). The relaxivity of Gd-TTC and Gd-BSA
were determined to be 0.029 uM-'s-1 and 0.051 uM 1-s 1 , respectively. Both Gd-TTC and
Gd-BSA exhibited similar behaviors and had linear relaxation times as a function of
concentration (R2 > 0.999), suggesting that there was minimal free gadolinium in the
solution remaining after dialysis purification.
2.4.3 Neuronal binding of Gd-TTC in vitro
Gadolinium conjugation could alter the ability of TTC to bind to neurons. We
incubated TTC, Gd-TTC, and Gd-BSA with N18-RE-105 neuroblastoma cells that are
known to express the GTIB ganglioside receptor for TTC on their surface. We incubated
each preparation with a primary antibody against TTC followed by a fluorescent
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secondary antibody, with appropriate washes in between the incubations. All incubations
were done on ice to minimize receptor internalization that may affect binding in
subsequent steps. Cells analyzed on flow cytometry showed high levels of fluorescence
for positive controls TTC and Gd-TTC, but not in Gd-BSA negative controls or
preparations lacking either a primary or secondary antibody (Figure lg-i). In some
preparations containing a secondary antibody, background fluorescence was observed;
however, this was almost two orders of magnitude lower than TTC or Gd-TTC samples,
and is expected to minimally contribute to the positive signal (Table 1). Interestingly, Gd-
TTC samples exhibited a dual peak, suggesting that protein conformation of Gd-TTC
may have been slightly affected by the conjugation. However, the overall in vitro cell
binding properties of TTC were preserved in the Gd-TTC conjugate.
2.4.4 Live animal 9.4T MRI imaging
Wildtype mice were injected with Gd-TTC unilaterally in the quadriceps and
allowed to recover for 24-48h prior to in vivo 7.4T MRI imaging of the spinal cord. T1-
weighted images of the lumbar section of the spinal cord showed areas of high magnetic
contrast that were concentrated on the injection side of the animal (Figure 2, top).
Contrast was observed in multiple spinal cord sections that were not adjacent, possibly a
result of discrete clusters of motor neurons originating from different areas within the
lumbar spinal cord. However, the localization of contrast was more central than was
expected given known neuroanatomy motor neuron innervation in the ventral horn. This
was observed consistently in several animals that were injected, and with different
preparations of contrast agent. Additionally, contrast intensity was variable in different
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animals suggesting that precise quantification of retrograde transport rates and efficiency
may be difficult using this approach. Independent T2-weighted imaging scans of non-
injected animals verified the interface of the white/gray matter, spinal cord, cerebral
spinal fluid, and vertebrae (data not shown). These imaging results taken together are
consistent with previously published studies of the mouse spinal cord in vivo and ex vivo
imaging132, 133. However, the precise localization of the contrast agent within the spinal
cord could not be determined because of visible motion artifacts (i.e. from animal
breathing) and we therefore turned to higher resolution imaging of the spinal cord of
excised mouse spinal cords.
2.4.5 Ex Vivo 14T MRI imaging (high resolution)
Spinal cords were excised from Gd-TTC injected animals and imaged ex vivo
using a 14T MRI to generate high resolution images that were free from fat or motion
artifacts. In a Ti-weighted MRI sequence, unilateral magnetic contrast was observed in
the ventral horn of the lumbar region (Figure 2, middle). Images from individual spinal
cord sections were processed by examining regions of similar magnetic contrast to further
investigate regions of high magnetic contrast intensity (Figure 2, bottom). Consistent
with previous observations, there was variability in the contrast intensity and localization
between the animals 47, 132. However, contrast was observed to be primarily localized
within expected regions, consistent with previous characterizations of TTC transport in
motor neurons .
2.4.6 Immunohistochemistry and Hematoxylin/Eosion Staining
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Spinal cords from Gd-TTC, TTC, or PBS unilaterally injected mice were fixed,
sectioned, and immunostained against TTC and NeuN to verify axonal retrograde
transport and further explore neuronal localization within the spinal cord. Spinal cord
sections showed unilateral positive staining for TTC concentrated in the ventral horn of
the lumbar region of the spinal cord (Figure 3). Furthermore, this was co-localized with
neuronal positive staining. Spinal cord sections from TTC and Gd-TTC injected mice
showed similar localization, intensity, and distribution. PBS or Gd-BSA injected animals
showed characteristic NeuN staining, but only background levels of TTC staining (data
not shown). These results suggest that axonal retrograde transport properties of TTC are
preserved in the Gd-TTC conjugate.
To determine whether any signs of acute inflammation were observed as a result
of the presence of the Gd-TTC conjugate, we sectioned and stained spinal cords with
hematoxylin and eosion. No differences were observed between injected animals (either
TTC or Gd-TTC) and PBS negative controls (Figure 4, top). These results suggest that an
injection of the Gd-TTC conjugate is well tolerated and biocompatible. This is consistent
with previous observations following the injection of TTC in rodents and the established
safety profile of gadolinium compounds used in the clinic 134-139
2.4.7 Biodistribution (in vivo)
We prepared europium conjugates to TTC and BSA to determine the in vivo
biodistribution of Gd-TTC relative to that of non-specific Gd-BSA. Eu-TTC and Eu-BSA
were prepared analogously to the gadolinium conjugates using the same amine-reactive
chelate. Both europium and gadolinium are lanthanide rare earth elements with similar
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molecular weights and are expected to attach to the chelate and subsequently the protein
in a stable non-reversible reaction. Therefore, the Eu-TTC biodistribution is expected to
resemble that of Gd-TTC. Europium can be neutron activated, generating unstable
radioactive byproducts that can be measured to quantify the amount of conjugate present
in tissue.
Adult mice were anesthetized and the quadriceps injected unilaterally with Eu-
TTC or Eu-BSA. Mice were sacrificed and the major organs removed 48 hours post
injection (spinal cord, blood, spleen, heart, lungs, liver, kidney, brain, injected
quadriceps, and uninjected quadriceps). Organs were processed, and analyzed using
neutron activation to determine semi-quantitative levels of Eu-TTC and Eu-BSA in each
organ (Figure 4, bottom). After 48 hours, the highest concentration of both Eu-TTC and
Eu-BSA were found in the quadriceps near the site of injection. These were not
significantly different from each other, but both were higher than their respective
uninjected quadriceps (p<0.01, n=4). Eu-TTC levels were found to be higher than Eu-
BSA in the kidney (p<0.001, n=4) and lower than Eu-BSA in the spleen (p<0.01, n=4),
lungs (p<0.05, n=4), and liver (p<0.01, n=4). This is likely a result of relative GTIB
ganglioside concentrations throughout the animal, which are known to be primarily
expressed in neurons but also expressed in other organs. We were not able to detect any
conjugate in either the brain or the spinal cord. This is likely because only a small amount
of the overall injected dose is transported to the central nervous system, or because the
neutron activation assay was not sensitive enough to detect the conjugate at the injected
levels. It is also possible that a different timepoint would yield detectable levels of the
contrast agent within the CNS. However, based on our previous work, we have seen high
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levels the native TTC protein at 24-48 hours. These results therefore suggest that only a
small amount of the overall injected dose reach the brain and spinal cord, but that this
amount can be detected both by MRI and by immunochemistry.
2.4.8 Gd-TTC as a Biomarkerfor ALS (in vivo)
We conducted proof-of-concept studies to test our hypothesis that the Gd-TTC
conjugate could be used as a minimally invasive biomarker for neurodegeneration,
utilizing a transgenic mouse model for amyotrophic lateral sclerosis. The G93A mouse
model that we used has been well-characterized and has a known disease progression that
resembles human ALS: 1) at 60 days, mice are visibly asymptomatic, 2) at 90 days,
symptoms including decreased muscle strength and mobility appear, and 3) at 120 days,
mice are highly immobile and have significantly impaired motor function 140-143
Transgenic ALS mice and wildtype controls were injected with Gd-TTC and sacrificed
48 hours post injection. Spinal cords were removed for 14T MRI spinal cord analysis,
and sectioned for immunohistochemistry staining of TTC on the same spinal cords. MRI
images of 60 day ALS animals showed similar magnetic contrast as wildtype controls
that was reduced in 120 day ALS animals (Figure 5, top left). Similar trends were
observed with immunohistochemistry staining for TTC (Figure 5, top right). Sections
taken from MRI images and immunohistochemistry staining from 90 day ALS animals
showed visibly similar intensity and localization as those from 60 day ALS and wildtype
mice (data not shown).
Images from injected animals (n=3-4 in each group) were analyzed using ImageJ
software to generate a histogram of known signal intensity in each lumbar horn and
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grouped into 256 bins of equal size. This data was then processed in Matlab to fit each
histogram to a normal distribution function, and the mean distribution value was used to
compare different samples. Data was sorted such that paired values were always
expressed as a ratio of the positive side to the negative side and expressed as a
normalized ratio. MRI images showed no differences between wildtype, 60 day ALS, and
90 day ALS mice, but a significant reduction in intensity for 120 day ALS mice
(p<0.001). Images processed from immunohistochemistry stains showed no difference
between wildtype and 60 day ALS mice, but a reduction in signal intensity for 90 day
ALS mice relative to wildtype (p<0.001) and reduced for 120 day ALS mice relative to
both wildtype and 60 day ALS mice (p<0.001). Normalized signal ratios were higher for
immunohistochemistry results than MRI, possibly a result of signal amplification during
primary and secondary antibody incubation. These results taken together suggest that
there are changes in axonal retrograde transport intensity that can be quantified
throughout ALS disease progression. It should also be noted that TTC is transported via
fast retrograde transport, which has previously been shown to not be impaired during
ALS disease progression. These data suggest that there may be differences in the
mechanism of transport for molecules that via fast axonal transport that remain unknown.
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2.5.0 Conclusions
We have developed a novel gadolinium tetanus toxin C fragment conjugate (Gd-
TTC) that was characterized by gel electrophoresis, MRI relaxivity, and in vitro cell
binding to N18-RE-105 neuroblastoma cells. Gd-TTC was retrogradely transported from
peripheral muscle to the spinal cord following a unilateral injection in mice as evidenced
by 9.4T live animal in vivo and 14T ex vivo MRI imaging and immunohistochemistry
staining for TTC and NeuN of the spinal cord. H&E staining and biodistribution studies
showed that Gd-TTC was well tolerated and bioavailable. We conducted a proof-of-
concept study and showed that the Gd-TTC conjugate could be used to quantify
differences in retrograde transport that were observed in the ALS transgenic mouse
model during the disease progression. The Gd-TTC conjugate could provide a biomarker
for neurodegeneration and make earlier diagnostics possible.
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2.7.0 Figures and Figure Legends
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2.7.1 Figure 1 - Synthesis and characterization of Gd-TTC: (a) Schematic of gadolinium
tetanus toxin C fragment contrast agent (not drawn to scale) showing stable amine site
conjugation. (b) Coomassie blue staining of Gd-TTC, TTC, Gd-BSA, and BSA with
protein standard after gel electrophoresis separation showing successful conjugation of a
pure product with a narrow size distribution. (c) Visual verification of magnetic contrast
of conjugates in a 96-well plate pulsed with a 90-180-90 inversion recovery MRI
protocol using a 1.5T magnet. Concentrations for each sample ranged from 3mg/mL to
190uL/mL in 1:2 dilutions. PBS was placed in wells around all samples to minimize
artifact from plate inhomogenities. (d-e) Magnetic relaxivity curves for Gd-TTC (d) and
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Gd-BSA (e) as measured using a modified NMR-Mouse. Concentrations for each sample
ranged from 5mg/mL to 40ug/mL in 1:2 dilutions. (f) Linear fit analysis for Gd-BSA
(black) and Gd-TTC (gray) for concentration dependent T1 values as determined for each
relaxivity value determined by the following equation: M () = M ( - e' ); = /
Linear behavior in both contrast agents indicates the absence of free gadolinium in
solution and successful conjugation. (g-i) Flow cytometry analysis of N18-RE-105
neuroblastoma cells after incubation on ice with TTC (g), Gd-TTC (h), and Gd-BSA (i)
and PBS (red), mouse monoclonal antibody against TTC (blue), secondary anti-mouse
fluorescent antibody (green), and monoclonal and secondary antibody (orange) with
appropriate washes, showing that gadolinium conjugation to TTC preserves
neuroblastoma binding.
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2.7.2 Figure 2 -MRI imaging of Gd-TTC injected wildtype mice: (Top) Live animal
(anesthetized) in vivo imaging of a mouse spinal cord 24 hours following a unilateral
quadriceps injection of Gd-TTC showing regions of enhanced contrast. Images were
obtained using a 9.4T MRI and were the result of six averages scanned with Ti-weighted
scan with a TE of 1000ms, a TR of 14.8ms, Imm interslice average, a field of view of
1.4cm x 1.4cm, and a resolution of 256x256. (Middle, Bottom) Representative high
resolution (ex vivo) images of excised spinal cords removed from mice 48 hours
following a unilateral quadriceps injection of Gd-TTC. Images were obtained using a 14T
MRI and were the result of six averages scanned with a TE of 300ms, a TR of 3.4ms,
0.85mm interslice average, a field of view of 9.5mmx9.5mm, and a resolution of
256x256 (middle). (bottom) Images were processed using Matlab to highlight regions of
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equal magnetic contrast intensity for 10 isolines (left) and for 50 isolines (right) to show
relative localization and intensity of the contrast agent. Magnetic contrast is visible in the
ventral horn in the lumbar section of the spinal cord.
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2.7.3 Figure 3 - Immunohistological staining for TTC: Mice were injected unilaterally
with TTC or Gd-TTC and sacrificed 48 hours post injection. The lumbar spinal cord was
sectioned and stained for TTC (red), NeuN (green), and DAPI (blue). Images were
obtained at 4x magnification (top), 20x magnification (middle) and 40x magnification
(bottom) that were centered on each side of the ventral horn of the spinal. TTC stained
sections (left) show a high level of asymmetry between the right side and the left side of
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the spinal cord in both TTC and Gd-TTC. NeuN staining was similar between TTC and
Gd-TTC injected mice (middle). Merged images showed that TTC and NeuN positive
staining were co-localized suggesting specific neuronal uptake of Gd-TTC that exhibits
similar properties as TTC.
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2.7.4 Figure 4 - Haematoxylin and Eosin Staining and in vivo biodistribution: (Top)
Mice were injected with PBS, TTC, or Gd-TTC unilaterally and sacrificed 48 hours post
injection. Lumbar spinal cords were sectioned, stained with H&E, and imaged for PBS
(top), TTC (middle), and Gd-TTC (bottom), at 4x (left) and 20x (right) magnification. No
observable asymmetries between the right and left side, or between the each material
injected were observed, suggesting only mild acute inflammation at the spinal cord as a
result of the TTC or Gd-TTC conjugate injection and transport. (Bottom) Eu-TTC or Eu-
BSA were injected unilaterally and mice were sacrificed 48 hours post injection. Tissue
from the following tissue was removed, neutron activated, and analyzed for radiolabeled
product: spinal cord (SC), blood, spleen, heart, lungs, liver, kidney, brain, injected
quadriceps, and uninjected quadriceps. Eu-TTC (black) showed higher levels in the
kidney, and lower levels in the liver, spleen, and lungs. Neither Eu-TTC or Eu-BSA were
detectable in the spinal cord or brain, suggesting a small amount of overall injected dose
is transported to this tissue. A high level of agent remained at the site of injection
indicating prolonged opportunity for transport via motor neurons.
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Figure 5
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2.7.5 Figure 5 - Gd-TTC as a biomarker for retrograde transport in ALS mice: (Top left)
14T MRI images of 60 day and 120 day ALS mice 48 hours following a unilateral
quadriceps injection of Gd-TTC. A high concentration of Gd-TTC is observed on a single
side in the ventral horn at 60 days, with reduced contrast differences after 120 days. (Top
right) Mice were immunostained for TTC showing consistent observations and reduced
axonal retrograde transport in 120 day ALS animals. (Bottom) Both MRI (left) and
immunohistochemistry differences were quantified and expressed as a normal ratio of
positive:non-positive signal demonstrating differences in transport efficiency over the
ALS disease progression.
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Chapter 3: Tetanus toxin C fragment conjugated nanoparticles
for targeted drug delivery to neurons 85
3.1.0 Abstract
The use of nanoparticles for targeted drug delivery is often facilitated by specific
conjugation of functional targeting molecules to the nanoparticle surface. We compared
different biotin binding proteins (avidin, streptavidin, or neutravidin) as crosslinkers to
conjugate proteins to biodegradable nanoparticles prepared from PLGA-PEG-biotin
polymers. Avidin gave the highest levels of overall protein conjugation, whereas
neutravidin minimized protein non-specific binding to the polymer. The tetanus toxin C
fragment (TTC), which is efficiently retrogradely transported in neurons and binds to
neurons with high specificity and affinity, retained the ability to bind to neuroblastoma
cells following amine group modifications. TTC was conjugated to nanoparticles using
neutravidin, and the resulting nanoparticles were shown to selectively target
neuroblastoma cells in vitro. TTC-conjugated nanoparticles have the potential to serve as
drug delivery vehicles targeted to the central nervous system.
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3.2.0 Introduction
Biodegradable polymers, including polylactic acid (PLA) and poly(lactic-co-
glycolic acid) (PLGA), have been used to create nanoparticles and microparticles that
encapsulate a variety of therapeutic compounds over time with favorable safety profiles
69. Polyethylene glycol (PEG) reduces systemic clearance rates in vivo 76, and the
functionalization of polymer end groups and subsequent conjugation of targeting moieties
(proteins, aptamers, and peptides) permits local drug delivery and reduced systemic
toxicity 75. N-hydroxysuccinimide (NHS) and 1-Ethyl-3-(3-dimethylaminopropyl)-
carbodiimide (EDC) are commonly used for protein conjugation and can generate a stable
covalent bond. One problem when using this and other similar techniques is the presence
of intermediaries with short half lives, which may lead to inefficient conjugations. In
contrast, non-covalent interactions between biotin and its binding proteins (avidin,
streptavidin, and neutravidin) are highly specific and do not involve unstable
intermediaries. Biotin binding proteins have previously been used to conjugate proteins to
the surface of microparticles and nanoparticles 144-150
A major challenge in treating neurodegenerative diseases is directly delivering
therapies to neurons in the central nervous system (CNS). The CNS is difficult to
penetrate because it is protected by the blood-brain barrier (BBB) 151. Recently,
nanoparticles synthesized from poly(butylcyanoacrylate) with polysorbate 80 152, and in
separate experiments liposomes conjugated to the antibody to the transferrin receptor,
have been used to bypass the BBB 153
Retrograde transport from distal axon terminals to the neuronal cell body is an
essential process in neurons; it transports enzymes, vesicles, and mitochondria, and is
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exploited by viruses and bacterial pathogens as a route to intoxicate motor neurons 154. It
is apparent that retrograde axonal transport of substances from the periphery to motor
neuron cell bodies can effectively penetrate the CNS and bypass the BBB 36. Thus, it may
be possible to target nanoparticles to CNS neurons by exploiting retrograde neuronal
transport.
One important element in our early studies has been the use of a non-toxic
fragment of tetanus toxin, known as tetanus toxin C fragment or TTC 84. TTC is the
neuronal binding portion of the native tetanus toxin. TTC demonstrates extremely high
affinity binding to the neuronal ganglioside GTlb that is the tetanus receptor, which is
located selectively on the surfaces of neurons 155. Moreover, once TTC binds to neurons,
it is readily endocytosed and efficiently carried via retrograde transport from the distal
axonal terminus to the neuronal cell body 55, 156
In this report, we compare the ability of different biotin binding proteins (avidin,
streptavidin, and neutravidin) to specifically conjugate a protein to the surface of PLGA-
PEG-biotin nanoparticles. We describe the use of TTC conjugated PLGA-PEG-biotin
nanoparticles as a drug delivery system that selectively targets neuronal cells in vitro.
This system may have applications for delivering therapeutics to neurons affected by
neurodegenerative diseases and may allow retrograde transport delivery to the central
nervous system.
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3.3.0 Methods
3.3.1 Preparation ofPLGA-PEG-COOH: One gram of PLGA-COOH (20kDa MW,
Lactel Absorbable Polymers) was dissolved in 4mL dichloromethane and stirred at RT in
the presence of NHS (1:8 PLGA:NHS molar ratio) and EDC (1:8 PLGA:EDC molar
ratio) to form an amine reactive ester. Unreacted NHS and EDC were removed using a
solution containing 70% ethyl ether and 30% methanol. Trace solvents were removed
under vacuum for 2 hours. The polymer was re-dissolved in 5 mL chloroform and
incubated under gentle stirring overnight with HC1.NH2-PEG-COOH (3400MW, Nektar
Therapeutics) or NH2-PEG-Biotin (3400MW, Laysan Bio) (1:1.3 PLGA:PEG molar
ratio). N-Ethyldiisopropylamine (DIEA) was also added to the HC1.NH2-PEG-COOH
solution. The polymer was washed with methanol to remove unreacted PEG. The final
PLGA-PEG-COOH/Biotin product was recovered using ethyl ether, vacuum dried for 2h,
and stored at -20 0C until use.
3.3.2 NMR analysis: Polymer was dissolved in deuterated chloroform (5-10mg/mL) and
placed in a glass NMR tube. Polymer was analyzed on a Bruker Avance 400Mhz NMR
spectrometer using standard proton NMR to verify PEG conjugation to PLGA. Samples
were analyzed for the presence of any intermediary products and to quantify the extent of
conjugation.
3.2.3 Preparation of nanoparticles (nanoprecipitation): Ten milligrams of PLGA-PEG-
COOH or PLGA-PEG-biotin was dissolved in 1.5mL acetone, and fluorescent
nanoparticles were made by also adding 200ul of coumarin-6 (1mg/mL in acetone, Sigma
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Aldrich) 57. Nanoparticles made of different mixtures of -COOH and -Biotin polymers
were prepared in the same way, similarly to methods previously described 158. Five
aliquots of 0.3 mL of the polymer solution were continuously injected with a glass
syringe to each of five stirring vials of 0.9 mL deionized water to form nanoparticles.
The tip of the syringe was submerged during particle formation. The vials were pooled,
the acetone solvent was evaporated at RT for lh, and nanoparticles were briefly
centrifuged (2000rcf, 10 seconds) to remove any visible aggregates. Nanoparticles were
concentrated and washed to remove any remaining acetone in an Amicon Ultra-4,
100kDa centrifugal filter (Millipore). Particles were redissolved in a minimal volume of
water and stored at 40C until use.
3.3.4 Protein attachment to nanoparticles: Five hundred microliters of nanoparticle
solution (-20mg polymer/mL) was incubated with 2mL avidin (Invitrogen) solution
(2mg/mL) and gently stirred for 30 minutes at RT to allow avidin conjugation to the
nanoparticle. Neutravidin (Pierce Biotechnology) or streptavidin (Invitrogen) were used
analogously for experiments using these as the crosslinker. Nanoparticles were washed
and free biotin binding protein was removed by 3 centrifugal washes (4,000rcf, 25C, -10
minutes) in an Amicon filter. Nanoparticles were resuspended in 500uL of water, and
biotinylated bovine serum albumin (BSA) or TTC (2mg/mL in PBS) were incubated with
the nanoparticles at RT under gentle stirring. Product was washed 3 times with PBS by
centrifugation using an Amicon filter (4,000rcf, 25C, -20 minutes) to remove unbound
protein. Nanoparticles were resuspended in a minimal volume of PBS and stored at 40 C
until analysis. For all free biotin conjugation experiments, free biotin was mixed with
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biotinylated TTC in different concentrations, and conjugated analogously. All fluorescent
measurements were made on a 1420 VICTOR3 plate reader (Perkin Elmer) and read in a
96-well plate in triplicate.
3.3.5 Preparation ofBSA-FITC and TTC-FITC: Ten milligrams of BSA was dissolved in
PBS (10mg/mL) or lmg of TTC was dissolved in PBS (2mg/mL), and incubated with
EZ-Link NHS-FITC (Pierce Biotechnology) (1-24:1 FITC:protein molar ratio) under
gentle stirring for 2h at RT. Reacted product was collected using a Zeba Desalt Spin
Column (Pierce Biotechnology), according to manufacturer's directions.
3.3.6 Biotinylation ofBSA and TTC: Ten milligrams of BSA was dissolved in PBS
(10mg/mL) or lmg of TTC was dissolved in PBS (2mg/mL), and incubated with EZ-Link
NHS-PEG4-biotin (Pierce Biotechnology) under gentle stirring for 2h at RT. Reacted
product was collected using a Zeba Desalt Spin Column (Pierce Biotechnology),
according to manufacturer's directions. Biotinylated BSA was incubated at a ratio of 20:1
NHS-PEG 4-biotin:BSA and biotinylated TTC was incubated at a ratio of 10:1 NHS-
PEG4-biotin:TTC in all experiments unless otherwise noted.
3.3.7 Biotinylation quantification: The extent of BSA and TTC biotinylation was
determined using a HABA-biotin quantification assay (Pierce Biotechnology), according
to manufacturer's directions. Briefly, the absorbance of the HABA-avidin solution was
measured at 500nm. 100uL of biotinylated BSA or TTC was then added to 900ul of the
HABA-avidin solution, and the absorbance at 500nm measured again. The molar
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concentration of biotin was calculated from the difference in absorbance after adding
biotinylated BSA, using a HABA-avidin extinction coefficient of 34,000 M-lcm-1 159. The
extinction coefficient for TTC was calculated by measuring the absorbance at 280nm of a
solution of biotinylated TTC whose concentration was measured by a micro BCA assay
(Pierce Biotechnology). The absorbance at 280nm was confirmed to be linearly
dependent on concentration using a series of TTC dilutions. The molar concentrations of
biotinylated BSA and TTC were determined by measuring the absorbance of the protein
solution at 280nm, and calculated using an extinction coefficient of 43,824 M-l cm'- for
BSA and the empirically derived extinction coefficient for TTC. The average number of
biotins conjugated to BSA and TTC was calculated as the ratio of biotin concentration to
biotinylated BSA/TTC concentration. All absorbance measurements were made on a
SpectraMax Plus 384 spectrometer (Molecular Devices) and read in a cuvette in
triplicate.
3.3.8 Nanoparticle characterization and schematic: Nanoparticle size and zeta potential
properties were characterized using a ZetaPALS dynamic light scattering instrument
(Brookhaven Instruments Corporation) as previously described 158. 3D schematics of the
nanoparticle and conjugation system were created using CN3D (NCBI) and 3ds Max
(Autodesk) software.
3.3.9 Flow cytometry: Cells were analyzed using a FACScan flow cytometer (Becton
Dickinson) to measure fluorescence (488nm excitation, 530nm and 650nm emission).
Cells were incubated with propidium iodide (5ug/mL), and cell populations were gated
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based on forward/side scatter and propidium iodide fluorescence to remove debris and
dead cells from analysis. A total of at least 10,000 gated events were obtained for each
sample. Data was analyzed using FlowJo software (Tree Star) to generate histograms of
each sample.
3.3.10 Cell culture: N18-RE-105 neuroblastoma, b.End3 brain endothelial, and HepG2
liver cells were grown with previous methods as those previously described 160-162
Briefly, neuroblastoma cells were cultured in DMEM and supplemented with HAT
supplement (100uM sodium hypoxanthine, 400nM aminopterin, 16uM thymidine), 10%
FBS, and 1% penicillin/streptomycin. HepG2 and b.End3 cells were grown in MEM and
DMEM, respectively, containing 10% FBS and 1% penicillin/streptomycin. All cells
were grown in filtered flasks in an incubator at 95% air and 5% carbon dioxide. Media
was changed every 48 hours, and cells were passaged with EDTA-trypsin when
confluent. All media reagents were purchased from Invitrogen. HepG2 and b.End3 cells
were purchased from ATCC, and N18-RE-105 cells were a generous gift of Dr. Jonathan
Francis at the Massachusetts General Hospital.
3.3.11 Statistics: An ANOVA analysis was conducted for all multiple point analysis, and
a Student's t-test was used for all statistical analysis between two groups, unless
otherwise indicated. A p-value less than 0.05 was considered significant. Results are
expressed as mean + SD unless otherwise indicated.
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3.4.0 Results and Discussion
3.4.1 Biotin binding proteins.for nanoparticle conjugation
We used biotin binding proteins to conjugate targeting molecules to the surface of
biodegradable nanoparticles for drug delivery (Figure la). The conjugation method uses
biotin-functionalized PLGA-PEG polymers and biotin binding proteins (avidin,
streptavidin, and neutravidin) as crosslinkers for conjugation (Figure ib) 163-165. This
system has the advantage of conjugating a targeting ligand to the surface of the
nanoparticle using highly specific biotin interactions. This may therefore have advantages
over other conjugation chemistries that do not distinguish between functional groups that
may be present on both the targeting ligand and the encapsulated therapeutic (e.g.
primary amines, thiols). Moreover, this system amplifies available protein conjugation
sites, because each biotin binding protein has four biotin binding sites, and avoids
unstable chemical intermediaries present in other protein conjugation reactions. The
bonds formed by the biotin interactions are highly stable, and the system can be
universally applied to conjugate other targeting molecules with accessible primary amine
groups.
3.4.2 NMR characterization
We prepared PLGA-PEG-biotin polymers by a one step synthesis conducted in
anhydrous organic solvents. Proton NMR revealed characteristic peaks of PLGA at 1.5
ppm, 4.8 ppm and 5.2 ppm in all PLGA dissolved polymer samples (Figure Ic-f). Peaks
were observed at 3.6 ppm in PLGA-PEG-COOH and PLGA-PEG-biotin, corresponding
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to the PEG chain (Figure 1 e-f). Using the integration of the relative molecular weights
and peaks, the conjugation efficiency of NH2-PEG-COOH and NH2-PEG-Biotin to
PLGA-COOH was estimated to be approximately 35%. NMR peaks in some samples
were detected at 1.2 ppm and 3.4 ppm and identified as residual diethyl ether (Figures id,
e, f). Biotin peaks following conjugation were not easily detected, presumably because
the relative biotin signal was masked by the signal from the polymer chain, even when a
lower MW PLGA polymer was used (-20kDa). This has previously been observed in
NMR analysis of high molecular weight polymer chains with end-group conjugation 146
3.4.3 Protein conjugation to nanoparticles
To show that biotin was functional and present on the surface of the nanoparticles,
we synthesized nanoparticles using a solvent/non-solvent nanoprecipitation method and
incubated them with avidin-FITC, followed by centrifugal washes. Nanoparticles were
made using either PLGA-PEG-COOH or PLGA-PEG-biotin polymers. Nanoparticles
formed from either a carboxyl or biotin end group that were not incubated with avidin-
FITC showed baseline fluorescence levels in a fluorescent plate reader, whereas
nanoparticles incubated with avidin-FITC had significantly higher binding with biotin-
functionalized polymer than carboxylic acid controls (Figure 2a, n=5-6, p<0.01).
Subsequent washes reduced but did not eliminate the amount of binding of the avidin-
FITC to the PLGA-PEG-COOH, indicating a small amount of non-specific binding,
likely a result of electrostatic interactions between the negatively charged polymer and
positively charged avidin.
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The previous experiments documented that one can conjugate avidin to the
surface of a nanoparticle via biotin end-groups. We next tested the possibility that avidin
could be used to attach a protein to the nanoparticle. We first conjugated biotin to BSA or
TTC in different molar ratios (1:1, 3:1, and 10:1, biotin:protein) and quantified the final
number of moles of biotin per mole of protein using a HABA-avidin assay. An
empirically derived extinction coefficient of 75,550 M-l cm- was used for TTC. As
predicted, incubation of protein with higher concentrations of NHS-PEG4-biotin led to
higher overall biotinylation (Figure 2b, ANOVA, p<0.01, n=3). At 10:1 conjugation
ratios, TTC showed higher levels of biotinylation than BSA (p<0.01). We therefore used
a higher 20:1 molar ratio of NHS-PEG 4-biotin:BSA and quantified the extent of
biotinylation. BSA showed slightly higher but not significant biotinylation for 20:1 than
for 10:1 ratios (2.2+0.10 vs. 2.0+0.03, ns). For all subsequent experiments, we used
protein that was conjugated with a 10:1 biotin:TTC ratio and a 20:1 biotin:BSA ratio.
We then used nonfluorescent avidin and biotinylated BSA-FITC (b-BSA-FITC)
to evaluate whether PLGA-PEG-biotin+avidin could be used to conjugate protein to
nanoparticles. We incubated nanoparticles with avidin, followed by three washes, and
subsequently with biotinylated BSA-FITC followed by three washes (Figure 2c).
Nanoparticles prepared from PLGA-PEG-biotin and subsequently incubated with avidin
and biotinylated BSA-FITC gave significantly higher fluorescence than negative controls
made from PLGA-PEG-COOH polymers or preparations without avidin (Figure 2d,
ANOVA, p<0.01, n=6). This suggests that functional biotin is present on the nanoparticle
surface, and that this could be used for protein conjugation. This system could be used as
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an alternative to NHS/EDC conjugations to avoid unstable intermediaries throughout the
conjugation process.
3.4.4 Comparison of different biotin binding proteins
In the previous experiments, some nonspecific binding of avidin-FITC (Figure 2a)
and biotin-BSA-FITC (Figure 2d) to the nanoparticle was observed. We predicted that
streptavidin (negatively charged) or neutravidin (an uncharged avidin derivative) may
reduce non-specific interactions and binding to the nanoparticle. We added each of these
three biotin binding proteins to either PLGA-PEG-COOH or PLGA-PEG-biotin
nanoparticles. Biotinylated BSA-FITC was added to nanoparticle preparations after
washing out unbound biotin binding protein. The mean fluorescence was measured on
independent preparations in triplicate using a fluorescence plate reader (Figure 2e).
Nanoparticles with different biotin binding proteins showed various levels of protein
binding (ANOVA, p<0.01, n=3-6). As predicted, avidin resulted in high levels of overall
protein conjugation to PLGA-PEG-biotin nanoparticles, significantly higher than
streptavidin (p<0.01) and neutravidin (p<0.05). Streptavidin and neutravidin fluorescence
values were not significantly different. Neutravidin led to relatively high levels of protein
conjugation but had lower overall non-specific binding to the nanoparticles than avidin
(p<0.01). Surprisingly, streptavidin led to non-specific binding to the nanoparticles and
observable nanoparticle aggregation (visual observations). These data suggest that avidin
has the advantage of generating high levels of conjugated (both specific and non-specific)
protein on nanoparticles, whereas neutravidin leads to highly specific protein conjugation
to nanoparticles. Neutravidin was used for all subsequent experiments.
C 2008 Massachusetts Institute of Technology. All rights reserved.
3.4.5 Protein functionality and specificity
TTC in its native form binds with high affinity and specificity to neurons. To test
whether conjugation of small molecules to TTC using NHS chemistry affects TTC
protein functionality, we conjugated FITC to TTC using NHS-FITC (1:1, 8:1, and 24:1
FITC:protein molar ratios), and incubated the fluorescent protein with N 18-RE- 105
neuroblastoma cells, which are known to express the ganglioside (GTIB) receptor for
TTC. BSA-FITC prepared analogously to TTC-FITC and matched in fluorescence and
concentration to TTC-FITC was used as a negative control. In all binding ratios, TTC
selectively bound to neuroblastoma cells, whereas BSA did not (Figure 3a-c). The higher
binding of BSA at higher fluorescent ratios may be a result of unbound NHS-FITC that
was not removed during protein purification. The double peak observed in TTC binding
may be a result of a heterogenous cell population that is observed by light microscopy
(visual observations). These data demonstrate that TTC preserves its ability to bind to
neurons following amine conjugation.
3.4.6 Nanoparticle aggregation
In the above paradigm, each nanoparticle binds multiple biotin-binding proteins.
Moreover, each neutravidin molecule has four biotin binding sites. For this reason,
nanoparticle cross-linking was sometimes observed in these experiments 166, 167. At least
two factors determine the propensity toward aggregation: the ratio of free neutravidin to
biotin on the nanoparticle surface in the first conjugation step, and the ratio of
biotinylated protein to nanoparticle-bound neutravidin in the second conjugation step.
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Therefore, we used two approaches to reduce aggregation. The first was to reduce the
available numbers of biotin molecules on the nanoparticle surface by creating particles
with various mixtures of PLGA-PEG-COOH and PLGA-PEG-biotin in increasing
COOH:biotin molar ratios. Nanoparticles prepared from PLGA-PEG-biotin polymers
show maximal aggregation at intermediate biotinylated TTC concentrations (<10 uM),
whereas increasing the PLGA-PEG-COOH molar ratio reduced aggregation at each
protein concentration (Figure 3d). Aggregation was not fully eliminated even at very low
PLGA-PEG-biotin concentrations, likely a result of some neutravidin non-specific
binding to the nanoparticle surface. The second approach we have used to reduce
aggregation is to competitively bind free biotin to neutravidin binding sites during the
biotin-TTC conjugation step. Increasing free biotin reduced aggregation and eliminated
aggregation at high free biotin concentrations (Figure 3e). We again note that increasing
concentrations of biotin-TTC also reduced but did not eliminate aggregation. For
subsequent experiments, we used 1.6uM free biotin and added TTC in excess of this
amount to reduce nanoparticle size, while ensuring that TTC was bound to the
nanoparticle surface.
3.4.7 In vitro cell specificity
We tested the ability of TTC to serve as a targeting protein for specific
nanoparticle delivery to neurons. We prepared PLGA-PEG-biotin nanoparticles
encapsulating fluorescent coumarin-6 and conjugated TTC to their surface.
Neuroblastoma cells were incubated with these nanoparticles as well as negative controls
(without both neutravidin and TTC, without TTC, without neutravidin, and with BSA
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instead of TTC). Cells were analyzed using flow cytometry and shown to be significantly
more fluorescent with TTC conjugated nanoparticles than any negative control (Figure
4a). Hep G2 liver (Figure 4b) or b.End3 endothelial cells (Figure 4c) were incubated with
TTC-conjugated or BSA-conjugated (negative control) nanoparticles. Both specific and
non-specific uptake ratios are summarized on Table 1. Non-specific binding or uptake
was observed in all cell types, which is consistent with previous cell targeting studies
using different ligands 168-170. This is possibly due to background levels of fluorescent
nanoparticles that remain after cell washes. Although non-specific binding was observed,
non-specific delivery of nanoparticles delivering therapeutic agents alone may not be
sufficient for efficacy, necessitating targeted delivery that may increase uptake by
specific cell types. The benefit of PEG is most clear in previous studies during in vivo
studies where PEG has been shown to increase nanoparticle half life by reducing
systemic clearance rates 171. TTC-conjugated nanoparticles showed high selectivity for
neuroblastoma cells, indicating that TTC-conjugated nanoparticles may be useful for
selective targeting of neurons. Because of the native properties of TTC, these
nanoparticles may allow for retrograde transport and provide a drug delivery system to
specifically target neurons.
3.4.8 Characterization of nanoparticles
Nanoparticle properties were characterized using dynamic light scattering (DLS)
to give size, polydispersity, and zeta potential in each preparation (see Table 2). PLGA-
PEG-COOH nanoparticles were not significantly different than PLGA-PEG-biotin
nanoparticles in size, but were more negative in zeta potential (n=3, p<0.05), presumably
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due to fewer COOH groups in biotin-conjugated nanoparticles. Nanoparticles showed a
slight increase in size upon addition of neutravidin, and the addition of the biotinylated
protein further increased the size of the nanoparticles.
3.5.0 Conclusions
We developed nanoparticles from PLGA-PEG-biotin polymers and used biotin
binding proteins (avidin, streptavidin, or neutravidin) as crosslinkers for protein
conjugation. The tetanus toxin C fragment was modified and conjugated to nanoparticles,
allowing targeted binding to neuroblastoma cells, while not targeting liver or endothelial
cells.
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3.7.0 Tables and Figures
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7.1 Figure 1: Protein conjugation to nanoparticles using biotin binding proteins.
Conceptual schematic (not to scale) illustrating (a) the cross-section of a biodegradable
polymer nanoparticle that is functionalized with the tetanus toxin C fragment (TTC) and
presumed to encapsulate a therapeutic substance, and (b) the conjugation system used to
attach functional TTC to the nanoparticle utilizing PLGA-PEG-biotin functionalized
biodegradable polymer, and biotinylated TTC with an avidin cross-linker, based on
previously published structures 163-165. Two of the four avidin subunits are shown for
illustrative purposes. Proton NMR spectra of (c) PLGA-COOH, (d) PLGA-biotin, (e)
PLGA-PEG-COOH, and (f) PLGA-PEG-biotin polymers dissolved in deuterated
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chloroform. Characteristic peaks are visible for PLGA (*) and PEG (#), but not for
conjugated biotin.
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3.7.2 Figure 2: Protein conjugation to PLGA-PEG-biotin nanoparticles. (a) PLGA-PEG-
COOH (-) and PLGA-PEG-biotin (+) nanoparticles incubated with the presence (+) or
absence (-) of avidin-FITC and analyzed on a fluorescent plate reader. (b) Quantified
extent of biotinylation for BSA (white) and TTC (gray) proteins for different NHS-PEG 4-
biotin:protein molar ratios. (c) Schematic representation of overall protein conjugation to
PLGA-PEG-COOH or PLGA-PEG-biotin polymer nanoparticles (as indicated). Avidin
(Step 1) and biotinylated BSA-FITC (Step 2) were conjugated in sequence to the
nanoparticle surface, with PBS washes to remove unbound protein at each step. (d)
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PLGA-PEG-COOH (-) and PLGA-PEG-biotin (+) nanoparticles incubated with the
presence (+) or absence (-) of avidin, subsequently incubated with biotinylated BSA-
FITC (b-BSA-FITC) and analyzed on a fluorescent plate reader showing selective protein
conjugation to nanoparticles. (e) Comparison of biotin binding proteins (BBP) as
crosslinkers for protein conjugation to nanoparticles. Data is expressed as mean + SEM.
PLGA-PEG-COOH (white, gray) and PLGA-PEG-biotin (black) nanoparticles were
prepared and incubated with avidin (left), streptavidin (middle), or neutravidin (right),
and subsequently with biotinylated BSA-FITC. Avidin showed the highest overall protein
conjugation, whereas neutravidin resulted in reduced non-specific interaction and the
most specific protein conjugation.
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3.7.3 Figure 3: TTC protein functionality and nanoparticle size optimization. Flow
cytometry analysis of N18-RE-105 neuroblastoma cells incubated with fluorescent TTC
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(green), fluorescent BSA (blue), or PBS control (red), for NHS-FITC:protein conjugation
ratios of 1:1 (a), 8:1 (b), and 24:1 (c). TTC remained functional following amine
conjugation and preserved its ability to target neurons (a-c). Dynamic light scattering
analysis of nanoparticle size following conjugation with neutravidin and biotinylated
TTC (d-e). (d) Nanoparticles prepared with different molar ratios of PLGA-PEG-COOH
to PLGA-PEG-biotin as indicated (control is 100% PLGA-PEG-Biotin), and (e) free
biotin competition with TTC-biotin conjugation to nanoparticles at different
concentrations of free biotin as indicated; control is without free biotin. These figures
show that nanoparticle aggregation can be reduced by decreasing the number of biotins
on the nanoparticle surface (d) or by free biotin competition during conjugation of the
biotinylated protein (e). For all sizing experiments, results are expressed as mean±SD of
3 independent size measurements of one preparation of nanoparticles.
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3.7.4 Figure 4: In vitro cell binding of TTC-conjugated nanoparticles. Flow cytometry
analysis of N18-RE-105 neuroblastoma cells (a), HepG2 liver (b), and b.End3 endothelial
(c), cells following incubation with TTC-conjugated nanoparticles (green), BSA-
conjugated nanoparticles (blue), or a PBS negative control (red). Other negative controls
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are shown for (a) for nanoparticles without neutravidin (purple), without TTC (orange),
and blank nanoparticles (black), demonstrating that TTC-conjugated nanoparticles
selectively target neurons.
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Table 1
Non-Specific
Uptake ratio
(BSA/PBS)
Specific Uptake
Ratio (TTC/PBS)
N18-RE-105
Neuroblastoma
2.76
25.50
Hep G2 Liver
4.31
4.87
b.End3 Endothelial
4.99
6.83
3.7.5 Table 1: Nanoparticle binding to cells. Summary of figure 4 flow cytometry
analysis for N 18-RE-105 neuroblastoma, HepG2, and b.End3 cells incubated with TTC
or BSA conjugated fluorescent nanoparticles and PBS (negative control). The specific
(TTC) and non-specific (BSA) uptake ratios show the fluorescence ratio of conjugated
nanoparticles to PBS treated negative controls. Results are expressed as mean
fluorescence of each gated live cell population. Each sample represents an analysis of at
least 10,000 live gated cells.
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Table 2
PLGA-PEG-COOH
PLGA-PEG-biotin
PLGA-PEG-
biotin+NA
PLGA-PEG-
biotin+NA+BSA
PLGA-PEG-
biotin+NA+TTC+free
biotin
Mean Size (nm)
135.7(1.1)
111.1(1.8)
144.1(2.4)
175.3(2.3)
255.2(6.3)
Zeta Potential (mV)
-32.07(3.19)
-23.28(1.17)
-0.497(0.402)
-3.37(3.86)
-5.85(5.00)
Polydispersity
Index
0.137(0.023)
0.227(0.006)
0.198(0.012)
0.226(0.012)
0.219(0.007)
3.7.6 Table 2: Nanoparticle characterization. Size, charge zeta potential, and
polydispersity index for each nanoparticle preparation indicated as determined by
dynamic light scattering. Results are expressed as mean (SD) for 3 size and zeta potential
measurements.
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Chapter 4: A porous photocurable elastomer for cell
encapsulation and culture 172
4.1.0 Abstract
Tissue engineering utilizing stem cells has the potential to provide new therapeutics for
amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease). Encapsulating cells within
a polymer matrix creates a three-dimensional (3D) scaffold that may more accurately
represent the native microenvironment and cell organization and may support neuronal
culture. Here we report a porous scaffold prepared from a photocurable elastomer,
poly(glycerol-co-sebacate)-acrylate (PGSA). The scaffold porosity, swelling, mass loss,
toxicity and mechanical properties, suggest that porous PGSA could be used to support
the growth and differentiation of encapsulated cells. Neuroblastoma (NB) and human
embryonic stem cells (hESCs) were encapsulated into the matrix and found to adhere to
the material and interact with each other within 24 hours. After 7 days, encapsulated NB
cells were found to grow, and form matrix fibrils and tissue. Undifferentiated hESCs
proliferated and differentiated in the PGSA scaffold. In vivo experiments showed that
both porous scaffolds have similar biocompatibility profiles as non-porous PGSA, but
porous PGSA promotes tissue ingrowth, as compared to non-porous PGSA. We therefore
propose that porous PGSA scaffolds can provide a logistical template for 3D growth of
cells and tissue engineering.
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4.2.0 Introduction
Tissue engineering of neurons may lead to more effective treatments for
amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease). This could be
accomplished either ex vivo or in vivo, the later of which would require that the cell
microenvironment support neuronal growth and proliferation. It is well-established that
differences exist between cells grown in two dimensional (2D) culture and cells found in
their native 3D environment, where cells interact with each other and the extracellular
matrix (ECM) to form tissue. These interactions lead to well established differences in
cell signaling, gene expression, and cellular organization 173-176. Furthermore, it is
increasingly accepted that physical cues play a role in cell growth and tissue assembly 177,
178. These signals are important in stem cells (SCs) during self renewal, proliferation, and
differentiation.
Stem cells have great potential both as a source of cellular tissue for regenerative
medicine and for investigating fundamental concepts in developmental biology 179, 180
Three-dimensional scaffolds can be used to provide a structural and logistic template for
SC attachment, growth and differentiation. These may more accurately mimic some
aspects of both chemical and physical signals and the native local microenvironment of
SCs 116, 181, 182
Various methods have been used to culture cells in a 3D environment, including
seeding or encapsulating cells into biomaterials. Scaffolds prepared from biodegradable
polymers (e.g. PLGA) are commonly used for cell seeding, but cell density throughout
the matrix may not be uniform and may affect cell fate and differentiation 117-120
Encapsulating cells within a biodegradable scaffold may lead to a more uniform cell
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distribution '83. Hydrogels are highly hydrated matrices prepared from either natural or
synthetic material networks that are widely used for embedding cells in a 3D
environment 184. In many applications, it is desirable to use scaffold prepared from
polymers with material properties that resemble those of the native ECM, a soft, tough,
and elastomeric network that provides mechanical stability and structural integrity to
cells.
Bioelastomer materials may provide a flexible scaffold for 3D culture of cells 185
In our previous studies, poly(glycerol sebacate) (PGS) was developed and shown to be
biocompatibile both in vitro and in vivo 121, 122. A recent modification to PGS
incorporated acrylate groups into the polymer backbone that allowed for photo-
polymerization while preserving the elastic and biocompatibility properties of PGS 186
Photopolymerization has been used as a means to encapsulate and support both mature
cells and human embryonic stem cells (hESC) 87-'191'. This modified elastomer,
poly(glycerol-co-sebacate)-acrylate (PGSA), polymerizes to form a uniform scaffold.
However, the density and hydrophobicity of the material, which lacks pores, does not
allow for rapid diffusion of media and therefore may not be well suited for cell
encapsulation. We hypothesized that porous PGSA could be used for cell encapsulation
and culture within an elastic scaffold.
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4.3.0 Methods
4.3.1 Cell culture and media: hESCs. Two NIH-registered hESC cell lines were used for
all studies (H9 and H13, WiCell Research Institute, Madison, WI; p19-30). Human ESCs
were grown on an inactivated mouse embryonic fibroblast (MEF) feeder layer in growth
medium (80% KnockOut DMEM, supplemented with 20% KnockOut Serum
Replacement, 4 ng/ml basic Fibroblast Growth Factor, 1 mM L-glutamine, 0.1 mM 3-
mercaptoethanol, 1% non-essential amino acids). Human ESCs were passaged every 4-6
days using lmg/ml type IV collagenase for 20-30 minutes. Neuroblastoma cells. N18-
RE-105 neuroblastoma cells were grown in DMEM supplemented with HAT supplement,
10% FBS, penicillin and streptomycin. Media was changed every 48 hours, and cells
were passaged with EDTA-trypsin for 5-7 minutes every 3-5 days when confluent.
Embryoid body (EB) media. Encapsulated hESCs were cultured with in EB media (80%
DMEM, supplemented with 20% defined FBS, 1 mM L-glutamine, 0.1 mM 3-
mercaptoethanol, 1% non-essential amino acids). All media components and reagents for
both hESCs and neuroblastoma culture were purchased from Invitrogen Corporation
(Carlsbad, CA), except for defined FBS, which was purchased from Hyclone (Logan,
UT).
4.3.2 Synthesis ofPGSA: All reagent were purchased from Sigma-Aldrich (St. Louis,
MO), PGS and PGSA were prepared as previously described 121, 186. Briefly, 20g PGS
pre-polymer was incubated in a round-bottom flask with 200 mL anhydrous
dichloromethane and 20mg 4-(dimethylamino)-pyridine (DMAP). The flask was cooled
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to 0 oC under positive N2 pressure. (0.34* 78 mmol) Acryloyl chloride and equimolar
triethylamine (0.32 mol per mol of hydroxyl groups on the PGS pre-polymer) were
slowly added to the flask and stirred for 24 h at RT. The resulting PGSA polymer was
dissolved in ethyl acetate, precipitated with ethanol, vacuum oven dried at 45 OC, and
stored at -20C until use.
4.3.3 Formation ofporous PGSA scaffolds: PGSA scaffolds were prepared by mixing the
PGSA pre-polymer with 0.1% photoinitiator (2,2-dimethoxy-2-phenyl-acetophenone,
wt%) and polymerized using a ultraviolet light (10 mW/cm 2, model 100AP , Black-Ray )
at RT for 10 minutes. To form PGSA15 and PGSA35 scaffolds, 15 and 35% glycerol
(wt%) was mixed with the PGSA pre-polymer containing photoinitiator and polymerized
analogously. Polymerization for all scaffolds occurred under sterile conditions using a
custom mold. Cylindrical scaffolds containing 25uL of pre-polymer were prepared for
both in vitro (3mm in diameter, 2mm thick) and in vivo (8mm in diameter, Imm thick)
experiments.
4.3.4 In vitro swelling and material loss: PGSA samples with 15% and 35% glycerol
(wt%) were weighed and incubated in media at 37 0 C. At time intervals between 1-35
days, the samples were removed from media, blotted, and weighed to record the wet
weight. The samples were then oven dried for five days at 600C and weighed to record
the dry weight. Swelling ratios were determined by the following formula:
SRt=(Wt/Dt)/(Wto/Dto), where SRt is the normalized swelling ratio at time = t, W, is the
weight of the scaffold at time = t, Wto is the initial weight of the scaffolds at t = 0, Dto is
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the dry weight of the scaffolds at t = 0,and Dt is the dry weight of the scaffold at time = t.
Mass loss was determining by the following formula: Mt=(Dt/It)/(Dto/Ito), where Mt
represents the normalized mass of the scaffold at time = t, It represents the initial dry
weight of the scaffolds at time =t, Io represents the initial dry weight of the scaffolds at
time =0, and Do and Dt and Wt represent the same as stated above. Results were
normalized to the average initial wet weight and the individual scaffold dry weight (for
swelling ratios) or the average initial dry weight and individual scaffold wet weight (for
mass loss) at each timepoint.
4.3.5 Mechanical tests: Tensile tests were conducted on dog-bone-shaped polymer strips
cut from photocured PGSA15 and PGSA35 sheets (test section dimensions roughly
10mm x 3.5mm x 1.2mm, n= 5 per composition) and were tested using an Instron 5542
according to ASTM standard D412-98a. All mechanical testing was performed under wet
conditions, specifically the photocured PGSA samples were incubated in PBS for 24 h
prior to testing. The samples were elongated at a constant deflection rate of 10 mm/min
and were all elongated to failure. Stress-strain properties were determined using
engineering stress and strain and the tensile modulus was calculated from the initial slope
(0-20%). The compressive modulus of the PGSA15, PGSA35, and swollen HA hydrogels
(2%, 50kDa) 192 was determined using parallel plate grips on the same Instron 5542 at a
constant deflection rate of 500 um/min. Samples for mechanical testing (n= 5 per
composition) were cylindrical (-1.5 mm height, -6.0 mm diameter) and were compressed
until failure or until 60% of the initial thickness was reached. None of the PGSA15 or
PGSA35 samples failed before reaching the maximum loading limit of the 50N load cell
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employed in all tests. The compressive modulus was determined as the initial slope of the
stress-strain curve (0-20% strain).
4.3.6 In vitro toxicity: Cell proliferation was detected the XTT kit (Sigma, St. Louis MO)
according to the manufacturer's instructions. Briefly, undifferentiated hESCs cultured in
the presence of PGSA macromer with glycerol (15% and 35%) and were incubated for 4
h in medium containing 20% (v/v) XTT solution. For analysis, 150 [l of the medium
were removed, placed in a 96-plate well and read in a microplate reader at 450 nm.
Encapsulation of hESCs and neuroblastomas into PSGA. For encapsulation studies, cells
were removed from culture by incubation with collagenase (hESCs) or with trypsin
(neuroblastomas). Approximately 3-6 x 106 hESCs or NBs were mixed with 50 gL PGSA
prepolymer (15% or 35% glycerol) and photocured as describe above. The crosslinked
polymers were immediately placed in 2mls EB media (for hESCs) or NB media (for NB
cells). Scaffolds with encapsulated cells were kept in culture for 1-7 days, and media was
changed daily.
4.3.7 Environmental Scanning Electron Microscope (ESEM): FEI/Phillips XL-30 Field
Emission ESEM was used to evaluate PGSA porosity, cell organization, and cell-material
interaction. Samples of PGSA (with or without cells) were removed from culture, fixed
with Accustain (Sigma-Aldrich, St. Louis, MO), and washed with PBS. Scaffolds were
cut horizontally cut in half and placed with inner side facing up on the ESEM platform.
ESEM images were taken with a beam intensity of between 5-30.0 keV at 0.4 Torr with
the gaseous secondary electron (GSE) detectors.
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4.3.8 Porosity analysis: Porosity of PGSA scaffolds was determined using ESEM images
and histological sections of scaffolds using the built-in area selection tool of ImageJ
software (NIH, Bethesda, MD). A total of 2 scaffolds and at least 10 images were
analyzed from two different scaffold preparations. The size of each pore and total number
of pores were determined for each image analyzed. The total percent porosity was
determined the ratio of the total pore area to the total scaffold area in each image.
4.3.9 In vivo biocompatibility: PGSA, PGSA15, and PGSA35 scaffolds (all without cells)
were prepared under sterile conditions and incubated in PBS for 48hrs. Female Lewis rats
(n=8) (Charles River Laboratories, Wilmington, MA) weighing 200-250 g were housed
in groups of 2 and had access to water and food ad libitum. Animals were cared for
according to the approved protocols of the Committee on Animal Care of the
Massachusetts Institute of Technology in conformity with the NIH guidelines for the care
and use of laboratory animals (NIH publication #85-23, revised 1985). The animals were
anaesthetized using continuous 2% isoflurane/O2 inhalation. Two rats per group per time
point received implants. This was done by three small midline incisions on the dorsum of
the rat and the implants were introduced in lateral subcutaneous pockets created by blunt
dissection. All animals remained in good general health throughout the study as assessed
by their weight gain. At each predetermined time point (1,3,5, and 7 weeks), one
randomly selected group of rats (n=2) was sacrificed, and the implanted scaffolds were
removed en bloc with the surrounding tissue (--15x5mm). The samples were fixed and
processed for histology as described below.
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4.3.10 Histology: PGSA scaffolds from both in vitro (with and without cells) and in vivo
(without cells) experiments were placed in Tissue-Tek OCT gel (Sakura Finetechnical
Co, Tokyo, JPN), frozen on dry ice, and stored at -800C till cryostat sectioning.
Sequential sections (8-15 jm) were stained with hematoxliyn and eosine (H&E).
Separate scaffolds from in vivo experiments were fixed with Accustain (Sigma-Aldrich,
St. Louis, MO) for 24hrs, dehydrated in graded ethanol (70 - 100%), embedded in
paraffin, sectioned using a microtome (4um), and stained with H&E.
4.3.11 Immunofluorescence. Cryosections were thawed and fixed with acetone for 5min
at room temperature. After blocking with 5% FBS, cells were stained with one of the
following primary antibodies: anti-cytokeratin 18 (1:50; Chemicon, Temecula, CA), anti-
a-feto protein (1:100; Dako Dako California Inc. Carpinteria, CA), and Brachyury
(1:100; R&D systems, Minneapolis,.MN). Cells were then rinsed three times with PBS
(Invitrogen corporation, Carlsbad, CA) and incubated for 30 min with suitable FITC-
conjugated (R&D systems, Minneapolis, MN) or Cy3-conjugated (Sigma, St Louis, MO)
secondary antibodies. Secondary antibody alone served as controls. The immuno-labeled
cells were examined using fluorescence microscopy (Zeiss, Germany).
4.3.12 Inflammatory response and in-growth characterization. The size of the
inflammatory active zone of implanted scaffolds was measured in histological sections
using the built-in calibration/length tool in AxioVision software (Zeiss, Oberkochen,
Germany). A total of 30 measurements (over 10 histological slices) were taken for each
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scaffold. Additionally, the number of in-growths was determined for each implanted
scaffold by counting pores with positive H+E staining and grouped by their size, small
(<50um) and large (>50um), at each timepoint. Results are presented as the average ± SD
for the (n=4).
4.3.13 Statistics: One-tailed student's t-tests with unequal variances were performed to
determine statistical significance, where appropriate (Microsoft Excel, Redmond, WA).
Parametric one-way and two-way ANOVA tests were also performed where appropriate
(GraphPad Prism 4.02, GraphPad Software, San Diego, CA). Significance levels were set
at: *p < 0.05, **p < 0.01, and ***p < 0.001. All results shown are mean±SD.
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4.4.0 Results
4.4.1 Characterization of PGSA scaffold porosity
We hypothesized that glycerol could be used during the PGSA polymerization
process to develop a porous scaffold. We reasoned that glycerol (utilized as a
cryoprotectant additive) is expected to be minimally toxic to cells, and is viscous, thus
minimizing material separation during polymerization. Glycerol was added in 15%
(PGSA15) and 35% (PGSA35) mass ratios with pre-polymer containing photoinitiator,
and polymerized using ultraviolet light under sterile conditions. Glycerol concentrations
higher than 35% did not form scaffolds that were structurally stable (visual observations;
data not shown). We used environmental scanning electron microscopy (ESEM) and light
microscopy of cryosectioned scaffolds to characterize the ultrastructure. Scaffolds
prepared from both 15% and 35% glycerol resulted in pore formation across the entire
scaffold. Macropores (>50m; Fig la-b) with interconnecting pores (20-5.0m; Fig 1)
were observed in both scaffolds, whereas micropores (<2.0Qm) were found in greater
number in PGSA35 scaffolds (Fig 1). The average macropore size were similar for both
scaffolds, whereas the total pore number was greater for PGSA35 scaffolds (Table 1;
*p<0.05). The total porosity (determined from macropores) was slightly higher in
PGSA15 scaffolds (Table 1; ***p<0.001).
4.4.2 Swelling and mass loss properties
To evaluate PGSA/glycerol scaffolds as a system for in vitro cell culture, we
studied their swelling and mass loss properties. PGSA/glycerol scaffolds were prepared
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as before and incubated in PBS for 1-35 days at 370 C. Both PGSA15 and PGSA35
swelled within 24 hours to 206±18.9% and 140±4.20% of their respective initial weights
(mean±SD, Figure 2A). The swelling ratios in both scaffolds showed a biphasic hydration
that peaked at 6 days, followed by decreasing swelling ratios in each scaffold (Figure
2A). These data are consistent with mass loss over 35 days that was observed for
PGSA15 (18.1±1.5%) and PGSA35 (27.5±4.9%) scaffolds (Fig 2B), and with previous
experiments that showed slow in vitro degradation rates of PGSA 186
4.4.3 Mechanical property characterization
To examine the mechanical properties of porous PGSA, we conducted a series of
tensile and compressive tests. Tensile test showed that stress-strain properties of both
PGSA15 and PGSA35 retained similar elastic behaviour to those of PGSA 186 (Fig 2C).
The ultimate strain for PGSA15 was similar to that of PGSA (Table 2), whereas the
ultimate strain for PGSA35 was significantly greater than either PGSA or PGSA15
(Table 2; **p< 0.01). The Young's modulus for PGSA15 was significantly greater than
for the value for PGSA35 (Table 2; *p< 0.05), while both were lower than that for PGSA
(Table 2). The ultimate stresses of the PGSA15 and PGSA35 were similar; however, both
values were less than the ultimate stress of PGSA (Table 2).
4.4.4 Toxicity
Previous studies have demonstrated that polymerized PGS and PGSA are
biocompatible and support the growth and proliferation of cells 12, 122186. Because the
photocuring process may lead to unpolymerized PGSA, we evaluated the effects of
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unpolymerized PGSA and glycerol on the toxicity of cells. We used hESCs for these
experiments because they are particularly susceptible to harmful culture conditions 193.
Human ESCs were cultured on a MEF feeder layer with 50 pl/ml PGSA15 and PGSA35,
concentrations simulating conditions in which none of the material polymerized. Human
ESCs formed characteristic colonies of proliferating cells in all culture conditions (Fig 3).
Comparison of the cell metabolism by an XTT assay showed that cell proliferation rates
were slightly reduced by PGSA15 and PGSA35 but not significantly different than
control conditions (Fig 3).
4.4.5 N18-RE-105 cell encapsulation and culture (in vitro)
We evaluated the ability of PGSA15 and PGSA35 scaffolds to encapsulate N18-
RE-105 neuroblastoma (NB) cells. NB cells were encapsulated by photopolymerization
in PGSA15 and PGSA35 scaffolds and grown in culture media for 1-7 days. After 1 day
in culture, ESEM analysis revealed that NB cells adhered to the scaffold wall (mainly
within macropores) and formed protrusions and apparent interconnections between each
other (Figure 4A-C). After 7 days, NB cells produced fibrils which coated entire pores,
suggesting that cells were producing components of the extracellular matrix on the PGSA
material (Fig 4D). NB cells continued to grow while forming 3D aggregates and were
found in both smaller interconnecting pores and macropores (Fig 4E-F). NB cells were
supported similarly in both PGSA15 and PGSA35 scaffolds, and no qualitative or
quantitative differences were observed between the scaffolds.
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4.4.6 Human embryonic stem cell encapsulation (in vitro)
To test whether PGSA scaffolds would support the culture of human embryonic
stem cell (hESCs), we encapsulated undifferentiated hESCs into scaffolds using an
analogous protocol used for the NB cell experiments. After 1 day in both PGSA15 and
PGSA35 scaffolds, hESCs were found to be organized in colonies primarily within the
PGSA macropores (Figure 4G-I). After 7 days, were found in interconnecting pores (Fig
4J), while forming tissue-like sheets that covered the entire scaffold (Fig 4K). Thick
histological sections revealed aggregates with various cell morphologies within the pores
(Fig 4L). Similarly to the NB cultures, no differences could be quantified between cells
grown in PGSA15 and PGSA35 scaffolds
4.4.7 Human ESC proliferation and differentiation (in vitro)
Histology sectioning showed that hESCs encapsulated in PGSA15 and PGSA35
scaffolds for 7 days are at a higher cell density then was observed after 1 day of culture,
suggesting that PGSA supports cell proliferation (data not shown). To further investigate
this, hESCs encapsulated into PGSA15 and PGSA35 scaffolds for 7 days were stained for
the Ki67 protein, which is expressed in proliferating differentiated cells 194. The majority
of encapsulated hESCs were observed to express Ki67 after 7 days in culture (Fig 5A-C).
We further found cells that were representative of all three germ layers in the
encapsulated differentiated hESCs (Fig 5D-F), suggesting that structures similar to EBs
were forming within the scaffold.
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4.4.8 Biocompatibility (in vivo)
To investigate the biocompatibility of porous scaffolds made from PGSA and
glycerol, we prepared PGSA15 and PGSA35 scaffolds without cells and implanted them
subcutaneously in rats for 1-7 weeks. The thickness of the inflammatory active zone was
quantified in each scaffold at four time points. Notably, there was an acute inflammatory
response in the PGSA35 scaffolds that was not present in the PGSA15 scaffolds, as
determined by the thickness of the active zone and the presence of characteristic signs of
inflammation throughout the muscle (Fig 6A). The elevated inflammatory response in the
PGSA35 scaffold that was observed at week 1 was not observed at later time points (Fig
6B). The active zone showed a decreasing inflammatory response for both PGSA15 and
PGSA35 scaffolds over a 7 week period, as was previously reported for PLGA and PGS
implants (Fig 6C;). The PGSA15 inflammatory response at all time points was similar to
that previously reported for PLGA and PGS 121, which are known to be highly
biocompatible.
4.4.9 Scaffold ingrowth (in vivo)
We examined whether an increase in porosity from glycerol in PGSA scaffolds
would promote the formation of tissue ingrowth in vivo. We observed that I week after
subcutaneous implantation, some ingrowth could be detected in both the PGSA15 and
PGSA35 scaffolds (Fig 7A), and ingrowth increased over 7 weeks post implantation (Fig
7B). The ingrowth was absent in the non-porous PGSA scaffolds made without glycerol.
The ingrowths in the PGSA15 and PGSA35 scaffolds were observed both at the
boundary of the scaffold and the surrounding tissue and within the scaffold pores (Fig
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7C). In contrast to the non-porous scaffolds (without glycerol), increasing glycerol mass
percentage was associated with an increase in both small ingrowth (Fig 7D), and large
ingrowth (Fig 7E), over time. These data suggest that porous PGSA promotes scaffold
ingrowth and could be used to support growth for tissue engineering applications.
4.5.0 Discussion
The modified elastomer, PGSA, polymerizes under physiological conditions and
allows the encapsulation of proteins and cells. Glycerol was chosen as a cell carrier due
to its: (1) common usage as a cell and tissue carrier for cryopreservation 195, and (2)
minimal reactivity with PGSA that may result in dispersed phase separation. Our results
show that mixing glycerol (15% or 35% (w/w)) with PGSA resulted in porous scaffolds.
Macropores (>50p.m) with interconnecting pores (20-50gtm) were observed in both
scaffolds, whereas micropores (<2Qtm) were found in greater number in PGSA35
scaffolds. The addition of porosity had a substantial effect on the mechanical properties
of PGSA, which is to be expected as increased porosity causes a decrease of load bearing
material per volume, however these changes in porosity did not cause a decrease in
ultimate strain. A softer substrate and the ability to tune the mechanical properties within
a given range could be advantageous as cell differentiation was shown to be affected by
substrate stiffness 196. The toxicity effects of unpolymerized PGSA/glycerol were found
to be minimal and most likely were magnified because unpolymerized material would
normally be removed during media changes. Overall, we reasoned that either the
PGSA15 or the PGSA35 scaffolds could be used to encapsulate and support the growth
of cells in 3D culture.
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Our laboratory and others have used methylacrylated and acrylated pre-polymer
in combination with photopolymerization to encapsulate cells in hydrogels and have
shown minimal effects of the UV light on cell viability, p53 accumulation, and gene
aberrations over long term culture 116, 89. NB cells were chosen because, like PGS, PGSA
has possible applications as a material that may promote nerve guidance 197. NB cells
encapsulated in PGSA proliferated and formed structures resembling neuronal like
spheres after one week in culture. Furthermore, after one week of encapsulation, the
surface of the PGSA was covered with ECM fibers suggesting that the NB cells created
their own 3D microenvironments by secretion of ECM. To examine the usage of PGSA
with hESCs, undifferentiated hESC colonies were encapsulated and cultured for one
week. Human ESCs proliferated and formed aggregates that resembled embryoid body
like structures within the pores, which contained representative cell types of all three
germ layers. Altogether, these results suggest that porous PGSA elastic scaffolds offer a
biocompatible scaffold with tuneable mechanical properties.
Examining the porous PGSA biocompatibility in vivo it was found that high levels
of glycerol (35%) resulted in acute inflammatory reaction which was decreased to basal
levels similar to PGSAl5 and PGSA '86 In growth into both PGSA15 and PGSA35 was
observed already after I week, which increased with time of transplantation. These
results suggest that porous PGSA promotes integration with the host circulation and
tissue, and therefore may be utilized for tissue engineering applications.
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4.6.0 Conclusions
We have utilized glycerol to create porous PGSA scaffolds, which were found to
maintain elastomeric mechanical properties, and defined porosity, swelling, mass loss,
and biocompatibility characteristics. Porous PGSA scaffolds were used to encapsulate
and support the growth of N18-RE-105 neuroblastoma and hESCs in vitro. Porous PGSA
scaffolds were biocompatible in vivo and allow host tissue ingrowth This data suggests
that bioelastic porous PGSA scaffolds could be used as an alternative to hydrogel culture
in vitro or as a scaffold for tissue engineering applications in vivo.
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4.8.0 Table and Figure Captions
0L I
4.8.1 Figure 1: Porous PGSA. ESEM images of PGSA15 and PGSA35 scaffolds at low
(left panels) and high (middle panels) magnification, showing the presence of macropores
(>50um) and interconnecting pores (20-50um, asterisks). Light microscopy images of
cryostat sectioned scaffolds (right panels) showing the presence of micropores (<20 tm
throughout the PGSA35 but not in the PGSA15 scaffolds.
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4.8.2 Figure 2: Swelling, mass loss, and mechanical characterization. (A) Normalized
swelling ratios and (B) normalized mass loss during in vitro incubation for 1-35 days, and
(C) Average tensile stress-strain properties of PGSA 15 (light) and PGSA35 (dark)
scaffolds.
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4.8.3 Figure 3: Toxicity ofPGSA monomer and glycerol. Light microscopy images of
undifferentiated hESCs grown on MEF feeder layers in the absence (control), or in the
presence of 50uL/mL PGSA pre-polymer (PGSA15 and PGSA35). Characteristic hESC
colonies are observed under all conditions. Arrows indicate PGSA and glycerol in media.
Cell proliferation graph quantified by an XTT cell proliferation assay showing slightly
reduced but not significantly different cell activity in PGSA 15 and PGSA35 conditions,
as compared to cells grown in control conditions. Scale bars=100tm.
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4.8.4 Figure 4: Cell encapsulation within Porous PGSA. ESEM and H&E staining
micrograhs showing encapsulated Ni 8-RE- 105 NB cells (A) after 1 day of culture found
primarily within macropores, (B) mainly located on the pore walls (indicated by arrows),
while (C) forming cellular interconnections among neighboring cells. After 7 days,
ESEM images showed that NB cells (D) produced fibrous components which coated
entire pores, (E) formed 3D aggregates and (F) bonds among cells within the aggregates.
Undifferentiated hESC colonies encapsulated in porous PGSA and cultured for 1 day
were also observed to (G-I) settle within the macropores. After 7 days, hESCs (J,K)
formed tissue like structures covering most of the scaffold pores, and (L) were organized
in 3D structures containing cells with various morphologies.
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4.8.5 Figure 5: Differentiated hESCs. Immunofluorescent staining of hESCs
encapsulated in porous PGSA and cultured for 7 days further revealed proliferating cells
positive for Ki67 in (A) low and (B-C) high magnification. Differentiated hESCs were
found to express early markers of the three germ layers: (D) brachury (mesoderm), (E)
cytokeratin 18 (ectoderm), and (F) a-Feto protein (endoderm). Scale bars A,D-F=50pm;
B-C- 10 m.
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4.8.6 Figure 6: In vivo Biocompatibility. Porous PGSA scaffolds were transplanted S.C in
rats. (A) After 1 week PGSA35 (i,ii) showed a thicker inflammatory zone surrounding
the scaffolds than PGSA15 (iii,iv). Inflammation in the muscle (arrowheads) was found
in PGSA35 scaffolds only. (B) After 3 weeks, the PGSA35 inflammatory zone was
reduced to comparable levels for PGSA 15. (C) Inflammatory zones of both scaffolds
were reduced along the 7-week experiment (p<0.001). Scale bar=-100tm.
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4.8.7 Figure 7: In vivo ingrowth. PGSA, PGSA 15, and PGSA35 scaffolds were
transplanted subcutaneously in rats. (A) H&E stained histological slices of explants
revealed tissue ingrowth in porous scaffolds after 1 week that were not observed in the
nonporous scaffolds (no glycerol), and (B) continued to persist in porous scaffolds with
almost no growth in the nonporous scaffolds (no glycerol). All boxes in upper panel are
shown at higher magnification in lower panels. (C) Different types of ingrowth could be
observed in implants including at the boundary of the scaffold and the surrounding tissue
(right) and within the scaffold pores (left). Presence of glycerol was found to be
associated with an increase in both (D) small and (E) large ingrowth. Scale bars= 100pm.
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Average Macropore
Size (um)
Pore Number
(# per mm2)
Porosity
(% volume)
PGSA15 86.8±23.2 0.44+0.10 18.1±2.10**
PGSA35 85.3+23.7 12.4+2.27 17.2±0.36
4.8.8 Table 1: Pore Characterization. Porosity properties of PGSA scaffold was
quantified from ESEM images analyses. Porosity was determined for macropores
(>50um) only by ESEM . Values shown are mean+SD.
Table 2
Ultimate strain (%) Young's modulus Ultimate stress
(kPa) (kPa)
PGSA15 57.0 ± 4.1% 59.9 ± 8.4 27.8 + 3.6
PGSA35 81.3 + 13%' 42.3 ± 5.0 30.3 ± 2.6
PGSA 186 60.1 5.7% 568 ± 220 270 ± 32
4.8.9 Table 2: Mechanical properties of porous PGSA. Mechanical properties as
determined from stress-strain relationships for PGSA15 and PGSA35 (n = 5 for each
condition) and values for PGSA as determined previously for comparison 86. Values
shown are mean±SD.
Table 3
PGSA15
PGSA35
IHA
Compression
modulus (kPa)
119 65"
80.2 + 28
34.1 + 10.6"
Stress at <60%
Strain (kPa)
266 ± 93
232 ± 71
144 . 89[a]
4.8.10 Table 3: Compressive properties ofporous PGSA. Mechanical properties as
determined from stress-strain relationships for PGSA15, PGSA35 and HA hydrogels (n =
5 for each condition). [a] Stress at failure. Values shown are mean±SD.
© 2008 Massachusetts Institute of Technology. All rights reserved.
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Chapter 5: Future Directions
5.1.0 ALS biomarkers
We have shown that Gd-TTC can be used to quantify differences in axonal
retrograde transport. It is clear that a functional measure of transport would help
clinicians to both diagnose and to monitor the progression and any recovery of ALS;
however, this there is still much work that must be done before there is widespread use of
a new biomarker for ALS. Specifically, we must characterize and optimize the dose and
transport timecourse of the contrast agent. A thorough imaging study must be conducted
that quantifies this rate, and to correlate differences that are observed with
immunohistochemistry staining. Ideally, serial sectioning would be used in parallel with
high resolution in vivo and ex vivo imaging to correlate differences observed and to
determine the cluster of motor neurons for positive transport. These studies would
provide insight into the mechanism of transport reduction that was observed in late stage
ALS transgenic animals: a decrease in overall efficiency (i.e. rate) of transport, or a
decrease in maximal transport rates.
New MRI imaging sequences could also improve quantification of transport rates
by reducing noise. Gating on animal breathing could reduce motion artifacts, but would
prolong the overall scan time. MRI coils that were specifically designed for spinal cord
images would also enhance signal to noise over the standard surface coils that were used
for these studies. Additionally, using iron in place of gadolinium as a contrast agent
could enhance the overall signal, but would introduce additional complications that
would need to be overcome and optimized in any subsequent study.
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Any biomarker for ALS would need to be extensively validated in larger animal
models for both efficacy and toxicity. These studies that were shown to be successful in
mice would likely be conducted in rats, including ALS transgenic rat models, before
moving into non-human primate models. Primate models would not include ALS
animals, but would provide toxicity studies that would be required before moving into
healthy humans and humans with ALS. However, our goal of developing a biomarker for
ALS retrograde transport remains unchanged.
5.2.0 Drug delivery to the CNS
Our goal of developing a drug delivery system that penetrates the CNS with high
efficiency and selectively targeted neurons in vivo remains largely unrealized. This could
be for a variety of reasons, including that nanoparticle size was too large, the use of TTC
as a carrier molecule was ineffective, and that there was a technical reason for failure (i.e.
radiolabeled molecules dissociated from the polymer nanoparticles). To address these
issues, a series of experiments could be designed. Reducing nanoparticle size has proven
difficult for a number of researchers, but progress is being made. Initial nanoparticle size
is largely determined by solvent and non-solvent combinations, and the size of
nanoparticles can easily reach 80nm or less. However, once protein is conjugated to the
nanoparticle, aggregation becomes a problem. This problem can be alleviated but not
eliminated by conducting the precipitation in PBS and maintaining this nanoparticle
solution for the duration of the preparations. Additionally, sucrose stabilization can
reduce aggregation during lyophilization and could be incorporated into future
experiments.
C 2008 Massachusetts Institute of Technology. All rights reserved. 128
It is possible that having higher concentrations of TTC, or utilizing other protein
or viral fragments would improve cellular uptake and improve overall delivery to the
CNS. Using avidin as a biotin binding molecule cross-linker or using a higher
concentration of PLGA-PEG-biotin could increase protein concentrations. However, this
would likely introduce additional problems with nanoparticle aggregation. If these
approaches are not successful at improving uptake, TTC-conjugated nanoparticles could
still have an application for local delivery. Thus, biodistribution studies should be
conducted that test this option as a delivery vehicle. However, even with these additional
experiments, it would be predicted that this drug vehicle would not be successful in
penetrating the CNS because of the low penetration rates of the blood brain barrier.
5.3.0 Neuronal stem cells
There are additional experiments that could be conducted to characterize the
timecourse for differentiation and the non-neuronal cell fraction before any tissue
engineering application would be realized. Our experiments have shown that PGSA was
well tolerated both in vitro and in vivo, but that hESC that were encapsulated into PGSA
differentiated into both neurons and non-neuronal fractions. In contrast, Matrigel
encapsulation appeared to have a higher concentration of cells expressing neuronal
markers than other cell gernn layers. Thus more experiments are needed to characterize
these differences in cell differentiation, and to quantify each cell fraction. The
immunohistochemistry studies should be expanded to incorporate fluorescent analysis
and dual staining, to determine specifically whether cells that have increased levels of
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neuronal stains also have a decreased level of undifferentiation markers (Oct4, SSEA4,
and Nanog).
The next phase of studies that could be conducted is to use encapsulated growth
factors and cytokines that promote neuronal differentiation. Specifically, this could start
by combining growth factors present in Matrigel with PGSA scaffolds, or to use
microparticle controlled release for these studies. There are a variety of factors that could
be considered, but it would be a logical first step to combine the two matrices that were
utilized for this thesis. Additionally, it would be beneficial to know whether any long
term genetic abnormalities were visible by conducting karyotyping experiments on long
term culture of encapsulated cells. These studies would move us closer to understanding
neuronal differentiation and to carefully controlling cell microenvironments for tissue
engineering applications.
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Appendix Summary
Appendix A: Authorship on Publications and Manuscripts
This contains a list of the publications and manuscripts that have led to the
majority of this thesis, including authors lists, order, and affiliations. When
noted, authors have contributed equally to manuscripts. Additionally, some of the
work has been presented at scientific conferences, including a 1) Keystone
Symposia: stem cells and their microenvironment (poster/presentation, March
2007) for the PGSA research, 2) US-Japan symposium on drug delivery systems
(poster/presentation, December 2007) for the Gd-TTC biomarker and TTC-
conjugated nanoparticles, and two separate departmental presentations given
through the biotechnology and toxicology seminar series.
Appendix B: Tetanus toxin C conjugated nanoparticles for in vivo delivery to the central
nervous system
This appendix provides supplemental data from Chapter 3, dealing with further in
vivo data supporting TTC-conjugated nanoparticle drug delivery to the CNS.
Appendix C: Human embryonic stem cell encapsulation in Matrigel for neuronal
differentiation.
This appendix details a new technique that we have utilized to encapsulate hESC
into Matrigel scaffolds within a 3D microenvironment. We provide data that
suggests that the Matrigel environment may induce neuronal differentiation and
support stem cell culture.
Appendix D.: Chemical structures and predicted NMR
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NMR results were compared with theoretical NMR signal, as determined by
ChemDraw software, which is commonly used by chemists to convert a chemical
structure into a signal. The following NMR spectra were analyzed: 1) PLA-PEG-
biotin and PLGA-PEG-biotin, 2) NHS, EDC, and Sulfo-NHS, 3) Sulfo-NHS-
biotin and NH2-PEG-biotin, 4) NH2-PEG-biotin theoretical NMR, 5) PLGA-
COOH theoretical NMR, 6) PLGA-PEG-COOH theoretical NMR, 7) NH2-PEG-
COOH theoretical NMR, 8) PLGA PEG-biotin theoretical NMR, 9) Biotin:
theoretical NMR, and 10) Summary predicted polymer NMR. In summary, most
of the peaks that were determined analytically were not similar to those that were
predicted, even when the predictions had a large degree of certainty associated
with the predictions.
Appendix E: Synthesis of PLGA-PEG-biotin
This contains a chemical equation overview of the process that was used to
synthesize PLGA-PEG-biotin using NHS and EDC modifications of COOH acid
groups at the terminal ends of the polymer.
Appendix F: Schematics of MRI contrast agent biomarkers
This contains a schematic of possible MRI contrast agents that could be used in
parallel with TTC modifications as a biomarker for neurodegenerative diseases
including ALS. These include: 1) Gd-TTC, which was the focus of our initial
studies, 2) an iron core nanoparticle that is conjugated to TTC with a dextran
outer shell and a -2nm core, 3) a biodegradable PLGA (or equivalent) polymer
nanoparticle with encapsulated Magnevist gadolinium-based MRI contrast agent,
and conjugated to TTC. The first agent has the advantage of having a
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size/molecular weight closest to that of TTC and is predicted to maintain the
native retrograde transport properties of TTC. The second agent is iron-based and
has extremely high contrast per nanoparticle. The third agent has the advantage
of being biodegradable with a well-established safety profile. We have utilized
all three systems in previous studies, with the best results coming from the first
agent, and thus that is the primary work that we present.
Appendix G.: Additional analysis ofMRI relaxivity
Our first studies with the Gd-TTC contrast agent were conducted in a 96-well
plate in a 1.5T MRI over a range of TE and TR signals. Thus, the relaxivity could
be measured for each contrast agent, but not nearly as accurately as those results
obtained from an NMR mini-spec. Gd-TTC, Gd-BSA, and iron core
nanoparticles (conjugated to either TTC or BSA) were analyzed in the MRI at
various dilutions. The results from these experiments agree well with those that
are presented in the thesis.
Appendix H: 4. 7T MRI Imaging (in vivo)
Initial MRI imaging experiments were conducted with live mice at 4.7T under
isoflurane anesthesia. Mice were injected with 50uL of Gd-TTC (3mg/mL), for a
total dose of 150ug of Gd-TTC, and imaged 24 hours post recovery. Shown are
two sequential sections of the mouse spinal cord for the thoracic (left) and lumbar
(right) regions. While there are regions of high MRI contrast intensity in the
lumber sections, further experiments suggested that these signals were caused by
artifacts and not as a direct result of Gd-TTC transport.
Appendix I.- 9.4T MRI Imaging (in vivo)
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These contain images of mice that were injected with Gd-TTC and were presented
earlier in the thesis. However, these images show the spinal cord with other
organs that are visible, and additional sections. It is possible to see the full extent
of the breathing and other artifacts that are visible throughout sections, and to see
the orientation of tissue throughout the entire animal. It is clear that MRI contrast
and the reduction of artifacts are not ideal, and that the imaging could be
improved by a combination of imaging sequences and MRI coil design.
Appendix J: Spinal cord staining of TTC transport (ex vivo)
Immunohistochemistry of mice spinal cord samples in the lumbar region 24 hours
after the injection of TTC protein. On the left are PBS negative controls, and on
the right are TTC injected mice, for low (top) and high (bottom) magnification.
These were stained with traditional DAB protocols. TTC localization is
concentrated on a single side of the mouse; however, positivity is also visible on
the contralateral side and around the edges of the tissue. Our desire to explore
neuronal localization with dual staining in injected animals led us to pursue
immunofluorescence for most experiments in this thesis.
Appendix K: Additional analysis of IlHC and MRI transport quantification
There are many ways that the immunohistochemistry and MRI data can be
analyzed and quantified to give comparisons between wildtype and ALS animals
at various ages. This shows examples of the method that was used and described
in detail during the thesis. Specifically, a histogram was generated for a region of
interest in the ventral horn of the lumbar spinal cord on each side. The histogram
corresponds to signal intensity levels, and the number of pixels in the image at
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each intensity. Thus, a normalized ratio can be generated by fitting each
histogram to a probability distribution function that accounts for differences in
staining, antibody, and fluorescence background in each tissue sample. Shown
are representative samples of wildtype and each age of ALS histograms.
Appendix L: Nanoparticle preparations to control size
One concern that we had when preparing nanoparticles for in vivo delivery of
therapeutics is that the nanoparticle size would be too large to allow for TTC-
facilitated transport. We tested a number of different polymer solvents and non-
solvents to reduce nanoparticle size. Here we give a table of combinations for a
PLGA polymer in each solvent, and the sizes of each nanoparticle preparation.
Appendix M. Immunohistochemistry staining of TTC-conjugated nanoparticles
We used traditional primary and secondary antibody immunofluorescent
experiments to determine whether TTC was conjugated to nanoparticles, and
whether this was specific when using NHS and EDC conjugation chemistry. This
experiment also suggested that the TTC protein conformation was preserved. The
figure shows greater fluorescence levels for TTC/NHS/EDC nanoparticles than
those of negative controls. Negative controls include those without a primary
antibody, secondary antibody, or without NHS/EDC.
Appendix N. Nanoparticle protein encapsulation and conjugation
We used a variety of methods to verify that proteins were encapsulated into
biodegradable polymers for early experiments, and also to show that avidin could
be used to specifically conjugate a protein to the polymer. (A) This shows that
biotinylated fluorescent BSA was conjugated to the nanoparticles only with avidin
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as a crosslinker, as evidenced by the visible fluorescent pellet of nanoparticles in
ependorf tubes. (B) Flow cytometry confirmed that populations of nanoparticles
were more fluorescent. (C-E) Fluorescent BSA protein was encapsulated into
nanoparticles via a double emulsion protocol, and nanoparticles were analyzed by
flow cytometry (C), and a BCA protein quantification assay (D-E). It was shown
that protein could be encapsulated using these methods, but encapsulation
efficiency of smaller molecule therapeutics was more quantitative via HPLC
assays and was the focus of this analysis.
Appendix 0: Flow cytometry analysis of biotin binding proteins
In addition to fluorescent quantification when comparing biotin binding proteins,
we also used flow cytometry. Our analysis showed that this method could be
used to show relative differences, but was less quantitative because it was greatly
affected by nanoparticle concentration in each sample, suggesting that a
population of nanoparticles was analyzed in each sample.
Appendix P: Cell binding of TTC-conjugated nanoparticles using NHS/EDC
Our initial experiments were focused on using NHS and EDC to conjugate TTC
onto nanoparticles as a drug delivery vehicle. We made the nanoparticles
fluorescent by encapsulating BSA-FITC via double emulsion, and then activated
COOH groups on the polymer similarly to those protocols previously described
169. An increase in NI 8-RE-105 neuroblastoma cell binding was observed in the
TTC conjugated nanoparticles; however, the overall binding ratio compared to
that of BSA conjugated nanoparticles was less than four fold. Thus, we
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investigated methods of improving protein levels on the nanoparticles and focused
on biotin binding proteins which gave higher overall binding ratios.
Appendix Q: TTC nanoparticles binding to Prostate cancer
Our studies investigating nanoparticle cell binding in vitro focused on several cell
lines as negative controls that were not neuroblastomas and therefore were not
predicted to express the TTC receptor, the GTIB ganglioside. However, we
surprising observed that one prostate line (LNCAP) had significantly higher
binding properties for TTC nanoparticles than for BSA negative controls. Upon
further investigation, we found that previous publications showed that there were
increased expression levels of the TTC binding ganglioside in LNCAP cells,
relative to other cell types including PC3 prostate cell lines '98. Thus, we suggest
that TTC nanoparticles may be useful in targeting prostate cancer, as this
ganglioside is also upregulated in human forms of prostate cancer.
Appendix R: TTC binding to neuroblastomas with polystyrene nanoparticles
In our earlier studies, we also used polystyrene nanoparticle beads to investigate
differences in cellular uptake in cell lines as a function of nanoparticle size.
There were significant increases in neuroblastoma binding after 30 minutes for
40nm and 200nm nanoparticles, and lum microparticles.
Appendix S: Diffusion through hydrogels
In our investigations of different scaffolds that could be utilized for cell
encapsulation studies, we utilized hyaluronic acid and measured the rate of
diffusion of some representative molecules of different sizes in the hydrogel
(VEGF, albumin, globulins, and glucose). Scaffolds were prepared in a custom
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molding, and then radiolabeled samples were taken from the supernatant, as
indicated by the schematic. The amount removed was accounted for
mathematically and was not predicted to change relative concentration levels
significantly. All molecules had rapid diffusion rates through the hydrogel, and
these studies could be expanded to other scaffolds.
Appendix T: Cancer Stem Cells
This provides further background about cancer stem cells, a field of growing
interest with therapeutically relevant applications. Further insight into the biology
behind cancer stem cells could provide additional applications for work in the
field of ALS.
Appendix U: References
This includes a list of references that have been cited throughout the thesis, in the
Nature journal format.
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Appendix B: Tetanus toxin C conjugated nanoparticles for in
vivo delivery to the central nervous system
A.B.1.0 Abstract
Amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease) is a neurodegenerative
disease of the central nervous system (CNS). We have expanded on our previous studies
utilizing TTC-conjugated PLGA-PEG nanoparticles to evaluate whether they would lead
to more effective therapeutic drug delivery systems targeting the CNS. Riluzole, the only
FDA-approved drug for ALS, was encapsulated within nanoparticles and showed to
exhibit a controlled release profile over a period of several days. TTC-conjugated
nanoparticles were shown to be biocompatible using H&E staining, and specifically
transported in vivo from the injection site in the peripheral quadriceps into the lumbar
region of the spinal cord. Furthermore, TTC-conjugated nanoparticles were co-localized
within lumbar spinal cord motor neurons. Radiolabeled biodistribution studies showed
that there was not a statistically significant difference between TTC-conjugated and
BSA-conjugated nanoparticles in their ability to reach the central nervous system. TTC-
conjugated nanoparticles could provide a drug delivery system that enables selective
targeting of motor neurons of the central nervous system.
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A.B.2.0 Introduction
Delivering therapeutic agents to the central nervous system (CNS) is of great
importance but has remained challenging in part because of difficulties in penetrating the
blood brain barrier (BBB), a layer of endothelial cells bound by tight junctions. Most
drugs that are larger than -400 daltons do not pass through the BBB with high efficiency
74. Various approaches have been used to administer agents to the CNS including
concentrated mannitol, vascular endothelial growth factor (VEGF), ultrasound,
encapsulation within nanoparticles, and retrograde transport. Of these, mannitol remains
the most widely used clinically, primarily for applications in cancer treatment.
Ultrasound and VEGF administration remain an active field of ongoing research. In
addition, nanoparticle (both non-targeted and targeted) and retrograde transport
approaches have been used successfully to penetrate the BBB.
Many nanoparticles are synthesized from commonly used polymers, including
polylactic acid (PLA), poly(lactic-co-glycolic acid) (PLGA), and polyglycolic acid
(PLG), which are used to encapsulate and release a therapeutic agent usually over a
period of days to months, with minimal toxicity 69. New polymers are being evaluated for
use as drug carriers that may have beneficial properties such as improvements in drug
loading efficiency, payload delivery, or release kinetics, but their toxicity profile must be
extensively validated before widespread clinical use. Generally, these properties are
different for each therapeutic compound and polymer but can be optimized for each
application.
Nanoparticles can be administered either through non-targeted or targeted
delivery. During the latter, a protein, aptamer, peptide sequence, or other targeting
© 2008 Massachusetts Institute of Technology. All rights reserved. 142
molecule specific for a receptor is attached to the outside of the polymer nanoparticle.
Targeted nanoparticles offer the potential for local delivery, reducing any systemic side
effects of the encapsulated therapeutic, and may reduce systemic clearance rates (i.e.
from the kidney, liver, or macrophages) 75. This is important as common routes of
nanoparticle administration include intravenous and intramuscular delivery, both of
which may lead to rapid clearance and reduced efficacy with certain applications. Many
studies have found that the incorporation of polyethylene glycol (PEG) to the polymer
chain reduces clearance rates and may improve overall efficacy 76
Most nanoparticles are not efficient at penetrating the CNS because of a
combination of their size, surface charge, and hydrophobic properties 74. However, their
smaller size (in comparison with larger microparticles) may allow for greater BBB
penetration. Recently, non-targeted polymer nanoparticles prepared from
polybutylcyanoacrylate (PCBA) polymer encapsulating a variety of drugs and coated
with a polysorbate 80 surfactant have been shown to penetrate the BBB 77-81. The
mechanism for uptake is not fully understood, but is proposed to take place via receptor
mediated endocytosis in brain endothelial cells (ref) 82. However, in contrast to PLA,
PLG, and PLGA polymers that are currently used in FDA-approved applications, PCBA
polymers would need to be studied more extensively before they are widely used
clinically 83
Targeted nanoparticles may allow for boundaries such as the BBB to be
penetrated by facilitating endocytosis or transcytosis across brain endothelial cells.
Another approach utilizes retrograde transport to bypass the BBB. Axonal retrograde
transport is an important cellular process used by neurons to transport proteins, small
© 2008 Massachusetts Institute of Technology. All rights reserved. 143
molecules, and even cell organelles from the terminal end of a neuron towards the cell
body. It is utilized by viruses (i.e. herpes) and bacterial toxins (i.e. tetanus toxoid) to
bypass the BBB and efficiently penetrate the CNS. Researchers have used retrograde
transport to deliver genes and protein conjugates to the CNS with therapeutic efficacy 36,
84. In addition, this approach offers the possibility of selectively targeting a specific
region of the CNS that is a function of the injection site. This is in contrast to non-
targeted intravenous administration that would likely penetrate the entire CNS equally.
However, one concern with using this approach is a possible immune response, which
may be particularly important in patients diagnosed with cancer or those taking
immunosupressive medications. The immune response will likely be a function of the
retrograde transport molecule used and previous immunizations to that molecule.
Recently, the tetanus toxin C fragment (the non-toxic binding portion of the tetanus
toxoid that is efficiently retrograde transported in neurons) was conjugated to
nanoparticles and shown to target neuroblastoma cells in vitro 85. It is not clear yet
whether this approach will lead to nanoparticles penetrating the CNS with high efficiency
in vivo.
Liposome nanoparticles prepared from lipids offer another alternative to deliver
therapeutics to the CNS. In particular, lipids may offer better loading efficiency for
negatively charged DNA or siRNA payloads than negatively charged polymers.
Liposomes that were conjugated to a transferrin or insulin receptor antibody (thought to
transcytosis across endothelial cells) were have been used for successful gene delivery
with a brain specific promoter (ref) 153, 199, 200. However, this approach is non-specific to
brain endothelial cells and requires a brain specific promoter to achieve selective CNS
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targeting. A different study addressed this issue by targeting magnetic liposomes to the
vasculature surriounding the CNS by generating a transient magnetic field 201'. This
approach may be used in parallel with a targeted liposome to penetrate the CNS while
reducing nonspecific uptake in other organs. In addition to these approaches, lipid
libraries similar to those that have been used for other organs could lead to new materials
that might efficiently penetrate the BBB and target CNS 20 2. In particular, these
liposomes may have applications for delivering interference RNA through shRNA,
siRNA, or RNAi molecules because their loading efficiency is generally higher than that
of negatively charged polymer nanoparticles.
The overall goal of this study is to advance our previous research that showed
TTC-conjugated nanoparticles were highly selective for neuroblastoma cells in vitro 8.5
and to evaluate whether these nanoparticles could be used as a drug delivery system to
selectively target the central nervous system in vivo.
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A.B.3.0 Methods
A.B. 3.1: Preparation of nanoparticles.: PLGA-PEG-biotin polymer and nanoparticles
were prepared as previously described 85. Briefly, PLGA-COOH (20kDa MW, Lactel
Absorbable Polymers) was activated with NHS (1:8 PLGA:NHS molar ratio) and EDC
(1:8 PLGA:EDC molar ratio) and subsequently incubated with NH2-PEG-Biotin
(3400MW, Laysan Bio) (1:1.3 PLGA:PEG molar ratio) to form PLGA-PEG-biotin.
Nanoparticles were prepared by PLGA-PEG-biotin (6.7mg/mL polymer in acetone)
nanoprecipitation into deionized water. Coumarin-6 (lmg/mL in acetone, Sigma Aldrich)
or drug (riluzole or thalidomide, 5-50% mass drug:polymer) were mixed with the
polymer prior for encapsulation studies. The solvents for the drugs and polymer that were
used included: acetone, acetonitrile, or DMSO, and were acetonitrile where not indicated.
Nanoparticles (500uL at -20mg polymer/mL) were incubated with neutravidin (2uL at
2mg/mL) (Pierce Biotechnology; Rockford, IL), subsequently mixed with biotinylated
TTC or BSA, and washed by centrifugation using an Amicon filter (4,000rcf, 25C, -20
minutes). Nanoparticles were concentrated and stored at 4C until use.
A.B.3.2 Measurement of encapsulation efficiency and release kinetics: Drugs were
encapsulated into polymer nanoparticles (as indicated above) and dialyzed against a
10,000 Da membrane (Pierce Biotechnology; Rockford, IL) at timepoints between 0-48
hours. Once removed, nanoparticles were snap frozen in liquid nitrogen and lyophilized
to remove liquid. The dry nanoparticles were dissolved in acetonitrile solvent, filtered
through a 0.224m syringe filter and analyzed using an Agilent 1100 high performance
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liquid chromatography (HPLC) (Agilent Technologies; Palo Alto, CA) with a C18
column (Alltech Associates; Deerfield, IL) in 100[L intervals with detection at 264k as
previously described 58, 203. All samples were processed with equal parts of water and
acetonitrile at constant 1ml/min flowrate for one hour. Various timepoints were taken to
generate release kinetics curves for each drug at different loading concentrations, and
total encapsulation efficiency was determined by known drug concentrations at initial
timepoints by normalizing to polymer peaks in the HPLC.
A.B.3.3 Animal study approval and injections: All animal protocols were approved by the
Committee on Animal Care at the Massachusetts Institute of Technology. Mice (8-16
weeks) were anesthetized with 130mg/kg ketamine and 10mg/kg xylazine via an
intraperitoneal injection. Mice were shaved and a small incision was made exposing the
right quadriceps under aseptic conditions. Three 25uL injections containing BSA-
conjugated, TTC-conjugated nanoparticles or a PBS negative control were made into the
muscle using a 26G Hamilton syringe (1.5mg total protein injected). Nanoparticles were
injected that contained coumarin-6, radiolabeled [3H]-PLGA (5 uCi per animal), or blank
drug, and were either conjugated to TTC or BSA. The wound was sutured and the animal
was allowed to recover.
A.B.3.4 Transcardial perfusion and spinal cord isolation: Animals for all spinal cord
sectioned experiments (H&E, fluorescent nanoparticles, and immunohistochemistry
staining) were sacrificed using CO 2 asphyxia. An incision was made opening the
animal's sternum, and a 30G needle was inserted into the left ventricle. The right atrium
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was cut, and the animal was perfused with PBS until blood cleared. Perfusion medium
was switched to 4% paraformaldehyde solution and perfused for 15 minutes. The spinal
cord was gently removed from the vertebrate using forceps and blunt dissection, and cut
into cervical, thoracic, and lumbar sections. Tissue was fixated in 4% paraformaldehyde
overnight. For immunohistochemistry experiments, tissue was incubated in 10% sucrose
for 12 hours, and then in 30% sucrose solution for 12 hours, each overnight at 4C until
sectioning. Tissue for hematoxylin and eosion staining was stored in PBS until mounting.
A.B.3.5 Hematoxylin and Eosion staining: Spinal cords from mice injected with TTC-
conjugated nanoparticles, BSA-conjugated nanoparticles, or PBS negative controls were
prepared as described previously 204. A Gemini automated (ThermoFisher Scientific;
Waltham, MA) staining machine was used for all H&E. Briefly, tissue was dehydrated in
graded ethanol (70 to 100%), embedded in paraffin and sectioned axially using a
microtome (4um). Tissue paraffin was removed with 3 changes of xylene, rehydrated
with graded ethanol, stained with Harris Hematoxylin (Surgipath Medical; Richmond, IL)
for four minutes, and then rinsed with water, 1% acid alcohol (1% HCI in 70% ethanol),
and then water in series. Tissue was then stained for blue nuclei using Scott's Tap water
substitute (Surgipath Medical; Richmond, IL) for one minute, washed and ethanol/xylene
dehydrated as previously, and mounted. Slides were photographed using an inverted
Nikon light microscope.
A.B.3.6 Immunohistochemistry staining for TTC and NeuN: Mice injected with either
TTC-conjugated or BSA-conjugated nanoparticles were sacrificed 24-48 hours post
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injection. Nanoparticles were fluorescent for all non-stained tissue, and non-fluorescent
for all immunohistochemistry stained tissue. Samples were placed in Tissue-Tek OCT gel
(Sakura Finetechnical Co; Tokyo, Japan), frozen on dry ice, and stored at -800 C till
cryostat sectioning. For all non-fluorescent samples, tissue was blocked and
permeabilized in using PBS containing 0.3% Triton-100 and 10% FBS for lh at RT.
Tissue was incubated with rabbit anti-TTC (1:1000, Rockland Immunochemicals;
Gilbertsville, PA) and mouse anti-NeuN (1:500, Chemicon; Billerica, MA) containing
0.1% Triton-100 and 10% FBS overnight at 4C. Tissue was washed in PBS 3x to remove
unbound primary antibodies. Tissue was incubated with Cy3 conjugated goat anti-rabbit
(1:1000, Jackson Immunoresearch; West Grove, PA) and FITC conjugated goat anti-
mouse (1:100, Sigma; St. Louis, MO) containing 0.1% Triton-100 and 10% FBS for 1.5
hours at RT. Tissue was washed 3x in PBS to remove unbound secondary antibody. For
all samples, tissue was mounted using Vectashield fluorescent mounting medium
containing DAPI (Vector Laboratories; Burlingame, CA) and imaged using a Nikon E800
microscope.
A.B.3.7 Cell culture and nanoparticle incubations: N18-RE-105 neuroblastoma and
HepG2 liver cells were grown with previous methods as those previously described 85, 160-
162. Briefly, neuroblastoma cells were cultured in DMEM and supplemented with HAT
supplement (100uM sodium hypoxanthine, 400nM aminopterin, 16uM thymidine), 10%
FBS, and 1% penicillin/streptomycin. HepG2 cells were grown in MEM containing 10%
FBS and 1% penicillin/streptomycin. All cells were grown in filtered flasks in an
incubator at 95% air and 5% carbon dioxide. Media was changed every 48 hours, and
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cells were passaged with EDTA-trypsin when confluent. Confluent neuroblastoma and
HepG2 cells were incubated with dilute radiolabeled nanoparticles at 37C for 30 minutes
prior to trypsin and processing for radiodetection. All media reagents were purchased
from Invitrogen. HepG2 cells were purchased from ATCC, and N 18-RE-105 cells were a
generous gift of Dr. Jonathan Francis at the Massachusetts General Hospital.
A.B.3.8 Nanoparticle biodistribution (in vivo) and tissue preparation/processing:
Radiolabeled nanoparticles (TTC or BSA conjugated) were prepared and injected
unilaterally into the mouse quadriceps as stated above. Separate animals were injected
with PBS negative controls. Mice were sacrificed 48 hours post injection, and the
following organs were harvested and weighed: heart, spleen, lung, liver, kidney, right
(injected) quadriceps, left (not injected) quadriceps, brain, spinal cord, bone, and blood.
The tritium content of each tissue sample was analyzed using a Packard Tri-Carb
Scintillation Analyser (Downers Grove, IL, USA) as protocols modified from those
previously described' 58. The tissues were measured in liquid solution with equal parts of
Hionic-Fluor scintillation cocktail (PerkinElmer, Boston, MA). Tissue was processed
prior to measuring in 2mL of Solvable (Packard) for 12h at 60C, and the resulting
solution was de-colored with 200 mL hydrogen peroxide for lh at 60C. The injected
stock solution was also measured and treated as an unknown sample to determine the
percentage of injected dose at each tissue. The wet weight of each organ was measured to
normalize radioactive counts to each gram of tissue. All sample analysis was conducted
immediately after the removal of tissue.
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A.B.4.0 Results and Discussion
A.B.4.1 Riluzole release kinetics from nanoparticles
We studied the release kinetics of riluzole after encapsulation into biodegradable
polymers of different molecular weights at various loading efficiencies. Riluzole was
chosen as a model drug because it is currently the only FDA approved drug for
amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease), a disease that would benefit
from drug controlled release and local delivery from nanoparticles. We utilized
nanoparticles prepared from PLGA-PEG polymer as previously described85, with
inherent viscosities of either 0.67 or 0.83 (in methylene chloride). Polymer solvents that
were used included acetone, acetonitrile, and dimethyl sulfoxide (DMSO). At 50% drug
loading, a burst release for all solvent and polymer viscosity conditions was observed
(Figure la), which is consistent with other release profiles for small molecule drugs20 3.
We then reduced the drug loading percentage to a 5% drug to polymer mass ratio. This
resulted in drug release profiles that were extended, with only 90% of the drug released
after 48 hours (Figure lb). This is a significant improvement on current riluzole
treatments which are administered twice daily, and could likely be further optimized to
extend the release profile.
A.B. 4.2 Biocompatibility of TTC-conjugated nanoparticles
Spinal cords from mice that were unilaterally injected with TTC or BSA
conjugated nanoparticles were fixed, sectioned, and stained with hematotoxylin and
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eosion to determine whether any signs of acute inflammation were observed. No
differences were observed between injected animals (either TTC or BSA conjugated
nanoparticles) (Figure 2) and PBS negative controls (data not shown). These results
suggest that an injection of the Gd-TTC conjugate is well tolerated and biocompatible.
This is consistent with previous observations following the injection of TTC in rodents
and the established safety profile of gadolinium compounds used in the clinic.
A.B.4.3 In vivo transport of TTC-conjugated nanoparticles
To evaluate whether nanoparticles were transported to the lumbar spinal cord
specifically (i.e. as a direct result of TTC conjugation), we prepared fluorescent
nanoparticles and conjugated them to either BSA or TTC. Nanoparticles were injected
unilaterally as before, and spinal cords were sectioned using a cryostat. Sections were
immediately mounted and stained with DAPI mounting medium to photograph sections
using a fluorescent microscope. All animals showed a small amount of non-specific
uptake on the uninjected side of the animal, likely a result of nanoparticles that were in
circulation. However, the intensity of fluorescence was significantly higher on the side
of injection, and was co-localized with DAPI stains (Figure 3), as indicated by three
different animals for representative traces. Spinal cords from mice that were injected
with BSA-conjugated nanoparticles were less intense than those from TTC-conjugated
mice (data not shown). These data suggest that TTC-nanoparticles promote delivery to
the spinal cord.
A.B. 4.4 Localization of TTC-conjugated nanoparticles in motorneurons
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Spinal cords from mice that were unilaterally injected with TTC or BSA
conjugated nanoparticles (non-fluorescent) were fixed, sectioned, and immunostained
against TTC and a NeuN neuronal stain to verify axonal retrograde transport and to
further explore neuronal localization within the spinal cord. Spinal cord sections from
mice following TTC-conjugated nanoparticle injection showed unilateral positive
staining for TTC concentrated in the ventral horn of the lumbar region of the spinal cord
(Figure 3, top). This was absent in spinal cord sections that were injected with BSA-
conjugated nanoparticles (Figure 3, bottom). Furthermore, TTC positive staining was co-
localized with neuronal positive staining in the positive samples. Spinal cord sections
from TTC injected mice showed similar localization, intensity, and distribution (data not
shown). PBS injected mice showed characteristic NeuN staining, but only background
levels of TTC staining (data not shown). These results suggest that axonal retrograde
transport properties of TTC-conjugated nanoparticles are preserved following
conjugation, and are able to facilitate nanoparticle transport into the lumbar region of the
spinal cord.
A.B. 4.5 Nanoparticle biodistribution (in vivo)
We prepared radiolabeled nanoparticles that were conjugated to either TTC or
BSA to determine relative nanoparticle biodistribution and to quantify how effective
TTC-conjugated nanoparticles were are at penetrating the CNS. Radiolabeled
nanoparticles (and PBS negative controls) were injected unilaterally into the quadriceps
of mice. Mice were sacrificed after 48 hours, and the following organs were recovered:
heart, spleen, lung, liver, kidney, right quadriceps (injected), left quadriceps, brain, spinal
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cord, femur bone, and blood. Tissue was processed and analyzed for radioactivity.
Overall, the biodistribution was similar for nanoparticles regardless of whether they were
conjugated to TTC or BSA. TTC-conjugated nanoparticles showed lower levels of
radioactivity in the brain (16.9±0.7 vs. 11.2±0.35, p<0.01), in the lung (18.3±2.4 vs.
11.5±0.02, p<0.05), and in the heart (18.4+2.8 vs. 11.7±1.5, p<0.05) than BSA-
conjugated nanoparticles. This result is most likely a result of high background levels
and a small relative level of enhanced transport efficiency of TTC-conjugated
nanoparticles relative to those of negative controls. Further studies will be required to
further investigate differences in central nervous system delivery that are a result of TTC-
mediated delivery and to validate this method as a drug delivery system.
A.B.5.0 Conclusions
We have expanded on our previous studies that showed TTC-conjugated
nanoparticles were highly specific for neuroblastoma cells in vitro85. We showed that
riluzole could be encapsulated within biodegradable nanoparticles and released over a
period of several days. TTC-conjugated nanoparticles were shown to be biocompatible
(as evidenced by H&E staining), transported specifically within the lumbar region of the
spinal cord, and co-localized with neurons. However, TTC-conjugated nanoparticles did
not show overall a greater level of penetration to the central nervous system. We have
developed a drug delivery system with potential to specifically and efficiently target the
central nervous system.
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A.B.7.0 Figures and Figure Legends
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A.B. 7.1 Figure 1 - Riluzole nanoparticle release kinetics: (a) Drug release kinetics over
48 hours for riluzole at 50% drug loading (drug to polymer mass ratio) for 0.67 and 0.83
inherent viscosity PLGA-PEG polymers, in acetone, acetonitrile, or DMSO, as indicated.
(b) Comparison of drug loading efficiency on release kinetics for 50% and 5% riluzole
loading. Drug release kinetics can be controlled by changing drug loading concentrations
and polymer ratios, as well as by changing polymer and solvent parameters.
© 2008 Massachusetts Institute of Technology. All rights reserved.
A)
1.00-
0.75.
0.50-Uo.
.N 0.25-
E
I-
157
© 2008 Massachusetts Institute of Technology. All rights reserved. 158
20x
4x Left Right
CL
m
&Z
0.
z
A.B. 7.2 Figure 2 - Haematoxylin and eosin staining of lumbar spinal cord sections
following BSA-NP and TTC-NP injections: Mice injected unilaterally with TTC-
conjugated or BSA-conjugated nanoparticles were sacrificed 48 hours post injection.
Lumbar spinal cords were sectioned, stained with H&E, and imaged for BSA-NP (top)
and TTC-NP (bottom), at 4x (left) and 20x (right) magnification. No observable
asymmetries between the right and left side, or between the each material injected were
observed, suggesting only mild acute inflammation at the spinal cord as a result of the
TTC or Gd-TTC conjugate injection and transport.
C 2008 Massachusetts Institute of Technology. All rights reserved.
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A.B. 7.3 Figure 3 - Retrograde transport for TTC-conjugated nanoparticles to the lumbar
spinal cord: Mice were injected unilaterally with fluorescent TTC-conjugated
nanoparticles, sacrificed after 48 hours, and then spinal cords stained with DAPI to
investigate nanoparticle localization in the spinal cord. The injection side (right) of the
spinal cord shows higher concentration of fluorescent nanoparticles localized within
DAPI positive regions, suggesting successful transport to the spinal cord.
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Figure 4
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A.B. 7.4 Figure 4 - Immunohistological staining for TTC: Mice were injected unilaterally
with nonfluorescent TTC-NP or BSA-NP and sacrificed 48 hours post injection. The
lumbar spinal cord was sectioned and stained for TTC (red) and NeuN (green). Images
that were obtained at 4x magnification showed that TTC positive staining was localized
unilaterally within the ventral horn of the spinal cord. Merged images showed that TTC
and NeuN positive staining were co-localized suggesting specific neuronal uptake of
TTC-NP.
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A.B. 7.5 Figure 5 - In vivo biodistribution.: Mice were injected with PBS, TTC-NP, or
BSA-NP unilaterally and sacrificed 48 hours post injection. Tissue from the following
tissue was removed and analyzed for radiolabeled product: heart, spleen, lung, liver,
kidney, right quad (injected side), left quadriceps (uninjected side), brain, spinal cord,
bone (femur), and blood for low (top) and high (bottom) scale analysis. A high level of
agent remained at the site of injection indicating prolonged opportunity for transport via
motor neurons. Overall, biodistribution including that in the central nervous system
(brain and spinal cord) of BSA and TTC-conjugated nanoparticles were similar.
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Appendix C: Human embryonic stem cell encapsulation in
Matrigel for neuronal differentiation
A.C.1.0 Abstract
Tissue engineering and stem cell research would move closer to clinical
applications in treating amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease) if
pure populations of precursor neural cells could be generated. We encapsulated
undifferentiated human embryonic stem cells (hESC) in Matrigel in a 3D culture. hESC
developed structures that resembled neural tubules after 4 days in culture and supported
cells in colony formation. hESC simultaneously exhibited expression levels for all three
germ layers (ectoderm, mesoderm, and endoderm) but stained with greatest intensity in
the neural ectoderm (nestin stain). Cells showed positive neural staining including nestin,
MAP2, B3-tubulin, Soxl, and TuJ suggesting neuronal differentiation. Additionally,
neural tubules were co-localized with increased expression of HIF-1 alpha suggesting
that oxygen tension may play a role in neuronal differentiation. Flow cytometry was
used to quantify markers for cell undifferentiation and neuronal markers in isolated single
cell populations over a 10 day culture in Matrigel. These results suggest that Matrigel
could be used as a scaffold for 3D hESC culture and neuronal differentiation.
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A.C.2.0 Introduction
Tissue engineering approaches offer a unique treatment modality for amyotrophic
lateral sclerosis (ALS, or Lou Gehrig's disease). One of the requirements of successful
treatments is likely the ability of scaffolds to support neuronal differentiation and growth
in a 3D environment. Recent studies have characterized some of the differences between
2D and 3D cell culture systems and have demonstrated that biophysical, biomechanical
and biochemical forces and signals play a critical role in determining cellular
organization and phenotypic expressionl 77' 205, 206. These same interactions affect human
embryonic stem cells (hESCs) differentiation and morphology 207 Despite this
knowledge, most hESC in vitro differentiation studies are carried out in 2D culture, either
directly on mouse embryonic fibroblasts (MEFs) or on modified surfaces coated with
ECM components such as Matrigel. Researchers have shown that coating a 2D culture
plate with Matrigel allows hESCs to remain undifferentiated and pluripotent when grown
in MEF conditioned media (CM) and low levels of human basic fibroblast growth factor
(hbFGF). Most studies that have used Matrigels to encapsulate cells have not provided a
truly 3D conformation because the relative thickness of Matrigel in most studies is small
compared to the size of a cell colony 208. Therefore, the effect of Matrigel in most of
these studies is limited to providing ECM components.
One leading application of using 3D cultures is for use with human embryonic
stem cell (hESC) culture because these cells are particularly sensitive to the effects of
their microenvironment on cell differentiation 209-213. hESC are used in research because
of their clinical uses that involves the repair of damaged organs and for tissue
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regeneration, including neuronal injury repair 95, 96. These cells have widespread
applications in diseases such as Parkinsons, amyotrophic lateral sclerosis, and spinal cord
injury following contact injury 214,215. A major complication in bringing these therapies
to the clinic is developing a system that has high levels of neurons in a mixed stem cell
population 16. hESC cell differentiation and pluripotency are regularly evaluated by
undifferentiation markers including Oct4, SSEA4, and Nanog, and evaluated for neuronal
cell characteristics by markers including nestin, MAP2, and beta tubulin 217. The
expression levels of these proteins can be induced by certain growth factors and
cytokines, as well as by cell microenvironment scaffolds and binding proteins. Many of
these matrix proteins and cytokines are present in Matrigel scaffolds and may direct
differentiation 218
Our goal is to utilize Matrigel scaffolds for hESC encapsulation within a 3D
scaffold, and to evaluate whether this matrix can be used to promote neuronal
differentiation.
© 2008 Massachusetts Institute of Technology. All rights reserved. 169
A.C.3.0 Methods
A. C.3.1 Cell culture and media: Two NIH-registered hESC cell lines were used for all
studies (H9 and H13, WiCell Research Institute, Madison, WI; p19-30). Human ESCs
were grown on an inactivated mouse embryonic fibroblast (MEF) feeder layer in growth
medium (80% KnockOut DMEM, supplemented with 20% KnockOut Serum
Replacement, 4 ng/ml basic Fibroblast Growth Factor, 1 mM L-glutamine, 0.1 mM f3-
mercaptoethanol, 1% non-essential amino acids). Human ESCs were passaged every 4-6
days using lmg/ml type IV collagenase for 20-30 minutes. To produce inactivated MEF,
activated MEF (Chemicon) were cultured in 85% DMEM containing 15% FBS, and
inactivated for 2 hours with DMEM containing 8ug/mL mitomycin-C (Sigma), detached
with 0.25% trypsin, and seeded at a density of 1.5-3.0 x 105 cells per well in a gelatin
coated 6-well plate. All media components and reagents for hESCs culture were
purchased from Invitrogen Corporation (Carlsbad, CA), except for defined FBS, which
was purchased from Hyclone (Logan, UT). Cell culture methods were modified from
those previously described 105, 172, 219
A. C.3.2 Condition media production: Mitomycin-C inactivated MEF cells were plated on
gelatin coated 6-well plates at 2x normal density. MEF were allowed to attach to the
plate for 24 hours, subsequently cultured in hESC media (replaced daily), and removed
every 24 hours to produce condition medium as previously described 0 5. This protocol
was completed for up to 10 days of media collection for each plate. Condition medium
was stored at -20 'C until use for up to one month.
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A.C.3.3 Matrigel hESC encapsulation andfixation: Undifferentiated hESC were removed
from culture and encapsulated within Matrigel scaffolds using a custom molding. hESC
harvested from one well of a 6-well plate were resuspended in 1 ml Matrigel. 25-100tl of
Matrigel was homogeneously poured in each molding and solidified at RT for 10 min.
The resulting cell encapsulated scaffolds were transferred into the wells of a 24-well
Ultralow adhesion plates (Corning) containing 1 ml of condition media. Condition media
was changed daily. Scaffolds were removed from culture at pre-determined timepoints
(0-20 days) and either fixed in Accustain (Sigma) formalin-free fixative for 20 minutes
for histological sectioning and analysis (H&E and peroxidase), or placed in Tissue-Tek
OCT gel (Sakura Finetechnical Co, Tokyo, JPN), frozen on dry ice, and stored at -800 C
and cryostat sectioned for all immunofluorescent staining.
A.C.3.4 Hematoxylin and Eosion (H&E) staining: Matrigel sections stained with H&E
were fixed and were prepared as described previously 204. A Gemini automated
(ThermoFisher Scientific; Waltham, MA) staining machine was used for all H&E.
Briefly, tissue was dehydrated in graded ethanol (70 to 100%), embedded in paraffin and
sectioned axially using a microtome (4um). Tissue paraffin was removed with 3 changes
of xylene, rehydrated with graded ethanol, stained with Harris Hematoxylin (Surgipath
Medical; Richmond, IL) for four minutes, and then rinsed with water, 1% acid alcohol
(1% HCI in 70% ethanol), and then water in series. Tissue was then stained for blue
nuclei using Scott's Tap water substitute (Surgipath Medical; Richmond, IL) for one
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minute, washed and ethanol/xylene dehydrated as previously, and mounted. Slides were
photographed using an inverted Nikon light microscope.
A. C.3.5 Immunofluorescence: Cryosections were thawed and fixed with acetone for 5min
at room temperature. After blocking with 5% FBS, sections were stained with a nestin
primary antibody (1:100 dilution, one hour) and an anti-mouse-Cy3 secondary antibody
(1:50 dilution, 30 minutes). Sections were then incubated with DAPI (1:200 dilution, 2
minutes) and mounted with fluorescent mounting medium (Dako). Negative controls
lacking either a primary or secondary antibody were used to verify specificity and to
determine minimal background levels. The immuno-labeled cells were examined using a
Zeiss fluorescence microscopy (Zeiss, Germany).
A. C.3.6 Immunohistochemistry and peroxidase staining: Matrigel sections were
embedded in paraffin prior to microtome sectioning (5um slices). The EnVision and
LSAB DakoCytomation kits were used for all immunohistochemically according to the
manufacturer's directions. Briefly, paraffin was removed by a xylene-ethanol dehydration
and permeabilized using 1 % Triton X100 (Sigma) with 1 % (w/v) BSA in PBS for 10
min. Sections were incubated with a primary antibody for each germ layer (CD34 at 1:20,
nestin at 1:20-100, or alpha-fetoprotein at 1:200), HIF-1 alpha (1:50), or neuronal
markers (nestin at 1:100, beta 3-tubulin at 1:20-200, TuJ at 1:50, Sox1 at 1:20-100, or
MAP2 at 1:50-200). Primary antibodies were incubated with a Dako diluent (Dako) and
incubated for 1 h at RT. The samples were then biotinylated for 30 minutes, incubated
with streptavidin-HRP for 30 minutes, and then a DAB chromogen substrate until color
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change was detected (-1-5 minutes). Samples were washed with PBS in between each
incubation, and each set of samples was incubated with DAB for the same time for each
antibody. Samples were then counterstained with a 1:4 dilution of Gill's hematoxylin
solution (Electron Microscopy Science) for 2-3 min. Samples were mounted and
photographed using a light microscope.
A. C.3.7 Flow cytometry: Cells that were removed from Matrigel were analyzed using a
FACScan flow cytometer (Becton Dickinson) to measure fluorescence (488nm
excitation, 530nm and 650nm emission). Cells were incubated with trypsin for 7 minutes
at 37C, inactivated, and then with dispase (50U/mL) to produce a single cell suspension.
A cell pellet was incubated with Intrastain fixative (Dako) for 15 minutes at RT, and
subsequently permeabilized according to the manufacturer's directions. Cells were
incubated with a fluorescent antibody including differentiation markers (Oct4-FITC,
SSEA4-PE, or Nanog-FITC), and neuronal markers (nestin-PE, B3-Tubulin-FITC, or
MAP2-FITC). Unbound antibody was removed by 3 washes in PBS and incubated with
propidium iodide (5ug/mL), and cell populations were gated based on forward/side
scatter and propidium iodide fluorescence to remove debris and dead cells from analysis.
A total of at least 10,000 gated events were obtained for each sample. Data was analyzed
using FlowJo software (Tree Star) to generate histograms of each sample.
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A.C.4.0 Results and Discussion
A. C.4. 1 hESC encapsulation within Matrigel and morphology
We hypothesized that Matrigel could be used to encapsulate stem cells, and that
the growth factors and matrix proteins within the material may promote neuronal
differentiation of undifferentiated human embryonic stem cells. Prior to these studies,
Matrigel has been used primarily as a dilute material to plate 2D culture dishes, or as a
partially embedded cell culture system. We instead utilized a custom molding and non-
diluted Matrigel to encapsulate undifferentiated human embryonic stem cells. hESC in
Matrigel showed cell spreading and the formation of tubule structures after a period of 4
days in culture by light microscopy (Figure 1). Cell spreading and protrusions were
interconnected and resembled axon structures. This is in contrast to the characteristic
morphology of undifferentiated hESC that grow together in colonies.
hESC that were embedded and directly analyzed by thin section H&E staining
showed morphology that resembled undifferentiated cells, suggesting that the method of
analysis did not lead to this morphology. This is in contrast to the distinct formation of
neuronal tubule structures after 4 and 10 days in Matrigel culture (Figure 2). hESC
continued to group into colonies and support each other, but organized into neural
formations. Cells did not form single cell formation suggesting continued cooperation
through cell signaling and matrix molecules that may further induce differentiation.
We then investigated whether morphology of encapsulated hESC was affected by
the size of the Matrigel scaffold. We prepared gels of sizes between 25uL and 100uL
with the same diameter and cultured hESC for between 4 and 10 days (Figure 3).
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Scaffolds that were formed showed greater density in the overall scaffold and resulting
cell colonies in 25uL gels than in larger 100uL gels, suggesting greater rates of
proliferation in smaller scaffolds. This may be a function of oxygen or micronutrient
consumption and resulting cell colonies. Overall, morphology was similar between
scaffolds and more investigation is needed to fully quantify differences in the scaffolds.
A. C. 4.2 Expression of di.ferentiation markers after Matrigel encapsulation
We then further investigated differentiation in hESC during Matrigel
encapsulation and culture. Matrigel scaffolds with hESC were cultured for 4-20 days and
stained for each layer of the germ layers and compared with undifferentiated controls
(Figure 4). hESC showed staining that was positive for each germ layer, however nestin
and ectoderm positive staining was significantly more intense and localized within
neuronal tubules than a-Fetoprotein (endoderm) of CD34 (mesoderm). These data
further suggest neuronal differentiation.
A. C. 4.3 Immunohistochemistry and neuronal differentiation
We investigated neuronal differentiation to further investigate the presence of
markers for neuronal differentiation. Matrigel scaffolds that were sectioned and stained
showed positive staining for B3-tubulin after 4 days, for Soxl after 20 days, for TuJ after
4 days, and MAP2 after 10 days in culture (Figure 5). Cell stains show positivity for
neuronal markers localized in neuron tubules. Additionally, there did not appear to be
visible or quantitative differences in expression levels between 4, 10, and 20 days in
culture for any of the neuronal markers (data not shown). In general, B3-tubulin and TuJ
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stains (both staining for tubulin but on different epitopes) showed positive but less
intense staining than nestin. The positive results for nestin staining were also confirmed
using immunofluorescence (Figure 6a). These results further give evidence for neuronal
differentiation in Matrigel scaffolds.
We next explored possible mechanisms for neuronal differentiation. In addition
to growth factors and matrix proteins that are present in Matrigel, oxygen tension could
play a role in neuronal differentiation. We next stained for HIF-1 alpha to investigate
localization. As predicted, we also observed high levels of this transcription factor
localized within neurotubules. These results suggest that oxygen tension may play a
critical role in neuronal differentiation and are consistent with previous studies 220
A.C.4.4 Flow cytometry of differentiation and neuronal markers
We next quantified relative differences in expression levels for markers of
undifferentiated stem cells (nanog, Oct4, and SSEA4) and neuronal markers (nestin and
MAP2) using flow cytometry. Cells were cultured for 0, 4, or 10 days in a Matrigel and
then removed and analyzed as single cells in suspension (Figure 7). Cells showed
relatively unchanged levels of expression of nanog and Oct4 expression, and higher
levels of SSEA4 expression after Matrigel culture. The SSEA4 levels were not predicted
and cannot be easily explained, but it should be noted that even undifferentiated cells
have highly variable expression levels of SSEA4.
In contrast, hESC showed significantly higher levels of nestin and MAP2 over the
culture period. Interestingly, undifferentiated cells showed a dual peak in expression of
MAP2 suggesting high basal levels of this neuronal marker in undifferentiated cells.
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Separate cell samples were stained with multiple antibodies for either neuronal or
undifferentiation markers. Results for these experiments were similar to those presented
for single antibody stains (results not shown). Cells were also stained with negative
controls for each isotype antibody to investigate non-specific binding and showed only
background levels of fluorescence (data not shown). Taken together, these results
suggest a high fraction of neuronal markers and expression over the Matrigel culture.
A.C.5.0 Conclusions
We have provided studies that demonstrate that hESC can be cultured by Matrigel
encapsulation. Matrigel scaffolds promote the formation of neuronal tubules and express
in these cells neuronal markers including nestin and MAP2. Cells furthermore showed
HIF-1 alpha localization suggesting oxygen tension may play a role in neuronal
differentiation. Flow cytometry confirmed quantitative differences in both markers for
hESC undifferentiation and neuronal markers over a 10 day Matrigel culture.
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A.C.7.0 Figure Legends
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Figure 1
A. C. 7.1 Figure 1 - Light microscopy of hESC encapsulated within Matrigel: (a)
undifferentiated hESC on a MEF feeder layer exhibiting characteristic colonies with
elongated MEF. (b) Differentiated hESC encapsulated within a 3D Matrigel scaffold after
4 days in culture as visualized by light microscopy. (c) higher resolution image of hESC
in Matrigel scaffolds after 4 days in culture showing characteristic cell spreading
resembling neuronal tubules.
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Figure 2
D d
A. C. 7.2 Figure 2 - hESC encapsulated within Matrigel: (a) undifferentiated hESC
encapsulated in Matrigel showing characteristic cell morphology. (b) region of interest in
the enlarged region of (a). (c) hESC after 4 days of Matrigel encapsulation showing
neuron tubule formation with an enlarged region of interest. (d) hESC after 10 days in
culture exhibiting neuron tubule formation.
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Figure 3
A. C. 7.3 Figure 3 - hESC encapsulated within Matrigel of different sizes affecting
morphology: hESC encapsulated within Matrigels after 4 days (a, b) for a 25uL (a) and
100uL Matrigel scaffold (b), and after 10 days (c, d) for 25uL (c) and 100uL (d)
scaffolds. The size of the Matrigel scaffold impacts overall cell morphology and density.
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Figure 4
A. C. 7.4 Figure 4 - Germ layer staining of hESC encapsulated within Matrigel after 4
days in culture: (a) undifferentiated control cells, (b, c) nestin for ectoderm at 50x (b) and
200x (c) magnification, (d) a-Fetoprotein for endoderm at 200x, and (e) CD34 for
mesoderm at 200x. Cells show strong positivity for nestin relative to other germ layers.
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Figure 5
A. C. 7.5 Figure 5 - Neuronal staining of hESC encapsulated in Matrigel: (a) day 4 B3-
tubulin, (b) day 20 Soxl, (c) day 4 TuJ, and (d) day 10 MAP2. Cell stains show
positivity for neuronal markers localized in neuron tubules.
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Figure 6
A. C. 7.6 Figure 6 - Immunofluorescent and immunohistochemistry staining of hESC in
Matrigel: (a) immunofluorescent staining for DAPI (blue) and nestin (red) after 4 days in
culture, and (b) HIF-la after 4 days in Matrigel culture. Nestin staining shows distinct
clusters of neuronal marker positive staining, and HIF-l a localization suggests the
mechanism for neuronal differentiation in Matrigel.
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Figure 7
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A. C. 7.7 Figure 7- Flow cytometry of single cell hESC populations after Matrigel
culture: Flow cytometry results of (a) Nanog, (b) Oct4, (c) SSEA4, (d) MAP2, and (e)
nestin. Cell populations in each sample include unstained cells (black), undifferentiated
cells (blue), day 4 Matrigel encapsulated cells (green), and day 10 Matrigel encapsulated
cells (red). Each cell population includes only gated events and includes at least 10,000
counted cells.
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Appendix D: Chemical structures and predicted NMR
Figure 1: PLGA-PEG-Biotin and PLGA-PEG-Biotin structure
PLA-PEG-Biotm
PLGA-PEG-I
Figure 2: NHS, EDC, and Sulfo-NHS Structure
NHS
EDC
C
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Figure 3: Sulfo-NHS-Biotin and NH2-PEG-Biotin Structure
Sudfo-NHS-biotin
NH2-PEG-Biotin
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Figure 4.: NH2-PEG-Biotin theoretical NMR
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Figure 5: PLGA-COOH Theoretical NMR
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Figure 6.: PLGA-PEG-COOH Theoretical NMR
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Figure 7: NH2-PEG-COOH Theoretical NMR
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Figure 8: PLGA-PEG-Biotin Theoretical NMR
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Figure 9.: Biotin: Theoretical NMR
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Figure 10: Summary predicted polymer NMR
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Appendix E: Synthesis of PLGA-PEG-biotin
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Appendix F: Schematics of MRI contrast agent biomarkers
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Appendix G: Additional analysis of MRI relaxivity
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Appendix H: 4.7T MRI Imaging (in vivo)
Thoracic Lumbar
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AnDendix I: 9.4T MRI Imaging (in vivo)
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Appendix J: Spinal cord staining of TTC transport (ex vivo)
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Appendix K: Additional analysis of IHC and MRI transport
quantification
Immunohistochemistry
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Appendix L: Nanoparticle preparations to control size
Nanoparticle Preparation
Preparation Solvent Non-Solvent Polymer RPM Size(nm)
1 DMSO water PLA 1200 n/a
2 DMSO water PLGA 1200 124.6
3 DMSO water PLA 2000 n/a
4 DMSO water PLGA 2000 119.3
5 DMSO Ethanol PLA 1200 219.3
6 DMSO Ethanol PLGA 1200 278.9
7 DMSO Ethanol PLA 2000 222.7
8 DMSO Ethanol PLGA 2000 264.1
9 DMSO Methanol PLA 1200 92
10 DMSO Methanol PLGA 1200 98.4
11 DMSO Methanol PLA 2000 86
12 DMSO Methanol PLGA 2000 91.9
13 DMSO Isopropanol PLA 1200 355.6
14 DMSO Isopropanol PLGA 1200 392.6
15 DMSO Isopropanol PLA 2000 342.1
16 DMSO Isopropanol PLGA 2000 380.6
L41
45
400
350
300
250
200
oC
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Appendix M: Immunohistochemistry staining of TTC-
conjugated nanoparticles
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Appendix N: Nanoparticle protein encapsulation and
conjugation
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Appendix O: Flow cytometry analysis of biotin binding
proteins
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Appendix P: Cell binding of TTC-conjugated nanoparticles
using NHS/EDC
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Appendix Q: TTC nanoparticles binding to Prostate cancer
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Appendix R: TTC binding to neuroblastomas with polystyrene
nanoparticles
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Appendix T: Diffusion through hydrogels
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Appendix T: Cancer Stem Cells
Researchers have suggested that normal stem cells may become cancer
stem cells (CSCs) by either genotypic or phenotypic changes that could give rise
to tumors 221. They reason that normal stem cells share certain characteristics
with cancer cells, specifically, high proliferation rates and immortality.
Alternatively, it has been postulated that cancer stem cells arise from progenitor
cells that under normal conditions have a finite number of mitotic cycles, but
acquire the ability to self-renew. Regardless of the source of CSC (which is still
under debate and is a field of active research), investigators have identified a
number of CSCs that share stem cell characteristics from humans, including
hematopoietic 222,223, mammary 224, prostate225 , melanoma 226, and brain 227 228
Cells were isolated using florescence or magnetic techniques in these studies with
markers that have previously been shown to be highly specific for stem cells.
Many of these cell lineages were capable of forming solid tumors, and could both
provide new in vitro and in vivo models for cancer research and guide clinical
therapeutic interventions. These topics are actively being researched and may
provide insight into non-cancer applications such as neurodegenerative disease.
O 2008 Massachusetts Institute of Technology. All rights reserved. 223
Appendix U: References
1. Cudkowicz, M. E. et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann
Neurol 60, 22-31 (2006).
2. DiBernardo, A. B. & Cudkowicz, M. E. Translating preclinical insights into
effective human trials in ALS. Biochim Biophys Acta 1762, 1139-49 (2006).
3. Lindhorst, S. & Cudkowicz, M. Is pentoxifylline safe and effective in patients
with amyotrophic lateral sclerosis? Nat Clin Pract Neurol 2, 364-5 (2006).
4. Traynor, B. J. et al. Neuroprotective agents for clinical trials in ALS: a systematic
assessment. Neurology 67, 20-7 (2006).
5. Lechtzin, N. How beneficial is noninvasive ventilation in patients with
amyotrophic lateral sclerosis? Nat Clin Pract Neurol 2, 356-7 (2006).
6. Lechtzin, N. Respiratory effects of amyotrophic lateral sclerosis: problems and
solutions. Respir Care 51, 871-81; discussion 881-4 (2006).
7. Maragakis, N. J. & Rothstein, J. D. Mechanisms of Disease: astrocytes in
neurodegenerative disease. Nat Clin Pract Neurol 2, 679-89 (2006).
8. Wong, P. C., Cai, H., Borchelt, D. R. & Price, D. L. Genetically engineered
mouse models of neurodegenerative diseases. Nat Neurosci 5, 633-9 (2002).
9. Rosen, D. R. Mutations in Cu/Zn superoxide dismutase gene are associated with
familial amyotrophic lateral sclerosis. Nature 364, 362 (1993).
10. Kirby, J. et al. Mutant SOD1 alters the motor neuronal transcriptome:
implications for familial ALS. Brain 128, 1686-706 (2005).
11. Broom, W. J. et al. Variants in candidate ALS modifier genes linked to Cu/Zn
superoxide dismutase do not explain divergent survival phenotypes. Neurosci Lett
392, 52-7 (2006).
12. Kawamata, C., Morita, M., Shibata, N. & Nakano, I. [Familial amyotrophic lateral
sclerosis (FALS) with a novel SOD1 gene mutation: a clinicopathological study].
Rinsho Shinkeigaku 47, 211-6 (2007).
13. Zimmerman, M. C., Oberley, L. W. & Flanagan, S. W. Mutant SOD1-induced
neuronal toxicity is mediated by increased mitochondrial superoxide levels. J
Neurochem 102, 609-18 (2007).
14. Kunst, C. B., Mezey, E., Brownstein, M. J. & Patterson, D. Mutations in SOD1
associated with amyotrophic lateral sclerosis cause novel protein interactions. Nat
Genet 15, 91-4 (1997).
15. Figlewicz, D. A. & Bird, T. D. "Pure" hereditary spastic paraplegias: the story
becomes complicated. Neurology 53, 5-7 (1999).
16. Pasinelli, P. & Brown, R. H. Molecular biology of amyotrophic lateral sclerosis:
insights from genetics. Nat Rev Neurosci 7, 710-23 (2006).
17. Shaw, P. J. Genetic inroads in familial ALS. Nat Genet 29, 103-4 (2001).
18. Dunussi-Joannopoulos, K., Weinstein, H. J., Arceci, R. J. & Croop, J. M. Gene
therapy with B7.1 and GM-CSF vaccines in a murine AML model. J Pediatr
Hematol Oncol 19, 536-40 (1997).
19. Haase, G. et al. Gene therapy of murine motor neuron disease using adenoviral
vectors for neurotrophic factors. Nat Med 3, 429-36 (1997).
© 2008 Massachusetts Institute of Technology. All rights reserved. 224
20. Aebischer, P. et al. Gene therapy for amyotrophic lateral sclerosis (ALS) using a
polymer encapsulated xenogenic cell line engineered to secrete hCNTF. Hum
Gene Ther 7, 851-60 (1996).
21. Miller, T. M. & Cleveland, D. W. Has gene therapy for ALS arrived? Nat Med 9,
1256-7 (2003).
22. Boillee, S. & Cleveland, D. W. Gene therapy for ALS delivers. Trends Neurosci
27, 235-8 (2004).
23. Azzouz, M. Gene Therapy for ALS: progress and prospects. Biochim Biophys
Acta 1762, 1122-7 (2006).
24. Yokota, T. [Gene therapy of ALS with short interfering RNA]. Brain Nerve 59,
1187-94 (2007).
25. Ralph, G. S. et al. Silencing mutant SOD using RNAi protects against
neurodegeneration and extends survival in an ALS model. Nat Med 11, 429-33
(2005).
26. Xie, J., Awad, K. S. & Guo, Q. RNAi knockdown of Par-4 inhibits neurosynaptic
degeneration in ALS-linked mice. J Neurochem 92, 59-71 (2005).
27. Vila, M. & Przedborski, S. Targeting programmed cell death in neurodegenerative
diseases. Nat Rev Neurosci 4, 365-75 (2003).
28. Anand, P. et al. Regional changes of ciliary neurotrophic factor and nerve growth
factor levels in post mortem spinal cord and cerebral cortex from patients with
motor disease. Nat Med 1, 168-72 (1995).
29. Subba Rao, K. Mechanisms of disease: DNA repair defects and neurological
disease. Nat Clin Pract Neurol 3, 162-72 (2007).
30. Gros-Louis, F. et al. Absence of mutations in the hypoxia response element of
VEGF in ALS. Muscle Nerve 28, 774-5 (2003).
31. Moreau, C. et al. Elevated IL-6 and TNF-alpha levels in patients with ALS:
inflammation or hypoxia? Neurology 65, 1958-60 (2005).
32. Moreau, C. et al. Paradoxical response of VEGF expression to hypoxia in CSF of
patients with ALS. J Neurol Neurosurg Psychiatry 77, 255-7 (2006).
33. Just, N. et al. High erythropoietin and low vascular endothelial growth factor
levels in cerebrospinal fluid from hypoxemic ALS patients suggest an abnormal
response to hypoxia. Neuromuscul Disord 17, 169-73 (2007).
34. Vande Velde, C. & Cleveland, D. W. VEGF: multitasking in ALS. Nat Neurosci
8, 5-7 (2005).
35. Storkebaum, E. et al. Treatment of motoneuron degeneration by
intracerebroventricular delivery of VEGF in a rat model of ALS. Nat Neurosci 8,
85-92 (2005).
36. Kaspar, B. K., Llado, J., Sherkat, N., Rothstein, J. D. & Gage, F. H. Retrograde
viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301,
839-42 (2003).
37. Dobrowolny, G. et al. Muscle expression of a local Igf-1 isoform protects motor
neurons in an ALS mouse model. J Cell Biol 168, 193-9 (2005).
38. Lepore, A. C. et al. Intraparenchymal spinal cord delivery of adeno-associated
virus IGF-1 is protective in the SOD G93A model of ALS. Brain Res 1185, 256-
65 (2007).
© 2008 Massachusetts Institute of Technology. All rights reserved. 225
39. Messi, M. L., Clark, H. M., Prevette, D. M., Oppenheim, R. W. & Delbono, O.
The lack of effect of specific overexpression of IGF-1 in the central nervous
system or skeletal muscle on pathophysiology in the G93A SOD-1 mouse model
of ALS. Exp Neurol 207, 52-63 (2007).
40. Weinmann, H. J., Brasch, R. C., Press, W. R. & Wesbey, G. E. Characteristics of
gadolinium-DTPA complex: a potential NMR contrast agent. AJR Am J
Roentgenol 142, 619-24 (1984).
41. Laniado, M., Weinmann, H. J., Schorner, W., Felix, R. & Speck, U. First use of
GdDTPA/dimeglumine in man. Physiol Chem Phys Med NMR 16, 157-65
(1984).
42. Widder, D. J., Greif, W. L., Widder, K. J., Edelman, R. R. & Brady, T. J.
Magnetite albumin microspheres: a new MR contrast material. AJR Am J
Roentgenol 148, 399-404 (1987).
43. Weissleder, R. et al. Ultrasmall superparamagnetic iron oxide: an intravenous
contrast agent for assessing lymph nodes with MR imaging. Radiology 175, 494-8
(1990).
44. Weissleder, R., Reimer, P., Lee, A. S., Wittenberg, J. & Brady, T. J. MR receptor
imaging: ultrasmall iron oxide particles targeted to asialoglycoprotein receptors.
AJR Am J Roentgenol 155, 1161-7 (1990).
45. Daniel, K. D. et al. Multi-reservoir device for detecting a soluble cancer
biomarker. Lab Chip 7, 1288-93 (2007).
46. Kim, G. Y., Josephson, L., Langer, R. & Cima, M. J. Magnetic relaxation switch
detection of human chorionic gonadotrophin. Bioconjug Chem 18, 2024-8 (2007).
47. Matthews, P. M. & Talbot, K. Magnetic resonance spectroscopic imaging--of
prognostic value in amyotrophic lateral sclerosis? Nat Clin Pract Neurol 3, 76-7
(2007).
48. Oberwittler, C., Masur, H., Ludolph, A. C. & Fahrendorf, G. MRI in ALS.
Neurology 42, 1641 (1992).
49. Midani, H., Truwit, C. L. & Parry, G. J. MRI in juvenile ALS: a patient report.
Neurology 50, 1879-81 (1998).
50. Ellis, C. M. et al. Diffusion tensor MRI assesses corticospinal tract damage in
ALS. Neurology 53, 1051-8 (1999).
51. Hecht, M. J. et al. MRI-FLAIR images of the head show corticospinal tract
alterations in ALS patients more frequently than T2-, T - and proton-density-
weighted images. J Neurol Sci 186, 37-44 (2001).
52. Hecht, M. J. et al. Hyperintense and hypointense MRI signals of the precentral
gyrus and corticospinal tract in ALS: a follow-up examination including FLAIR
images. J Neurol Sci 199, 59-65 (2002).
53. Iwasaki, Y., Ikeda, K., Ichikawa, Y., Igarashi, 0. & Kinoshita, M. MRI in ALS
patients. Acta Neurol Scand 107, 426 (2003).
54. Lee, Y. C., Markus, R. & Hughes, A. MRI in ALS: corticospinal tract
hyperintensity. Neurology 61, 1600 (2003).
55. Abe, K. MRI in ALS: corticospinal tract hyperintensity. Neurology 63, 596-7;
author reply 596-7 (2004).
56. Angenstein, F. et al. Age-dependent changes in MRI of motor brain stem nuclei in
a mouse model of ALS. Neuroreport 15, 2271-4 (2004).
© 2008 Massachusetts Institute of Technology. All rights reserved. 226
57. Stommel, E. W. & Cohen, J. A. MRI in ALS: corticospinal tract hyperintensity.
Neurology 63, 596-7; author reply 596-7 (2004).
58. Kassubek, J. et al. Global brain atrophy and corticospinal tract alterations in ALS,
as investigated by voxel-based morphometry of 3-D MRI. Amyotroph Lateral
Scler Other Motor Neuron Disord 6, 213-20 (2005).
59. Blain, C. R. et al. A longitudinal study of diffusion tensor MRI in ALS.
Amyotroph Lateral Scler, 1-8 (2007).
60. Iwata, N. K. et al. Evaluation of corticospinal tracts in ALS with diffusion tensor
MRI and brainstem stimulation. Neurology 70, 528-32 (2008).
61. Sivaraman, A. et al. A microscale in vitro physiological model of the liver:
predictive screens for drug metabolism and enzyme induction. Curr Drug Metab
6, 569-91 (2005).
62. Brem, H. et al. Biocompatibility of a biodegradable, controlled-release polymer in
the rabbit brain. Sel Cancer Ther 5, 55-65 (1989).
63. Kim, G. Y. et al. Resorbable polymer microchips releasing BCNU inhibit tumor
growth in the rat 9L flank model. J Control Release 123, 172-8 (2007).
64. Langer, R., Brem, H. & Langer, L. F. New directions in CNS drug delivery.
Neurobiol Aging 10, 642-4; discussion 648-50 (1989).
65. Langer, R., Brem, H. & Tapper, D. Biocompatibility of polymeric delivery
systems for macromolecules. J Biomed Mater Res 15, 267-77 (1981).
66. Lesniak, M. S., Langer, R. & Brem, H. Drug delivery to tumors of the central
nervous system. Curr Neurol Neurosci Rep 1, 210-6 (2001).
67. Li, Y. et al. In vivo delivery of BCNU from a MEMS device to a tumor model. J
Control Release 106, 138-45 (2005).
68. Madrid, Y., Langer, L. F., Brem, H. & Langer, R. New directions in the delivery
of drugs and other substances to the central nervous system. Adv Pharmacol 22,
299-324 (1991).
69. Langer, R. Drug delivery and targeting. Nature 392, 5-10 (1998).
70. Akinc, A., Anderson, D. G., Lynn, D. M. & Langer, R. Synthesis of poly(beta-
amino ester)s optimized for highly effective gene delivery. Bioconjug Chem 14,
979-88 (2003).
71. Akinc, A., Lynn, D. M., Anderson, D. G. & Langer, R. Parallel synthesis and
biophysical characterization of a degradable polymer library for gene delivery. J
Am Chem Soc 125, 5316-23 (2003).
72. Anderson, D. G., Lynn, D. M. & Langer, R. Semi-automated synthesis and
screening of a large library of degradable cationic polymers for gene delivery.
Angew Chem Int Ed Engl 42, 3153-8 (2003).
73. Anderson, D. G. et al. A polymer library approach to suicide gene therapy for
cancer. Proc Natl Acad Sci U S A 101, 16028-33 (2004).
74. Liu-Snyder, P. & Webster, T. J. Designing drug-delivery systems for the nervous
system using nanotechnology: opportunities and challenges. Expert Rev Med
Devices 3, 683-7 (2006).
75. Huynh, G. H., Deen, D. F. & Szoka, F. C., Jr. Barriers to carrier mediated drug
and gene delivery to brain tumors. J Control Release 1 10, 236-59 (2006).
C 2008 Massachusetts Institute of Technology. All rights reserved. 227
76. Pepinsky, R. B. et al. Improved pharmacokinetic properties of a polyethylene
glycol-modified form of interferon-beta-la with preserved in vitro bioactivity. J
Pharmacol Exp Ther 297, 1059-66 (2001).
77. Calvo, P. et al. Long-circulating PEGylated polycyanoacrylate nanoparticles as
new drug carrier for brain delivery. Pharm Res 18, 1157-66 (2001).
78. Ambruosi, A. et al. Biodistribution of polysorbate 80-coated doxorubicin-loaded
[14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to
glioblastoma-bearing rats. J Drug Target 14, 97-105 (2006).
79. Ambruosi, A., Yamamoto, H. & Kreuter, J. Body distribution of polysorbate-80
and doxorubicin-loaded [14C]poly(butyl cyanoacrylate) nanoparticles after i.v.
administration in rats. J Drug Target 13, 535-42 (2005).
80. Alyautdin, R. N. et al. Delivery of loperamide across the blood-brain barrier with
polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 14, 325-
8 (1997).
81. Gulyaev, A. E. et al. Significant transport of doxorubicin into the brain with
polysorbate 80-coated nanoparticles. Pharm Res 16, 1564-9 (1999).
82. Silva, G. A. Nanotechnology approaches for drug and small molecule delivery
across the blood brain barrier. Surg Neurol 67, 113-6 (2007).
83. Olivier, J. C. et al. Indirect evidence that drug brain targeting using polysorbate
80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res
16, 1836-42 (1999).
84. Benn, S. C. et al. Tetanus toxin fragment C fusion facilitates protein delivery to
CNS neurons from cerebrospinal fluid in mice. J Neurochem 95, 1118-31 (2005).
85. Townsend, S. A. et al. Tetanus toxin C fragment-conjugated nanoparticles for
targeted drug delivery to neurons. Biomaterials 28, 5176-84 (2007).
86. Collard, J. F., Cote, F. & Julien, J. P. Defective axonal transport in a transgenic
mouse model of amyotrophic lateral sclerosis. Nature 375, 61-4 (1995).
87. Breuer, A. C. & Atkinson, M. B. Fast axonal transport alterations in amyotrophic
lateral sclerosis (ALS) and in parathyroid hormone (PTH)-treated axons. Cell
Motil Cytoskeleton 10, 321-30 (1988).
88. Williamson, T. L. & Cleveland, D. W. Slowing of axonal transport is a very early
event in the toxicity of ALS-linked SOD 1 mutants to motor neurons. Nat
Neurosci 2, 50-6 (1999).
89. Guo, Z., Kindy, M. S., Kruman, I. & Mattson, M. P. ALS-linked Cu/Zn-SOD
mutation impairs cerebral synaptic glucose and glutamate transport and
exacerbates ischemic brain injury. J Cereb Blood Flow Metab 20, 463-8 (2000).
90. Kieran, D. et al. A mutation in dynein rescues axonal transport defects and
extends the life span of ALS mice. J Cell Biol 169, 561-7 (2005).
91. Tovar-y-Romo, L. B. & Tapia, R. Cerebral neurons of transgenic ALS mice are
vulnerable to glutamate release stimulation but not to increased extracellular
glutamate due to transport blockade. Exp Neurol 199, 281-90 (2006).
92. Bock, N. A., Paiva, F. F., Nascimento, G. C., Newman, J. D. & Silva, A. C.
Cerebrospinal fluid to brain transport of manganese in a non-human primate
revealed by MRI. Brain Res 1198, 160-70 (2008).
© 2008 Massachusetts Institute of Technology. All rights reserved. 228
93. Mimeault, M. & Batra, S. K. Concise review: recent advances on the significance
of stem cells in tissue regeneration and cancer therapies. Stem Cells 24, 2319-45
(2006).
94. Di Giorgio, F. P., Carrasco, M. A., Siao, M. C., Maniatis, T. & Eggan, K. Non-
cell autonomous effect of glia on motor neurons in an embryonic stem cell-based
ALS model. Nat Neurosci 10, 608-14 (2007).
95. Levenberg, S., Burdick, J. A., Kraehenbuehl, T. & Langer, R. Neurotrophin-
induced differentiation of human embryonic stem cells on three-dimensional
polymeric scaffolds. Tissue Eng 11, 506-12 (2005).
96. Levenberg, S. et al. Differentiation of human embryonic stem cells on three-
dimensional polymer scaffolds. Proc Natl Acad Sci U S A 100, 12741-6 (2003).
97. Chung, B. G. et al. Human neural stem cell growth and differentiation in a
gradient-generating microfluidic device. Lab Chip 5, 401-6 (2005).
98. Papanikolaou, T. et al. In vitro generation of dopaminergic neurons from adult
subventricular zone neural progenitor cells. Stem Cells Dev 17, 157-72 (2008).
99. Galli, R., Gritti, A., Bonfanti, L. & Vescovi, A. L. Neural stem cells: an overview.
Circ Res 92, 598-608 (2003).
100. Kennea, N. L. & Mehmet, H. Neural stem cells. J Pathol 197, 536-50 (2002).
101. Rappa, G. et al. Efficient expansion and gene transduction of mouse neural
stem/progenitor cells on recombinant fibronectin. Neuroscience 124, 823-30
(2004).
102. Yamada, M., Uchida, K., Hayashi, T., Mine, Y. & Kawase, T. Vigorous neuronal
differentiation of amplified and grafted basic fibroblast growth factor-responsive
neurospheres derived from neuroepithelial stem cells. Cell Transplant 13, 421-8
(2004).
103. Gotz, M. & Barde, Y. A. Radial glial cells defined and major intermediates
between embryonic stem cells and CNS neurons. Neuron 46, 369-72 (2005).
104. Vazin, T., Chen, J., Lee, C. T., Amable, R. & Freed, W. J. Assessment of
Stromal-Derived Inducing Activity in the Generation of Dopaminergic Neurons
from Human Embryonic Stem Cells. Stem Cells (2008).
105. Gerecht, S. et al. Hyaluronic acid hydrogel for controlled self-renewal and
differentiation of human embryonic stem cells. Proc Natl Acad Sci U S A 104,
11298-303 (2007).
106. Svendsen, C. N. & Langston, J. W. Stem cells for Parkinson disease and ALS:
replacement or protection? Nat Med 10, 224-5 (2004).
107. Vastag, B. Stem cells step closer to the clinic: paralysis partially reversed in rats
with ALS-like disease. Jama 285, 1691-3 (2001).
108. Lepore, A. C. et al. Long-term fate of neural precursor cells following
transplantation into developing and adult CNS. Neuroscience 142, 287-304
(2006).
109. Yan, J. et al. Extensive neuronal differentiation of human neural stem cell grafts
in adult rat spinal cord. PLoS Med 4, e39 (2007).
110. Homer, P. J. et al. Proliferation and differentiation of progenitor cells throughout
the intact adult rat spinal cord. J Neurosci 20, 2218-28 (2000).
C 2008 Massachusetts Institute of Technology. All rights reserved. 229
111. Chi, L., Gan, L., Luo, C., Lien, L. & Liu, R. Temporal response of neural
progenitor cells to disease onset and progression in amyotrophic lateral sclerosis-
like transgenic mice. Stem Cells Dev 16, 579-88 (2007).
112. Hedlund, E., Hefferan, M. P., Marsala, M. & Isacson, O. Cell therapy and stem
cells in animal models of motor neuron disorders. Eur J Neurosci 26, 1721-37
(2007).
113. Ziv, Y., Avidan, H., Pluchino, S., Martino, G. & Schwartz, M. Synergy between
immune cells and adult neural stem/progenitor cells promotes functional recovery
from spinal cord injury. Proc Natl Acad Sci U S A 103, 13174-9 (2006).
114. Silani, V., Cova, L., Corbo, M., Ciammola, A. & Polli, E. Stem-cell therapy for
amyotrophic lateral sclerosis. Lancet 364, 200-2 (2004).
115. Suzuki, M. & Svendsen, C. N. Combining growth factor and stem cell therapy for
amyotrophic lateral sclerosis. Trends Neurosci (2008).
116. Elisseeff, J., Ferran, A., Hwang, S., Varghese, S. & Zhang, Z. The role of
biomaterials in stem cell differentiation: applications in the musculoskeletal
system. Stem Cells Dev 15, 295-303 (2006).
117. Cimetta, E. et al. Enhancement of viability of muscle precursor cells on 3D
scaffold in a perfusion bioreactor. Int J Artif Organs 30, 415-28 (2007).
118. Vunjak-Novakovic, G. et al. Dynamic cell seeding of polymer scaffolds for
cartilage tissue engineering. Biotechnol Prog 14, 193-202 (1998).
119. Dar, A., Shachar, M., Leor, J. & Cohen, S. Optimization of cardiac cell seeding
and distribution in 3D porous alginate scaffolds. Biotechnol Bioeng 80, 305-12
(2002).
120. Alvarez-Barreto, J. F., Linehan, S. M., Shambaugh, R. L. & Sikavitsas, V. I. Flow
perfusion improves seeding of tissue engineering scaffolds with different
architectures. Ann Biomed Eng 35, 429-42 (2007).
121. Wang, Y., Ameer, G. A., Sheppard, B. J. & Langer, R. A tough biodegradable
elastomer. Nat Biotechnol 20, 602-6 (2002).
122. Wang, Y., Kim, Y. M. & Langer, R. In vivo degradation characteristics of
poly(glycerol sebacate). J Biomed Mater Res A 66, 192-7 (2003).
123. Maxwell, M. M., Pasinelli, P., Kazantsev, A. G. & Brown, R. H., Jr. RNA
interference-mediated silencing of mutant superoxide dismutase rescues
cyclosporin A-induced death in cultured neuroblastoma cells. Proc Natl Acad Sci
USA 101, 3178-83 (2004).
124. Raoul, C. et al. Lentiviral-mediated silencing of SOD1 through RNA interference
retards disease onset and progression in a mouse model of ALS. Nat Med 11, 423-
8 (2005).
125. Miller, R. G., Mitchell, J. D., Lyon, M. & Moore, D. H. Riluzole for amyotrophic
lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst
Rev, CD001447 (2002).
126. Miller, R. G., Mitchell, J. D., Lyon, M. & Moore, D. H. Riluzole for amyotrophic
lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph Lateral Scler
Other Motor Neuron Disord 4, 191-206 (2003).
127. Miller, R. G., Mitchell, J. D., Lyon, M. & Moore, D. H. Riluzole for amyotrophic
lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst
Rev, CD001447 (2007).
© 2008 Massachusetts Institute of Technology. All rights reserved. 230
128. Bonifacino, J. S. & Rojas, R. Retrograde transport from endosomes to the trans-
Golgi network. Nat Rev Mol Cell Biol 7, 568-79 (2006).
129. Hyams, J. S. Organelle transport: retrograde step for microtubules. Nature 330,
106 (1987).
130. Hendry, I. A. & Hill, C. E. Retrograde axonal transport of target tissue-derived
macromolecules. Nature 287, 647-9 (1980).
131. Banks, P. Retrograde transport in axons. Nature 287, 12-3 (1980).
132. Bilgen, M., Al-Hafez, B., Berman, N. E. & Festoff, B. W. Magnetic resonance
imaging of mouse spinal cord. Magn Reson Med 54, 1226-31 (2005).
133. Bonny, J. M. et al. Nuclear magnetic resonance microimaging of mouse spinal
cord in vivo. Neurobiol Dis 15, 474-82 (2004).
134. Herborn, C. U. et al. Clinical safety and diagnostic value of the gadolinium
chelate gadoterate meglumine (Gd-DOTA). Invest Radiol 42, 58-62 (2007).
135. Marzella, L., Blank, M., Gelperin, K. & Johann-Liang, R. Safety risks with
gadolinium-based contrast agents. J Magn Reson Imaging 26, 816; author reply
817 (2007).
136. Pedersen, M. Safety update on the possible causal relationship between
gadolinium-containing MRI agents and nephrogenic systemic fibrosis. J Magn
Reson Imaging 25, 881-3 (2007).
137. Francis, J. W. et al. Tetanus toxin fragment C as a vector to enhance delivery of
proteins to the CNS. Brain Res 1011, 7-13 (2004).
138. Francis, J. W. et al. A survival motor neuron:tetanus toxin fragment C fusion
protein for the targeted delivery of SMN protein to neurons. Brain Res 995, 84-96
(2004).
139. Francis, J. W., Hosler, B. A., Brown, R. H., Jr. & Fishman, P. S. CuZn superoxide
dismutase (SOD-1):tetanus toxin fragment C hybrid protein for targeted delivery
of SOD-1 to neuronal cells. J Biol Chem 270, 15434-42 (1995).
140. Alexander, G. M. et al. Effect of transgene copy number on survival in the G93A
SOD1 transgenic mouse model of ALS. Brain Res Mol Brain Res 130, 7-15
(2004).
141. Heiman-Patterson, T. D. et al. Background and gender effects on survival in the
TgN(SOD 1-G93A)1Gur mouse model of ALS. J Neurol Sci 236, 1-7 (2005).
142. Matsumoto, A. et al. Disease progression of human SODI (G93A) transgenic
ALS model rats. J Neurosci Res 83, 119-33 (2006).
143. Miana-Mena, F. J. et al. Optimal methods to characterize the G93A mouse model
of ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 6, 55-62 (2005).
144. Nobs, L., Buchegger, F., Gurny, R. & Allemann, E. Poly(lactic acid)
nanoparticles labeled with biologically active Neutravidin for active targeting. Eur
J Pharm Biopharm 58, 483-90 (2004).
145. Nobs, L., Buchegger, F., Gurny, R. & Allemann, E. Biodegradable nanoparticles
for direct or two-step tumor immunotargeting. Bioconjug Chem 17, 139-45
(2006).
146. Gref, R., Couvreur, P., Barratt, G. & Mysiakine, E. Surface-engineered
nanoparticles for multiple ligand coupling. Biomaterials 24, 4529-37 (2003).
147. Cannizzaro, S. M. et al. A novel biotinylated degradable polymer for cell-
interactive applications. Biotechnol Bioeng 58, 529-35 (1998).
© 2008 Massachusetts Institute of Technology. All rights reserved. 231
148. Weiss, B. et al. Coupling of Biotin-(poly(ethylene glycol))amine to Poly(d,l-
lactide-co-glycolide) Nanoparticles for Versatile Surface Modification. Bioconjug
Chem (2007).
149. Ben-Shabat, S., Kumar, N. & Domb, A. J. PEG-PLA block copolymer as
potential drug carrier: preparation and characterization. Macromol Biosci 6, 1019-
25 (2006).
150. Fischer, S., Foerg, C., Ellenberger, S., Merkle, H. P. & Gander, B. One-step
preparation of polyelectrolyte-coated PLGA microparticles and their
functionalization with model ligands. J Control Release 111, 135-44 (2006).
151. Pardridge, W. M. Blood-brain barrier delivery. Drug Discov Today 12, 54-61
(2007).
152. Kreuter, J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv
Rev 47, 65-81 (2001).
153. Shi, N., Zhang, Y., Zhu, C., Boado, R. J. & Pardridge, W. M. Brain-specific
expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci U S
A 98, 12754-9 (2001).
154. Lalli, G. & Schiavo, G. Analysis of retrograde transport in motor neurons reveals
common endocytic carriers for tetanus toxin and neurotrophin receptor p75NTR. J
Cell Biol 156, 233-9 (2002).
155. Shapiro, R. E. et al. Identification of a ganglioside recognition domain of tetanus
toxin using a novel ganglioside photoaffinity ligand. J Biol Chem 272, 30380-6
(1997).
156. Sinha, K. et al. Analysis of mutants of tetanus toxin Hc fragment: ganglioside
binding, cell binding and retrograde axonal transport properties. Mol Microbiol
37, 1041-51 (2000).
157. Panyam, J., Sahoo, S. K., Prabha, S., Bargar, T. & Labhasetwar, V. Fluorescence
and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-
co-glycolide) nanoparticles. Int J Pharm 262, 1-11 (2003).
158. Cheng, J. et al. Formulation of functionalized PLGA-PEG nanoparticles for in
vivo targeted drug delivery. Biomaterials 28, 869-76 (2007).
159. Fasman, D. G. Practical Handbook of Biochemistry and Molecular Biology (CRC
Press, Boston, 1992).
160. Malouf, A. T., Schnaar, R. L. & Coyle, J. T. Characterization of a glutamic acid
neurotransmitter binding site on neuroblastoma hybrid cells. J Biol Chem 259,
12756-62 (1984).
161. Lewis, W. et al. Fialuridine and its metabolites inhibit DNA polymerase gamma
at sites of multiple adjacent analog incorporation, decrease mtDNA abundance,
and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl
Acad Sci U S A 93, 3592-7 (1996).
162. Piro, O. & Broze, G. J., Jr. Role for the Kunitz-3 domain of tissue factor pathway
inhibitor-alpha in cell surface binding. Circulation 110, 3567-72 (2004).
163. Knapp, M., Segelke, B. & Rupp, B. The 1.61 Angstrom Structure of the Tetanus
Toxin Ganglioside Binding Region: Solved by MAD and Mir Phase Combination.
Am. Crystallogr. Assoc. 25, 90 (1998).
164. Chen, J. et al. MMDB: Entrez's 3D-structure database. Nucleic Acids Res 31,
474-7 (2003).
O 2008 Massachusetts Institute of Technology. All rights reserved. 232
165. Pugliese, L., Coda, A., Malcovati, M. & Bolognesi, M. Three-dimensional
structure of the tetragonal crystal form of egg-white avidin in its functional
complex with biotin at 2.7 A resolution. J Mol Biol 231, 698-710 (1993).
166. Costanzo, P. J., Patten, T. E. & Seery, T. A. Nanoparticle agglutination:
acceleration of aggregation rates and broadening of the analyte concentration
range using mixtures of various-sized nanoparticles. Langmuir 22, 2788-94
(2006).
167. Costanzo, P. J., Patten, T. E. & Seery, T. A. Protein-Ligand Mediated
Aggregation of Nanoparticles: A Study of Synthesis and Assembly Mechanism.
Chem. Mater. 16, 1775 -1785 (2004).
168. Farokhzad, O. C. et al. Targeted nanoparticle-aptamer bioconjugates for cancer
chemotherapy in vivo. Proc Natl Acad Sci U S A 103, 6315-20 (2006).
169. Farokhzad, O. C. et al. Nanoparticle-aptamer bioconjugates: a new approach for
targeting prostate cancer cells. Cancer Res 64, 7668-72 (2004).
170. Zhou, W. et al. Efficient intracellular delivery of oligonucleotides formulated in
folate receptor-targeted lipid vesicles. Bioconjug Chem 13, 1220-5 (2002).
171. Gref, R. et al. Biodegradable long-circulating polymeric nanospheres. Science
263, 1600-3 (1994).
172. Gerecht, S. et al. A porous photocurable elastomer for cell encapsulation and
culture. Biomaterials 28, 4826-35 (2007).
173. Abbott, A. Cell culture: biology's new dimension. Nature 424, 870-2 (2003).
174. Postovit, L. M., Seftor, E. A., Seftor, R. E. & Hendrix, M. J. A three-dimensional
model to study the epigenetic effects induced by the microenvironment of human
embryonic stem cells. Stem Cells 24, 501-5 (2006).
175. Lee, G. Y., Kenny, P. A., Lee, E. H. & Bissell, M. J. Three-dimensional culture
models of normal and malignant breast epithelial cells. Nat Methods 4, 359-65
(2007).
176. Debnath, J. & Brugge, J. S. Modelling glandular epithelial cancers in three-
dimensional cultures. Nat Rev Cancer 5, 675-88 (2005).
177. Ingber, D. E. Cellular mechanotransduction: putting all the pieces together again.
Faseb J 20, 811-27 (2006).
178. Heidemann, S. R. & Wirtz, D. Towards a regional approach to cell mechanics.
Trends Cell Biol 14, 160-6 (2004).
179. Gerecht-Nir, S. & Itskovitz-Eldor, J. Human embryonic stem cells: a potential
source for cellular therapy. Am J Transplant 4 Suppl 6, 51-7 (2004).
180. Weissman, I. L. Translating stem and progenitor cell biology to the clinic: barriers
and opportunities. Science 287, 1442-6 (2000).
181. Taqvi, S. & Roy, K. Influence of scaffold physical properties and stromal cell
coculture on hematopoietic differentiation of mouse embryonic stem cells.
Biomaterials 27, 6024-31 (2006).
182. Lutolf, M. P. & Hubbell, J. A. Synthetic biomaterials as instructive extracellular
microenvironments for morphogenesis in tissue engineering. Nat Biotechnol 23,
47-55 (2005).
183. Haines-Butterick, L. et al. Controlling hydrogelation kinetics by peptide design
for three-dimensional encapsulation and injectable delivery of cells. Proc Natl
Acad Sci U S A 104, 7791-6 (2007).
© 2008 Massachusetts Institute of Technology. All rights reserved. 233
184. Cushing, M. C. & Anseth, K. S. Materials science. Hydrogel cell cultures. Science
316, 1133-4 (2007).
185. Webb, A. R., Yang, J. & Ameer, G. A. Biodegradable polyester elastomers in
tissue engineering. Expert Opin Biol Ther 4, 801-12 (2004).
186. Nijst, C. L. E. et al. (2007).
187. Drury, J. L. & Mooney, D. J. Hydrogels for tissue engineering: scaffold design
variables and applications. Biomaterials 24, 4337-51 (2003).
188. Ferreira, L. S. et al. Bioactive hydrogel scaffolds for controllable vascular
differentiation of human embryonic stem cells. Biomaterials (2007).
189. Gerecht, S. et al. (2007).
190. Chung, C. et al. Effects of auricular chondrocyte expansion on neocartilage
formation in photocrosslinked hyaluronic acid networks. Tissue Eng 12, 2665-73
(2006).
191. Burdick, J. A. & Anseth, K. S. Photoencapsulation of osteoblasts in injectable
RGD-modified PEG hydrogels for bone tissue engineering. Biomaterials 23,
4315-23 (2002).
192. Burdick, J. A., Chung, C., Jia, X., Randolph, M. A. & Langer, R. Controlled
degradation and mechanical behavior of photopolymerized hyaluronic acid
networks. Biomacromolecules 6, 386-91 (2005).
193. Amit, M. et al. Clonally derived human embryonic stem cell lines maintain
pluripotency and proliferative potential for prolonged periods of culture. Dev Biol
227, 271-8 (2000).
194. Guillaume, D. J., Johnson, M. A., Li, X. J. & Zhang, S. C. Human embryonic
stem cell-derived neural precursors develop into neurons and integrate into the
host brain. J Neurosci Res 84, 1165-76 (2006).
195. Sumida, S. Transfusion and transplantation of cryopreserved cells and tissues.
Cell Tissue Bank 7, 265-305 (2006).
196. Engler, A. J., Sen, S., Sweeney, H. L. & Discher, D. E. Matrix elasticity directs
stem cell lineage specification. Cell 126, 677-89 (2006).
197. Sundback, C. A. et al. Biocompatibility analysis of poly(glycerol sebacate) as a
nerve guide material. Biomaterials 26, 5454-64 (2005).
198. Low, J. A., Magnuson, B., Tsai, B. & Imperiale, M. J. Identification of
gangliosides GD1b and GTlb as receptors for BK virus. J Virol 80, 1361-6
(2006).
199. Zhang, Y., Schlachetzki, F. & Pardridge, W. M. Global non-viral gene transfer to
the primate brain following intravenous administration. Mol Ther 7, 11-8 (2003).
200. Shi, N. & Pardridge, W. M. Noninvasive gene targeting to the brain. Proc Natl
Acad Sci U S A 97, 7567-72 (2000).
201. Riviere, C. et al. Magnetic targeting of nanometric magnetic fluid loaded
liposomes to specific brain intravascular areas: a dynamic imaging study in mice.
Radiology 244, 439-48 (2007).
202. John, M. et al. Effective RNAi-mediated gene silencing without interruption of
the endogenous microRNA pathway. Nature 449, 745-7 (2007).
203. Gu, F. et al. From the Cover: Precise engineering of targeted nanoparticles by
using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A
105, 2586-91 (2008).
C 2008 Massachusetts Institute of Technology. All rights reserved. 234
204. Sheehan, D. C. & Hrapchak, B. B. Theory and practice of histotechnology
(Mosby, St. Louis, 1980).
205. Gerami-Naini, B. et al. Trophoblast differentiation in embryoid bodies derived
from human embryonic stem cells. Endocrinology 145, 1517-24 (2004).
206. Liu, H., Collins, S. F. & Suggs, L. J. Three-dimensional culture for expansion and
differentiation of mouse embryonic stem cells. Biomaterials 27, 6004-14 (2006).
207. Kleinman, H. K., Philp, D. & Hoffman, M. P. Role of the extracellular matrix in
morphogenesis. Curr Opin Biotechnol 14, 526-32 (2003).
208. Battista, S. et al. The effect of matrix composition of 3D constructs on embryonic
stem cell differentiation. Biomaterials 26, 6194-207 (2005).
209. Philp, D. et al. Complex extracellular matrices promote tissue-specific stem cell
differentiation. Stem Cells 23, 288-96 (2005).
210. Mohr, J. C., de Pablo, J. J. & Palecek, S. P. 3-D microwell culture of human
embryonic stem cells. Biomaterials 27, 6032-42 (2006).
211. Liu, H., Lin, J. & Roy, K. Effect of 3D scaffold and dynamic culture condition on
the global gene expression profile of mouse embryonic stem cells. Biomaterials
27, 5978-89 (2006).
212. Zhang, S. Designer self-assembling Peptide nanofiber scaffolds for study of 3-d
cell biology and beyond. Adv Cancer Res 99, 335-62 (2008).
213. Zhang, S., Gelain, F. & Zhao, X. Designer self-assembling peptide nanofiber
scaffolds for 3D tissue cell cultures. Semin Cancer Biol 15, 413-20 (2005).
214. Pacary, E. et al. Synergistic effects of CoC1(2) and ROCK inhibition on
mesenchymal stem cell differentiation into neuron-like cells. J Cell Sci 119, 2667-
78 (2006).
215. Rawal, N., Parish, C., Castelo-Branco, G. & Arenas, E. Inhibition of JNK
increases survival of transplanted dopamine neurons in Parkinsonian rats. Cell
Death Differ 14, 381-3 (2007).
216. Ma, W. et al. CNS stem and progenitor cell differentiation into functional
neuronal circuits in three-dimensional collagen gels. Exp Neurol 190, 276-88
(2004).
217. Ning, H., Lin, G., Lue, T. F. & Lin, C. S. Neuron-like differentiation of adipose
tissue-derived stromal cells and vascular smooth muscle cells. Differentiation 74,
510-8 (2006).
218. Kleinman, H. K. & Martin, G. R. Matrigel: basement membrane matrix with
biological activity. Semin Cancer Biol 15, 378-86 (2005).
219. Notarianni, E. & Evans, M. J. Embryonic stem cells : a practical approach
(Oxford University Press, Oxford ; New York, 2006).
220. Feraud, O., Debili, N., Penninger, J. M. & Kroemer, G. Cavitation of embryoid
bodies requires optimal oxidative phosphorylation and AIF. Cell Death Differ 14,
385-7 (2007).
221. Tan, B. T., Park, C. Y., Ailles, L. E. & Weissman, I. L. The cancer stem cell
hypothesis: a work in progress. Lab Invest 86, 1203-7 (2006).
222. Bonnet, D. & Dick, J. E. Human acute myeloid leukemia is organized as a
hierarchy that originates from a primitive hematopoietic cell. Nat Med 3, 730-7
(1997).
© 2008 Massachusetts Institute of Technology. All rights reserved. 235
223. Lapidot, T. et al. A cell initiating human acute myeloid leukaemia after
transplantation into SCID mice. Nature 367, 645-8 (1994).
224. Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J. & Clarke, M. F.
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci
U S A 100, 3983-8 (2003).
225. Collins, A. T., Berry, P. A., Hyde, C., Stower, M. J. & Maitland, N. J. Prospective
identification of tumorigenic prostate cancer stem cells. Cancer Res 65, 10946-51
(2005).
226. Fang, D. et al. A tumorigenic subpopulation with stem cell properties in
melanomas. Cancer Res 65, 9328-37 (2005).
227. Hemmati, H. D. et al. Cancerous stem cells can arise from pediatric brain tumors.
Proc Natl Acad Sci U S A 100, 15178-83 (2003).
228. Singh, S. K. et al. Identification of a cancer stem cell in human brain tumors.
Cancer Res 63, 5821-8 (2003).
C 2008 Massachusetts Institute of Technology. All rights reserved. 236
